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Abstract 
The Burden of Infection-Associated and Common Cancers Among South Asians and 
Other Asian Subpopulations in the United States, 1999-2009 
 
Neena Sarah George 
 
 
 
Cancer surveillance systems often do not provide detailed estimates of disease among 
racial/ethnic minorities due to the use of combined racial groups such as Asian/Pacific 
Islander.  The current cancer burden in the South Asian population in the U.S. is largely 
unknown due to the lack of studies that examine this group separately from other 
Asian/Pacific Islander populations.  We utilized SEER data to examine differences in 
stage at diagnosis and survival of infection-associated (liver, stomach, and cervical) and 
common (breast) cancers among South Asians compared to other Asian subpopulations 
in the U.S.  SEER-Medicare data were used to assess the association between primary 
care physician visits and these cancer outcomes among these groups.  In our study of 
infection-associated cancers, it was found that South Asians had the highest proportion 
(48%) of late stage liver cancer cases compared to the other Asian subpopulations 
examined.  When examining breast cancer outcomes among the Asian subpopulations, 
the highest risk for late stage diagnosis when compared to non-Hispanic whites was 
found among South Asians, with 3% (OR=0.97; 95% CI 0.81, 1.16) reduced risk for late 
stage diagnosis for this group.  When examining those diagnosed at early-stage disease, 
South Asians had 39% significant reduced risk (95% CI 0.44, 0.84) of death when 
compared to non-Hispanic whites.  Among those diagnosed with late-stage disease, this 
group had 20% reduced risk (95% CI 0.59, 1.09) of death when compared to non-
Hispanic whites.  Primary care visits were associated with decreased risk of late stage  
vii 
diagnosis of breast cancer among both Asians and non-Hispanic whites.  Asians in the 
highest quartile of total physician visits had 57% (OR=0.43; 95% CI 0.27, 0.70) 
decreased risk of late stage diagnosis compared to those in the lowest quartile.  Our 
findings provide evidence for the need to examine Asian subpopulations as individual 
groups rather than using the aggregate racial/ethnic category known as Asian/PI.  True 
heterogeneity in cancer outcomes exists within these separate groups and requires 
targeted interventions for specific subpopulations. 
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1.  BACKGROUND AND LITERATURE REVIEW 
 
 
Cancer is a significant cause for public health concern among Asian Americans in the 
U.S.  This racial/ethnic population is the only one for which the number of deaths 
annually attributable to cancer exceeds that of heart disease.  Though this group reports 
lower rates for major cancers, such as lung, colon, and prostate, they report high rates of 
cancers associated with infectious agents.  These include cancers of the liver, stomach, 
and cervix [1].   
 
The U.S. Census characterizes Asian Americans as those who originate from the Far 
East, Southeast Asia, and the Indian subcontinent.  Those who originate from these 
countries are extremely diverse in terms of factors such as time since immigration to the 
U.S., languages spoken, socioeconomic status, and religion. These are all factors which 
may impact chronic health outcomes.  These racial/ethnic groups have been found to 
differ in their outcomes for cancer and other chronic conditions [1].  In addition, cultural 
factors, such as diet and tobacco use, likely play a role in differing patterns of cancer 
incidence and survival [2].  Thus, combining all Asian-Americans into one category may 
mask significant differences related to incidence and survival that are inherent within the 
subpopulations [3].   
 
Through the use of cancer surveillance systems such as state cancer registries, we are 
able to monitor temporal patterns of cancer incidence, mortality, and overall survival.  
The introduction of national comprehensive surveillance programs, such as the National 
Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) program 
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has enabled us to examine trends in cancer occurrence. However, these systems are often 
limited for detailed estimates of disease occurrence across many racial/ethnic minorities 
due to the use of combined racial/ethnic groups such as Asian/PI.  The use of such 
combined categorizations of race obscures significant differences in cancer occurrence 
patterns among specific racial/ethnic groups, such as those of South Asian origin [4].  
Though they are the third largest Asian subpopulation [3], South Asians comprise a 
racial/ethnic group residing in the U.S. whose cancer experience has not been well 
examined and documented in the literature [5].  Thus, in order to better understand and 
address the cancer burden on the South Asian population, this study will examine this 
racial/ethnic group separately from other Asian/PI populations. 
        
Three infection-associated cancers which are common among those of Asian origin have 
been chosen for analysis in this study.  These include cancers of the liver, stomach, and 
cervix.  A common cancer which will be analyzed is breast cancer.  Cancer of the breast 
has been chosen to represent a non-infection associated cancer for purposes of 
comparison.  We would like to examine whether the same differences in stage at 
diagnosis and survival are seen for this cancer compared to the other infection-associated 
cancers.  For example, the subpopulation that has been found to have the most advanced 
stage at diagnosis for liver cancer may not also have advanced stages of breast cancer.  
Thus, there may be a significant impact of a specific country of origin for an outcome 
among infection-associated cancers that is not also seen for breast cancer.  Incidence rates 
of these cancers were examined by Miller et al in 2008 [4].  We aim to update and extend 
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these results by examining stage at diagnosis and survival of these cancers by Asian 
subpopulation. 
 
1.1. Liver cancer 
1.1.1. Epidemiology in the U.S. 
The most common malignancy of the liver is known as hepatocellular carcinoma (HCC) 
[6]
.  Almost 90% of primary liver cancers diagnosed in the United States are classified as 
HCCs, with the remaining 10% classified as intrahepatic cholangiocarcinomas (ICC) [7].  
Since the majority of primary liver cancers are HCCs, these two terms are often used 
interchangeably [8].  The incidence of HCC in the U.S. has been historically lower 
compared to other regions of the world, such as East Asia.  However, it has been found 
that in recent years age-adjusted incidence rates have significantly increased and 
mortality rates have increased more rapidly compared to other leading cancers [7].  The 
overall age-adjusted incidence rates of HCC tripled between 1975 and 2005, increasing 
from 1.6 per 100,000 to 4.9 per 100,000.  In addition, it was found that incidence was 
almost three times greater among men compared women during this time period.  
Asian/Pacific Islanders had the highest age-adjusted incidence rates between 1992 and 
2005, followed by Hispanics, blacks, American Indians/Alaska Natives, and whites [7].  In 
the U.S. in 2013, liver cancer is expected to be the fifth leading cause of cancer mortality 
among men, accounting for 5% of cancer deaths and the ninth leading cause of cancer 
mortality among women, accounting for 2% of cancer deaths [9].  The 5-year survival rate 
is about 10% since most patients with HCC are diagnosed at advanced stages of disease 
and are only candidates for palliative care as treatment [7].  
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Chronic infections with hepatitis C virus (HCV) and hepatitis B virus (HBV) are the 
leading causes of HCC in the U.S.  HCC accounted for almost 18,910 deaths in the U.S. 
in 2010, with at least half of these attributable to HCV infection.  Recent analyses of 
mortality rates through 2004 have indicated a decrease in deaths associated with HBV 
and an increase in deaths associated with HCV.  It is expected that between 2010 and 
2019, there will be a 2-fold increase in HCV-associated deaths, leading to direct medical 
costs exceeding $6.7 billion.  It is estimated that between 800,000 and 1.4 million persons 
in the U.S. currently have chronic HBV infections.  Among those infected, almost 50% 
are of Asian descent.  In addition, almost 3.2 million persons are living with chronic 
HCV infections [10]. 
 
It is believed that the true burden of chronic HBV infection in the U.S. is largely 
unknown due to the lack of routine screening and the absence of comprehensive 
surveillance programs for HBV.  In addition, the majority of those with HBV infection in 
the U.S. are likely foreign-born immigrants, who are unaware of their HBV status.  It has 
been found that only 0.1-0.2% of U.S.-born individuals are infected with chronic HBV.  
In 2009, it was estimated that the number of foreign-born individuals living in the U.S. 
with chronic HBV infection was 1.32 million (95% CI 1.04-1.61).  The countries from 
which the largest number of infected individuals originated included China (12.3% of 
Chinese immigrants), Vietnam (12.5% of Vietnamese immigrants), and the Philippines 
(7.4% of Filipino immigrants).  This underestimation of the burden of chronic HBV in 
the U.S. highlights the fact that about 60-70% of those who are infected are undiagnosed 
and only almost 50% of those who are diagnosed receive proper treatment.  Cultural, 
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personal, economic, and environmental factors likely promote barriers which contribute 
to the high proportion of foreign-born individuals who are unaware of their infection 
status.  The prevalence of chronic HBV in the U.S. is likely to increase due to ongoing 
immigration of foreign-born individuals from countries in Asia with intermediate and 
high endemicity [11].  
 
1.1.2. Risk factors 
1.1.2.1. Hepatitis B virus (HBV) 
Chronic infection with HBV is the most common cause of HCC worldwide [12].  Almost 
5% of the global population (350-400 million people) has a chronic HBV infection.  
Almost 75% of those infected are Asian [13].  More than 50% of HCC cases globally and 
70-80% of cases in highly endemic areas are attributable to HBV infection.  The 
relationship between HBV infection and HCC was reported first in 1975.  Several 
mechanisms have been proposed in recent years to describe the role of HBV in HCC 
etiology.  One such mechanism is HBV DNA integration into the host genome.  Such 
integration would allow for persistence of the virus in the liver and induce genetic 
alterations.  Indirect mechanisms, such as HBV causing chronic hepatic injury and 
hepatocyte regeneration, have also been proposed.  The mechanism of chronic infection 
has been recognized as an important risk factor due to its accompanying biologic 
processes of liver cell necrosis, inflammation, fibrosis, and cytokine synthesis.  Repeated 
necrosis of hepatocytes in the liver due to chronic infection leads to rapid regeneration 
which may cause accumulation of mutations.  HBV-associated HCC occurs as a result of 
chronic inflammation and continuous regeneration of cells, usually occurring after 25-30 
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years of infection.  Lifetime risk of HCC in an individual that is chronically infected is 
almost 10-25%.  Those with chronic HBV infection and underlying liver cirrhosis have 
increased risk of HCC [12].   
 
HBV infection acquired during childhood typically leads to chronic lifelong infection and 
is typical in areas where HBV is endemic.  If infection is acquired during adulthood, the 
result will usually be symptomatic acute hepatitis and gradual clearance of the infection 
in most patients.  In the U.S. where HBV prevalence is low, the majority of those with 
acute HBV infection are adults and chronic infection will persist in only about 1-5% of 
those who are newly infected.  The incidence of acute HBV in the U.S. has decreased 
steadily by 80% between 1987 and 2004.  This reduction in incidence is attributable to 
many factors such as universal vaccination of infants at birth and vaccination of 
previously unvaccinated adults at increased risk for the infection [14].  In areas of low 
HBV endemicity but large populations of Asian immigrants, such as the U.S., almost 70-
80% of HBV-associated HCC cases will be of Asian origin [12].       
 
As stated previously, Asian immigrants residing in the U.S. have a greater prevalence of 
HBV infection compared to non-Hispanic whites and other U.S.-born persons.  It is the 
main factor that contributes to the disproportionately high incidence of liver cancer 
among those of Asian origin.  Chronic HBV infection is prevalent among about 10% of 
those residing in eastern and southeastern Asia, as well as among immigrants from these 
regions [15].  It is estimated that 10% of Chinese-Americans are infected [16].  The 
prevalence in Vietnamese-Americans ranges from 7% to 14% [17].  The prevalence of 
HBV among Japanese-Americans, ranging from 0.6% to 1.1%, is fairly low compared to 
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other Asian subpopulations.  Fairly high prevalence is found among Filipino-Americans 
ranging from 4.2% to 9% [18].  The prevalence among South Asians in the U.S. has not 
been thoroughly examined.  However, it is estimated that prevalence among those of 
South Asian origin range from 2% to 2.6% [19]. 
 
1.1.2.2. Hepatitis C virus (HCV) 
Almost 170 million people worldwide are chronically infected with HCV [20].  Recent 
trends of increased incidence of HCC in developed regions, such as North America and 
Europe, have been attributed to HCV infection.  Many forms of biological evidence 
indicate a strong association between HCV and HCC.  HCV RNA does not integrate into 
the host genome as found among those with HBV infections.  However, it can be found 
in the serum, liver, and tumor tissues of patients diagnosed with HCC.  HCV likely 
increases the risk for HCC through promotion of fibrosis and cirrhosis.  In fact, the 
majority of HCV-associated HCC cases are among patients with underlying cirrhosis.  
Most cases of HCC occur after 25 to 30 years of chronic infection with HCV.  This 
interval of time also reflects the time that is necessary for development of cirrhosis [21].  
In addition, it has been reported that 5-10% of patients with HCV infection will develop 
cirrhosis after 10 years of infection.  This likelihood is 10- to 20- fold greater than among 
those who are HBV infected [22].  
 
In the U.S., HCV infections are the most common bloodborne infections.  The most 
significant means of viral transmission is through exposure to the blood of an infected 
individual.  Common modes of transmission include intravenous drug use and sexual 
8 
 
contact with an infected individual [23].  It is believed that the HCV epidemic in the U.S. 
began in the 1960s and peaked in the 1980s when risk factors for HCV transmission, such 
as injection drug use, needle sharing, transfusion of unscreened and contaminated blood, 
and unsafe sexual behaviors were rampant.  Thus, the incidence of HCV-associated HCC 
is expected to increase as those infected with HCV develop cirrhosis and subsequently 
HCC [21].  Increasing incidence rates of liver cancer among Hispanics, whites, and blacks 
in the U.S. are attributed primarily to HCV infection [15].  Unlike HBV, effective 
vaccination against HCV is not yet available.  This is due to factors such as the high 
propensity of HCV to induce persistent chronic infection and evidence that convalescent 
individuals can be re-infected following new exposure [22]. 
 
The prevalence of HCV infection ranges from ≤1% -2% in developed countries to 6% in 
countries such as Vietnam where the infection is endemic [24].  In the U.S., the prevalence 
is believed to be approximately 1.8% [23].  Studies of Asian-Americans have shown that 
rates of HCV prevalence reflect those of their countries of origin [24].  The prevalence of 
infection among Chinese is about 3.2% [25].  Fairly low prevalence rates of 0.4% and 
0.49% have been reported among those of Filipino and Japanese origin, respectively.  
The prevalence of HCV among South Asians residing in the U.S. has not been examined 
thoroughly but is believed to range between 0.8% among Indians to 5.3% in Pakistanis 
[26]
.  The rate of HCV is especially high in Pakistan largely due to reuse of syringes and 
needles.  The practice of re-selling used needles as new instruments in drug stores is 
common in certain areas resulting in widespread use of unsterilized and infected needles.  
One study reported that among 68% of injections that were administered in two different 
districts in Pakistan, only 54% used needles which were new and freshly opened [27]. 
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1.1.2.3. Aflatoxin 
Aflatoxin is a mycotoxin produced by fungi belonging to the Aspergillus species.  
Contamination by aflatoxin mainly occurs as a result of improper storage of cereals, 
peanuts, and vegetables [6].  It is estimated that approximately 4.5 billion people 
worldwide are at risk for aflatoxin exposure through dietary intake.  Areas at the highest 
risk of exposure are tropical and subtropical regions where maize and peanuts are 
consumed regularly [28].  Numerous prospective studies have shown strong associations 
between aflatoxin exposure and subsequent liver cancer.  Aflatoxins, especially aflatoxin 
B1 (AFB1), have therefore been confirmed to have a carcinogenic role in liver cancer 
etiology.  In addition, they may also interact with HBV infection to cause cancer [6].  
Several studies have found that aflatoxin exposure and HBV infection may have a 
synergistic effect to increase risk of HCC in areas where both are prevalent [28].  AFB1 
exposure is usually prevalent in regions where HBV infection is also prevalent [6].  These 
include areas of the developing world, such as Asia and Africa.  A recent meta-analysis 
which reviewed studies conducted in China, Taiwan, and sub-Saharan Africa reported 
that the population attributable risk (PAR) of aflatoxin-related liver cancer was 17% 
overall and 21% in populations with high rates of HBV infection.  Thus, reducing 
aflatoxin exposure to levels classified as non-detectable could possibly reduce HCC rates 
in high-risk areas by about 17% [28].  Though exposure to aflatoxins is controllable 
through proper food storage methods, the regions of the world where exposure is 
prevalent do not have adequate resources to implement such control measures.  The 
majority of agricultural land in Asia and Africa is in areas where climates are favorable to 
Aspergillus growth.  Maize and groundnuts, two staples of Asian and African diets, are 
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the most conducive to Aspergillus proliferation and contamination.  Since those residing 
in these areas can not afford to consume a diet rich in other nutrients, these foods 
contribute greatly to daily intake and thus results in high exposure to aflatoxins [29]. 
 
1.1.2.4. Alcohol 
Alcohol consumption is associated with an increased risk of liver cancer.  There is no 
clear “safety threshold” for the effects exerted by alcohol on the liver.  A meta-analysis 
examining this association found a dose-response relationship with 25, 50, and 100 grams 
of alcohol intake per day associated with relative risks of 1.19 (95% CI 1.12, 1.27), 1.40 
(95% CI 1.25, 1.56), and 1.81 (95% CI 1.50, 2.19), respectively.  The most probable 
biological mechanism through which alcohol exerts its effect is through the onset of liver 
cirrhosis [6].  Almost 90% of ingested alcohol is metabolized in the liver and alcohol 
metabolism is the main cause of liver damage [30].  Cirrhosis is likely the most significant 
risk factor for HCC in regions such as North America where there is low prevalence of 
other factors such as HBV and HCV infections and exposure to aflatoxins [6].  In the U.S., 
about 32% of HCC cases are attributable to chronic heavy alcohol use [31].  A Swedish 
cohort study found that among subjects diagnosed with both alcoholism and cirrhosis, the 
relative risk of liver cancer was 16.5 (95% CI 12.7, 21.2).  Infection with HCV may 
accelerate the course of alcoholic liver disease and lead to the onset of HCC at younger 
ages among drinkers compared to non-drinkers [6].  Alcohol consumption among those 
with HCV infection increases HCC risk by approximately 2-fold compared to those with 
HCV infection and do not consume alcohol [31].  However, alcohol is associated with 
HCC, regardless of the presence of either HBV or HCV infection.   It is likely that higher 
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levels of consumption are necessary for development of cancer when viral infection is 
absent [20].  Several studies have provided strong evidence to support the notion of 
synergism between HCV infection and alcohol in liver disease etiology.  Among those 
with HCV-associated disease, those with HCC or cirrhosis reported higher alcohol intake 
compared to those at less advanced stages of disease.  In addition, cohort studies 
conducted among those with HCV-associated liver disease have reported that 
consumption of alcohol increases the rate of disease progression of fibrosis and 
carcinogenesis of the liver [32]. 
 
1.1.2.5. Smoking 
Tobacco smoking is believed to be associated with increased risk of liver cancer.  A 
meta-analysis examining this association reported an odds ratio of 1.56 (95% CI 1.29, 
1.87) among current smokers compared to never-smokers [6].  The biological mechanism 
through which smoking exerts its effect on HCC etiology remains unclear.  Animal 
studies have shown that tobacco-associated carcinogens can initiate tumor formation in 
the liver and inactivate tumor suppressor genes [33].  Since smokers have been shown to 
consume more alcohol than non-smokers, and heavy alcohol consumption is a risk factor 
for liver cancer, it may confound the association between smoking and liver cancer.  
However, there are numerous studies that have adequately controlled for this 
confounding and have concluded that smoking is itself an independent risk factor.  Such 
studies include those conducted among Chinese and Japanese women, who likely do not 
consume heavy amounts of alcohol.  Large case-control and cohort studies from the U.S. 
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and Asia have found relative risks between smoking and HCC to range between 1.5 to 
2.5 [34].   
 
1.1.3. Rationale for analyses 
Liver cancer remains to be one of the most significant health disparities between Asian 
Americans and non-Hispanic whites in the U.S.  They are 2.7 times more likely to 
develop the disease and 2.4 times more likely to die as a result.  Though the burden of 
liver cancer is relatively low in the U.S., it remains as the second most common cause of 
mortality attributable to cancer in Asian American men.  Regardless of medical advances 
for other cancer sites, the 5-year survival rate for liver cancer is still below 10%.  This 
highlights the need for increased prevention targeted towards the high-risk Asian 
American population [35].   
 
Despite recent successes in reducing the incidence of acute and chronic HBV infections 
in children and adolescents in the U.S., chronic HBV infection remains an important 
public issue among Asian/Pacific Islander adults residing in the U.S.  Almost 10% of this 
population is chronically infected with HBV in comparison to less than 0.5% of the 
overall U.S. population.  It has been shown that if left untreated, chronic infection of 
HBV results in death due to liver failure or cancer in approximately 1 in 4 people.  These 
outcomes are the cause of death in approximately 3000 to 5000 individuals annually in 
the U.S.  The significant racial/ethnic disparity in burden of chronic HBV infection in the 
U.S. is largely due to the fact that 67% of the Asian/Pacific Islander population is 
foreign-born.  Those that comprise this group are originally from countries where HBV 
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infection is endemic.  In addition, most of these chronic infections were likely acquired 
before adulthood.  Due to the high prevalence of chronic infection in this population, 
liver cancer incidence is more than 3-fold higher among males of Asian/Pacific Islander 
origin compared to white males.  In addition, almost 60-80% of liver cancer cases in this 
population are due to infection with HBV [36]. 
 
It is likely that part of the racial/ethnic disparity in liver cancer is also due to undiagnosed 
chronic HBV infection.  Since there usually are no apparent symptoms of chronic 
infection, those that are affected are unaware of their infection.  It has been reported that 
almost 60% of those with HBV infection do not experience any symptoms.  The lack of 
screening in high-risk populations from regions of high endemicity also contributes 
greatly to under-diagnosis of HBV.  Screening rates as low as 8% have been reported 
among urban foreign-born Asian/Pacific Islander communities.  Several personal and 
environmental factors likely contribute to this lack of screening and awareness of 
infection status, especially among foreign-born populations that are at high risk.  These 
include lack of correct information about the disease, cultural beliefs regarding primary 
care and physician visits, and fear of stigmatization from their communities [37].  All of 
these factors, which are prevalent among Asian immigrants, likely contribute to late stage 
at diagnosis and subsequent poor prognosis of liver cancer among this group.   
 
It has been reported that approximately 40,000 immigrants with chronic HBV infections 
enter the U.S. each year, with 50% of these individuals classified as Asian [36].  HBV 
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infection is prevalent in Asia and is thus the most common cause of liver cancer in this 
region.  Over 80% of liver cancer cases globally occur in developing countries and China 
alone accounts for more than 55% of total cases.  The age-adjusted incidence rate of liver 
cancer in California was reported to be 23.3 per 100,000 among Chinese males compared 
to 6.8 per 100,000 among non-Hispanic white males.  The rates for other Asian 
subpopulations such as Japanese and Filipino males were similarly increased compared to 
non-Hispanic white males at 9.3 and 16.8 per 100,000 respectively [1].  Though the South 
Asian population is rapidly growing in the U.S, the liver cancer burden of this group has 
not been adequately examined.  A study conducted in California found that this group 
had increased incidence rates compared to non-Hispanic whites.  The incidence rate 
among South Asian males was found to be 10.4 per 100,000 compared to 6.3 per 100,000 
among non-Hispanic white males [38].   
 
As seen in Table 1-1, the majority of studies examining liver cancer incidence among 
Asian subpopulations in the U.S. have been restricted to California since it has the largest 
Asian population in the country and its comprehensive state cancer registry which 
collects detailed information regarding health status among ethnic minority groups [1].  In 
order to better understand the burden of liver cancer among Asian subpopulations in the 
U.S, it is necessary to examine stage at diagnosis and survival in the country as a whole.  
This will allow for better prevention and management efforts, such as educating this 
population about HBV screening and increasing vaccination efforts among adults who 
were not previously vaccinated as children. 
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1.2. Stomach cancer 
1.2.1. Epidemiology in the U.S. 
In 2013, it is expected that 21,600 new cases of stomach cancer will be diagnosed in the 
U.S., while 10,990 deaths will be attributed to the disease [9].  It currently ranks 14th 
among the most incident malignancies in the U.S [43].  Stomach cancer incidence and 
mortality rates are twice as high among Asian/Pacific Islander populations in the U.S., 
compared to whites.  This is likely attributable to the increased prevalence of chronic 
infection with Helicobacter pylori (H. pylori) in these populations.  Stomach cancer is 
also more commonly diagnosed in males compared to females.  Among Asian/Pacific 
Islanders, the incidence rate was found to be 16.1 per 100,000 among males and 9.3 per 
100,000 among females.  Among whites, the incidence rate was found to be 8.4 per 
100,000 among males and 4.0 per 100,000 among females.  Over the past decade (2000-
2009), some of the largest declines in annual mortality rates have been for cancers of the 
stomach (3.1%) [9].  Few cases of gastric cancer are diagnosed at early stages of disease in 
the U.S.  Thus, the 5-year survival rate is relatively low at less than 20%.  It has been 
reported that gastric cancers diagnosed among those of Asian origin carry a more 
favorable prognosis compared to non-Asians, suggesting that host-related factors also 
likely play a role in prognosis [44].   
 
Almost 90% of gastric tumors are adenocarcinomas of two main histologic subtypes: 
well-differentiated (intestinal type) and undifferentiated (diffuse type).  Intestinal type 
tumors are more common in high-risk regions, such as East Asia, Eastern Europe, and 
Central and South America.  Diffuse type tumors follow a more uniform geographic 
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distribution.  It is believed that decreasing incidence of intestinal type adenocarcinomas 
accounts for the majority of the recent declining trend of gastric cancers worldwide [44].  
Stomach cancers are often further classified into two distinct entities: proximal (cardia) 
and distant (non-cardia) tumors [43].  Though a decreasing trend for distal tumors has been 
observed, incidence of proximal tumors has been increasing, especially among men.  
Proximal malignancies now account for almost half of gastric cancers among males in the 
U.S [44].       
 
A recent study examining cancer incidence and mortality among Asian-American 
immigrants reported that stomach cancer was among the most common cancers in these 
groups.  Incidence rates were especially high among Korean and Japanese men at 55.0 
and 29.3 per 100,000, respectively [4].  This is expected since Korea and Japan have 
reported the highest rates of stomach cancer in the world [44].  Stomach cancers were also 
among the top four causes of cancer mortality among the majority of Asian groups 
examined.  Previous studies conducted among immigrant populations have suggested 
early exposure to H. pylori and dietary factors likely play a role in stomach cancer 
incidence among those of Asian origin [4].  The unusually high rates of stomach cancer 
found in Korea are likely due to traditional dietary patterns which include frequent intake 
of foods high in salt and nitrites or nitrates [1]. 
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1.2.2. Risk factors 
1.2.2.1. Helicobacter pylori (H. pylori) 
H. pylori, a gram-negative spiral bacterium known to infect nearly half of the global 
population, is the most well-known risk factor for stomach cancer [45].  H. pylori have the 
ability to invade and colonize the stomach and subsequently engage in direct interactions 
with gastric epithelial cells [46].  However, only a small percentage of those with the 
infection will develop the disease [45].  Regions with high rates of stomach cancer will 
typically also have increased prevalence of H. pylori infection.  The association between 
H. pylori infection and increased risk of gastric cancer has been well established by 
previous studies.  An increased risk of developing adenocarcinoma up to 6-fold has been 
reported for infected patients [46].  It was classified as a group 1 carcinogen by the 
International Agency for Research on Cancer in 1994.  The biological mechanism 
through which infection triggers carcinogenesis involves a progressive sequence of 
events as follows: (1) gastric lesions resulting from chronic gastritis, (2) gastric atrophy, 
(3) intestinal metaplasia, (4) dysplasia, and (5) gastric adenocarcinoma [44].     
 
In Asia, there is widespread geographic variation in seroprevalence rates of H. pylori 
infection.  In addition, though the incidence of stomach cancer largely reflects 
seroprevalence rates of infection, there are groups with high seroprevalence that also 
have low rates of cancer.  Within the Asian-Pacific region, there is considerable variation 
in H. pylori infection between countries and also among specific communities within 
countries.  In Bangladesh the seroprevalence of infection was reported as 92%, while the 
overall rate in India was 79%.  However, India is classified as a low-risk region for 
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gastric cancer where the age-standardized incidence rate is about 5.7 per 100,000.  In 
contrast, high-risk regions for gastric cancer (Japan, China, Korea) where the 
seroprevalence ranges from 39.3% to 59.6% report age-standardized incidence rates 
ranging from 41.4 to 69.7 per 100,000.  This paradox is referred to as the “Asian 
Enigma” and is likely attributable to host genetic factors and other environmental factors 
such as diet and smoking [47].  
 
In developed countries such as the U.S., the prevalence of H. pylori infection varies 
according to age, ethnicity, and socioeconomic status.  In contrast, prevalence in 
developing countries is less variable and less dependent on age and socioeconomic status.  
Consequently, prevalence of infection in developed countries is higher among 
immigrants compared to native-born individuals.  Most immigrants in the U.S. originate 
from countries where H. pylori infection is prevalent among young adult populations.  A 
study conducted in New York City found that seroprevalence of infection among East 
Asian immigrants was greater than 70% [48].  The prevalence of H. pylori infection in the 
U.S. is reported to be less than 20% among those 20 years of age and 50% among those 
50 years of age.  The prevalence of infection in Japan is also less than 20% at 20 years.  
However, it increases to 80% among those over 40 years.  In Korea, 90% of adults over 
age 20 years who are reported to be asymptomatic are infected.  The drastic increase in 
prevalence with increasing age observed in these countries is mostly due to an apparent 
cohort effect, rather than older age at infection since H. pylori is mostly acquired during 
childhood by oral ingestion.  The likelihood of infection is associated with lifestyle and 
living conditions during childhood such as overcrowding and poor sanitation [44]. 
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1.2.2.2. Diet 
Salt intake has been shown to be a risk factor for gastritis and amplify the effects of 
gastric carcinogens [49].  A recent meta-analysis of prospective studies examining the 
association between salt intake and stomach cancer risk reported that “high” (RR=1.68; 
95% CI 1.17, 2.41) and “moderately high” (RR=1.41; 95% CI 1.03, 1.93) intake were 
both associated with increased risk compared with “low” intake [50].  Mucosal damage 
caused by salt intake also likely increases the risk for persistent infection with H. pylori 
[49]
.  High consumption of salt-preserved foods and nitrosamines, such as those present in 
smoked fish and pickled vegetables, also likely increase the risk stomach cancer.  
Geographic variation in stomach cancer mortality rates has been shown to correlate with 
levels of daily salt consumption.  In many developing countries, salting is used as a 
means of food preservation.  The decline of stomach cancer in developed nations, such as 
the U.S., is attributed to the widespread use of refrigeration as the common method of 
food storage.  It has been hypothesized that H. pylori infection acts synergistically with 
dietary factors to promote carcinogenesis [51]. 
 
Fruit and vegetable consumption has been shown to protect against stomach cancer risk.  
A large prospective study reported that intake of 2-5 daily servings of fruits and 
vegetables resulted in 44% reduced risk of cancer (HR= 0.56; 95% CI 0.34, 0.93) when 
compared to less than 1 daily serving [49].  Anticarcinogenic components of these foods, 
such as vitamins, carotenoids, and flavonoids, likely play a role in the observed protective 
effects through processes such as modulation of DNA methylation, protection from DNA 
damage, and promotion of apoptosis [52].  
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1.2.2.3. Alcohol 
Though the association between alcohol consumption and stomach cancer risk has been 
examined in numerous studies, results remain inconsistent [53].  Recently, four large 
prospective studies concluded that there was insufficient evidence to support the 
association between total alcohol consumption and stomach cancer risk [54].  When this 
association was examined in the European Prospective Investigation into Cancer and 
Nutrition (EPIC) cohort, it was found that heavy alcohol consumption (≥60 g/d) was 
positively associated with gastric cancer risk (HR=1.65; 95% CI 1.06, 2.58) when 
compared to very light consumption (0.1-4.9 g/d).   In addition to ingestion of the 
nitrosamine NDMA, heavy alcohol consumption also increases exposure to ethanol and 
its major metabolite acetaldehyde, a known carcinogen.  Acetaldehyde has been found to 
induce DNA lesions and bind to enzymes which are involved in DNA repair and 
antioxidant protection.  The potential mechanism through which alcohol exerts its effect 
on stomach cancer risk is likely through the combined effects of acetaldehyde and 
nitrosamines in the gastric mucosa [53].  
 
1.2.2.4. Smoking 
Smoking has been examined as a risk factor for stomach cancer risk in numerous studies.  
In 2002, the International Agency for Research on Cancer reported that there was 
“sufficient” evidence to support a causal relationship as a result of moderately increased 
risk that was reported in both cohort and case-control studies.  A recent prospective study 
conducted in Shanghai, China concluded that ever smokers were at increased risk of 
stomach cancer (HR=1.59; 95% CI 1.27, 1.99) compared with non-smokers after 
adjustment for confounders, such as alcohol intake.  The statistically significant positive 
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association reported in this high-risk population between smoking and stomach cancer 
risk among non-drinkers suggested an independent role of tobacco use in the risk for 
stomach cancer.  The biological mechanism through which smoking leads to increased 
stomach cancer risk is not well understood.  However, it has been shown that tobacco 
smoke contains more than 60 known carcinogens.  Thus, nitrosamines and other nitroso 
compounds in cigarette smoke are likely involved in gastric carcinogenesis.  In addition, 
it has also been shown that smoking is associated with increased frequency of 
progression from normal gastric mucosa to precancerous lesions [55].  
 
 
1.2.3. Rationale for analyses 
Asian Americans are the only major racial/ethnic group in the U.S. that experiences more 
annual deaths due to cancer than heart disease.  They are at higher risk for tumors 
associated with infectious agents, such as stomach cancer.  Incidence rates for stomach 
cancer among certain subpopulations of Asian-American men have been reported as 6-
fold higher compared to non-Hispanic white men.  A study conducted in California 
reported that the incidence rate for Korean men was approximately 54.6 per 100,000, 
while the rate for non-Hispanic white men was 9.5 per 100,000.  Mortality attributable to 
stomach cancer was also greatest among Korean males (35.2 per 100,000) and females 
(13.9 per 100,000) compared to other racial/ethnic groups [1]. 
 
It has been observed that Asian populations with more recent immigration histories to the 
U.S., such as Koreans and Vietnamese, experience a greater burden of cancers that are 
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usually not found at high rates in developed countries.  The unusually high rates of 
stomach cancer found among Korean-Americans are one such example of this trend [1].  
However, despite higher incidence of gastric cancer, Asian countries consistently report 
more favorable outcomes related to disease compared to Western countries.  This can be 
seen when examining 5-year survival in Japan (40-60%) compared to the U.S. and 
Europe (15-20%).  A potential reason for these variations in survival between regions 
likely includes inherent differences in tumor biology.  In Western countries, proximal 
(cardia) gastric tumors are more common while the majority of tumors found in Asia are 
distal (non-cardia) tumors [56].   
 
As described previously, the presence of the “Asian enigma” does not allow for accurate 
estimates of stomach cancer burden if various Asian populations are combined to create 
one group known as Asian/Pacific Islander.  Rates of H. pylori infection and subsequent 
gastric cancer rates vary greatly among the different Asian regions.  Thus, it is necessary 
to examine the role of race/ethnicity on gastric cancer outcomes in order to tailor 
interventions to those at greatest risk of unfavorable outcomes.  To date, the national 
burden of stomach cancer in Asian subpopulations has not been examined extensively in 
the U.S.  As seen in Table1-2, gastric cancer incidence has not been examined 
thoroughly using all available national SEER registries.  Kamineni et al examined the 
burden of gastric cancer among U.S.-born and foreign-born Asian immigrants in 
California between 1973 and 1986 [57].  We aim to update and extend these results to 
include additional subpopulations and all available nationwide SEER registries to 
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describe current differences in stage at diagnosis and survival of stomach cancer in the 
U.S. 
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1.3. Cervical cancer 
1.3.1. Epidemiology in the U.S. 
In 2013, it is estimated that 12,340 new cases of cervical cancer will be diagnosed in the 
U.S.  In addition, it will be associated with 4,030 deaths [9].  It is currently the 13th most 
common cancer among women in the U.S.  Rates of incidence and mortality have 
decreased by more than 75% since the 1940s due to the introduction and implementation 
of screening and treatment of pre-cancerous lesions in the cervix.  The age-adjusted 
incidence has decreased from 14.8 per 100,000 in 1975 to 6.6 per 100,000 in 2008.  
Though the overall incidence and mortality rates of cervical cancer have decreased in 
recent years, disparities in burden of disease persists.  More than 60% of cases in the U.S. 
are diagnosed in underprivileged groups including racial/ethnic minorities and women 
living in poverty who are less likely to have access to screening and treatment [59].  The 
highest incidence rates are reported for Hispanic women (14.4 per 100,000), while the 
lowest rates are reported for Asian/Pacific Islander women (8.8 per 100,000) [60].  
Fortunately, more than half of all cervical cancers are usually diagnosed at the localized 
stage [61].  
 
The introduction of the Papanicolaou (Pap) test in the 1940s led to the widespread 
decrease in cervical cancer incidence in the U.S. and other developed countries.  Since 
most cervical carcinomas are classified as squamous cell carcinomas (SCC), the decline 
in incidence and mortality can be attributed largely to the ability of screening tests to 
detect pre-invasive SCC.  However rates of the rarer subtype, cervical adenocarcinoma 
(AC), have been on the rise in developed nations in North America and Europe as well as 
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developing nations such as India and Japan.  This increase in incidence may be due to 
improved methods of screening which now allow for increased recognition and detection 
of AC lesions that were previously undetected and classified as unknown histology in 
earlier decades [62].  It is known that the Pap test can more readily detect squamous cell 
types rather than glandular cell types which give rise to ACs.  This is due to the anatomy 
of the cervix since endocervical tissue which contains glandular cells is more difficult to 
sample during a Pap test compared to the squamous epithelium of the ectocervix.  This is 
also the cause of late stage presentation and diagnosis that is often reported for ACs [63]. 
 
Several studies have documented lower rates of cancer screening overall among Asian 
Americans.  While disparities in screening between non-Hispanic whites, Latinos, and 
blacks in the U.S. can be explained by socioeconomic status and access to care, this is not 
the case for Asian Americans.  For this population, the most significant factors that play a 
role in reduced rates of screening are nativity and language.  Most Asians in the U.S. are 
foreign-born and migrate from countries where limited attention is given to chronic 
disease prevention and where population-based screening services are not available.  A 
study examining screening behaviors among Chinese, Filipino, Vietnamese, Korean, 
Japanese, South Asian, and Cambodian populations in the U.S. found that foreign-born 
status and living in the U.S. fewer years were both significantly and independently 
associated with lower rates of cervical cancer screening compared to those classified as 
U.S.-born.  Foreign-born Asians were also more than twice as likely as U.S.-born non-
Hispanic whites to report that the most important factor contributing to not undergoing 
screening tests was because “they haven’t had problems or symptoms.”  Thus, certain 
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subpopulations of Asian women still remain at increased risk for cervical cancer due to 
lack of screening.  It is the leading type of cancer among Korean, Vietnamese, and 
Cambodian women, while high mortality rates are found among Chinese women.  
Significant disparities remain in cervical cancer screening, regardless of insurance, access 
to care, and socioeconomic status [64]. 
 
1.3.2. Risk factors 
1.3.2.1. Human papillomavirus (HPV)  
Human papillomavirus (HPV) has long been identified as a necessary cause of cervical 
cancer.  The natural history of cervical cancer begins by acquiring a sexually transmitted 
carcinogenic HPV infection [65].  Virtually all cases are attributable to persistent infection 
with one of almost 15 types of oncogenic genotypes of HPV.  HPV16 and HPV18 are the 
two most common forms of HPV and responsible for 70% of all cervical cancers and 
almost 50% of cervical intraepithelial neoplasia grade 3 (CIN3) [66].  Almost half of all 
HPV infections are undetectable within 6-12 months and greater than 90% of infections 
clear within a few years [67].  Knowledge of HPV’s role in the etiology of cervical cancer 
has led to preventive methods, such as vaccines and HPV-based screening, that focus on 
early stages of infection [65]. 
 
Cervical cancer develops through progression of four stages of carcinogenesis: HPV 
infection, viral persistence rather than clearance, development of high-grade precursor 
lesion, and invasion. It is known that most sexually active women are infected with at 
least one form of HPV during their lifetime.  In addition, millions of women are 
diagnosed annually with some form of abnormality when screened for cervical lesions.  
27 
 
However, almost all abnormalities are cleared without need for treatment.  The majority 
of cervical HPV infections are cleared or suppressed within 1-2 years after exposure by 
cell-mediated immunity mechanisms.  Longer persistence of HPV leads to decreased 
probability of clearance and increased likelihood of pre-cancer diagnosis [66].   About 
10% of carcinogenic infections that persist for several years are strongly associated with 
an increased risk of pre-cancer.  In the pre-cancer stage, undifferentiated cells with fixed 
genetic abnormalities replace the majority of the cervical epithelium.  The interval 
between infection and first evidence of a pre-cancerous lesion is usually about five years.  
Average age at diagnosis of pre-cancer is usually between 25 and 35 years, dependent 
upon age at first intercourse and the intensity of screening within the population.  HPV16 
is the most carcinogenic genotype, with an absolute risk of pre-cancer diagnosis at almost 
40% following 3-5 years of persistent infection.  The age range at which risk of invasive 
cervical cancer peaks in unscreened populations is usually between 35 and 55 years.  This 
peak in incidence occurs much earlier than for most other adult cancers.  One reason for 
this early age at diagnosis is likely that cervical cancers occur as a result of HPV 
infections acquired in late adolescence and early adulthood.  In addition, the interval 
between infection and development of pre-cancer is relatively short.  HPV16, 18, and 45 
are found in more cancers and pre-cancers compared to other genotypes.  An important 
distinction between infection and pre-cancer is integration of HPV DNA into the host 
genome, since integration is associated with invasive cancer.  Continuous transcriptional 
activity from HPV oncogenes is necessary for maintenance of the cancer [66]. 
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In the U.S., HPV is believed to be the most sexually transmitted infection.  Prevalence of 
the infection is usually reported to be the highest among young persons within a few 
years following first sexual intercourse.  According to the NHANES 2003-2004, HPV 
prevalence (44.8%) was highest among females aged 20 to 24 years.  In addition, there 
was a statistically significant trend for increasing prevalence for each year of age between 
14 and 24 years.  The overall HPV prevalence among females aged 14 to 59 years was 
26.8% [68].    
 
The prevalence of HPV infection among Asian subpopulations in the U.S. has not been 
extensively studied.  However, geographical variation in the prevalence of HPV 
genotypes has been examined.  It has been reported that though high-risk HPV types 52 
and 58 are not commonly found in most populations, they are common among Chinese 
and Japanese women.  A study in Vietnam reported that the prevalence of HPV infection 
among women aged 25 years and older is about 7.6% to 10.9%.  This high prevalence is 
one explanation for the significantly high incidence of cervical cancer reported among 
Vietnamese women in the U.S. who have reported low rates of Pap test screening [69].  A 
recent population-based study conducted in China found the prevalence of HPV among 
the general population to be about 18.4% [70].  Relatively high rates of HPV infection 
(>10%) are also found among women of South Asian origin [71]. 
 
1.3.2.2. Oral contraceptive use 
The likelihood of a woman infected with HPV subsequently progressing to persistent 
infection or cervical cancer may be affected by other factors, such as use of hormonal 
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contraceptives.  A systematic review of this association concluded that the relative risk of 
cervical cancer increased with increasing duration of use of oral contraceptives among 
women who were HPV-positive.  The relative risks associated with duration of use less 
than 5 years, 5-9 years, and 10 years or more were as follows: 0.90 (95% CI 0.70, 1.20), 
1.30 (95% CI 1.00, 1.90), and 2.50 (95% CI 1.60, 3.90) respectively [72].  The biological 
mechanisms associated with contraceptive use through which infection progresses to 
carcinogenesis remain unclear.  It has been hypothesized that contraceptive use may 
affect the likelihood of clearance or persistence of HPV infection.  It may also affect the 
regression or progression of pre-neoplastic and neoplastic lesions [73]. 
 
1.3.2.3. Parity 
Multiparity has been associated with increased cervical cancer risk for several decades.  
While it has been argued that other reproductive characteristics may affect this 
relationship, an independent role in cancer risk has been observed for multiparity while 
also controlling for potential confounders that indicate sexual habits and behaviors.  A 
pooled analysis investigating this association found that high parity increased the risk of 
squamous cell carcinoma of the cervix among women classified as HPV-positive.  The 
odds ratio associated with seven or more full-term pregnancies and risk of cervical cancer 
was 3.80 (95% CI 2.70, 5.50) compared with nulliparous women.  When comparing 
women with seven or more full-term pregnancies to those who had one or two full-term 
pregnancies, the odds ratio was found to be 2.30 (95% CI 1.60, 3.20).  Serum 
concentrations of progesterone and estrogen increase steadily during pregnancy and reach 
their highest concentrations during the last weeks before delivery.  These hormonal 
30 
 
variations are likely a cause for alterations in the transformation zone of the cervix, where 
most cancerous lesions are thought to arise.  Thus, the role of high parity on cervical 
cancer risk may be through its effect on the transformation zone by causing it to be 
vulnerable to direct exposure from HPV infection [74]. 
 
1.3.2.4. Smoking 
Several studies have found an association between smoking and increased risk of cervical 
cancer and its immediate precursor, cervical intraepithelial neoplasia grade 3 (CIN3).  
Biological plausibility that provides support for this association includes the presence of 
nicotine derived carcinogens found in cervical mucus following smoking.  A study 
examining the role of smoking as a risk factor for CIN3 among HPV-positive women 
found that current smokers (OR=1.70; 95% CI 1.40, 2.10) and past smokers (OR=1.70; 
95% CI 1.20, 2.40) were at increased risk for CIN3 or cancer compared to non-smokers.  
In addition, greater intensity of smoking and duration strengthened the magnitude of this 
association.  It is likely that smoking exerts an effect on the interaction between HPV 
infection and biological processes in the host through a mechanism which increases the 
likelihood of pre-malignant change in the cervix.  Since the presence of carcinogenic 
metabolites produced by smoking has been detected in cervical secretions, smoking may 
increase the risk for CIN3 by promoting viral persistence or through producing genomic 
damage through genotoxins [75]. 
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1.3.3. Rationale for analyses 
Major health disparities in cervical cancer incidence and mortality have been documented 
among Asian-American women.  Women of Vietnamese origin have incidence rates that 
are up to five times higher than non-Hispanic white women in the U.S. [76].  A study 
examining the burden of cervical cancer among Asian populations in California found 
that it greatly varies among subpopulations.  Vietnamese and Korean women were found 
to have greater incidence rates compared to non-Hispanic whites.  In addition, it was 
found that the rates found among Asian women in the U.S. broadly mirrored rates found 
in their countries of origin.  The exception to this general finding was among South Asian 
women.  Though relatively high cervical cancer incidence rates are found in India, the 
South Asians living in California had the lowest rates compared to other subpopulations.  
This difference in rates is likely attributable to the high level of education found among 
South Asians in the U.S. compared to other Asian populations [77].   Studies conducted 
among Asian-American women have shown that this group lacks proper knowledge 
regarding cervical cancer risk and testing.  In addition, cultural attitudes towards sexual 
activity may also contribute to the disparity and lower rates of screening [76]. 
 
Though great advances in early detection of cervical cancer have been achieved in the 
U.S. through improved screening practices, the burden of disease remains 
disproportionately high among immigrant and minority women.  It has been estimated 
that 50% of those diagnosed with cervical cancer have never been screened.  More than 
half of the total deaths due to cervical cancer in the U.S. occur among foreign-born 
women.  In addition to cultural and socioeconomic barriers to proper screening, these 
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women also experience less timely contact overall with the health care system.  Despite 
the potential to reduce disparities in cervical cancer outcomes through widespread HPV 
vaccine coverage, these sociocultural barriers prevent proper vaccination among 
immigrant women and adolescent girls [78].  Although factors contributing to low 
prevalence of screening have been identified among Asian immigrant women, few 
programs have been developed to increase screening uptake in this population.  The 
majority of interventions have targeted Vietnamese-American women and have been 
community-based [79]. 
 
As stated previously, distinct differences in overall incidence of cervical cancer have 
been found among Asian subpopulations residing in California.  Evaluation of this group 
as an aggregate will therefore mask true variations that are associated with known and 
unknown socioeconomic, cultural, and behavioral differences [80].  As shown in  
Table 1-3, the burden of cervical cancer in these individual subpopulations has not been 
extensively examined using all of the available registries in SEER.  Such differences 
among racial/ethnic groups may suggest varying ages at onset of infection and may 
require changes in recommendations for immunizations and screening in certain 
populations.  Thus, we aim to examine subpopulations of the Asian population to 
describe current differences in stage at diagnosis and survival of cervical cancer in the 
U.S.  Assessment of these differences will allow us to determine which specific 
subpopulations are in need of targeted interventions to reduce the burden of this disease. 
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 1.4. Breast cancer 
1.4.1 Epidemiology in the U.S. 
Breast cancer is the most common cancer and the second leading cause of death 
attributable to cancer among women in the United States [9].  There are currently 
approximately three million women in the U.S. who have been diagnosed with invasive 
breast cancer [81].  It has been estimated that breast cancer will account for about 29% of 
new cancer cases diagnosed among women in 2013.  This amounts to approximately 
232,340 incident cases.  In addition, breast cancer is the second leading cause of cancer 
mortality among women and accounts for about 14% of deaths [9].  The median age of 
diagnosis has been reported to be 61 years.  When examining age at diagnosis, 20% of 
cases occur among those younger than 50 years and 60% of cases occur among those 65 
years and older.  Diagnosis occurs at a localized stage for 60% of cases [81].  
 
In 2010, breast cancer was reported as the cancer site with the highest cost of care, with 
almost $16.5 billion in medical expenditures.  It is projected that this cost will increase 
32% by 2020 [82].  In elderly populations, the cost of breast cancer care amounts to $1,923 
in average monthly expenditure.  Due to longer than usual survival compared to other 
cancer sites, patients diagnosed with breast cancer face higher costs during the time 
between initial diagnosis and the last year of life [83]. 
 
Historically, trends in breast cancer incidence can be summarized as follows: stable 
increase from 1940s to 1979, steep increase from 1980 to 1999, decrease from 2000 to 
2003, and relatively stable rates after 2003 [84].  The increase in incidence reported in the 
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1980s was likely attributable to the introduction of mammography screening.  In addition, 
changes in reproductive behaviors were also occurring during this time, such as delayed 
pregnancy and having fewer children.  Use of menopausal hormones likely contributed to 
the increase in incidence in the late 1990s.  The decline in rates found in the early 2000s 
was likely due to decreased use of menopausal hormones following the publication of 
results from the Women’s Health Initiative reporting the association between these 
hormones and increased risk of breast cancer [85].  Unfortunately, incidence rates did not 
continue to decrease after 2003.  Several factors may contribute to this apparent 
stabilization of incidence.  One possible explanation may be the relatively stable rates of 
mammography screenings that have been conducted since 2000 [86].  When examining 
breast cancer mortality rates, increasing trends were observed between 1975 and 1990.  
Rates decreased by about 2.2% per year between 1990 and 2007.  This decrease in 
mortality rates was greater among women younger than 50 years compared to those 50 
years or older.  The decline in mortality rates was largely due to improvements in both 
early detection and treatment [85]. 
 
1.4.2. Risk factors 
1.4.2.1. Endogenous sex hormones 
Estrogen and progesterone are sex hormones produced by the ovaries.  Cumulative 
exposures to these hormones through various reproductive processes contribute breast 
carcinogenesis through their ability to stimulate cell proliferation.  The likelihood of 
genetic mutations is increased through the effects of estrogen which include stimulating 
ductal growth and increasing rates of cell proliferation.  Progesterone also stimulates cell 
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proliferation.  Cumulative exposure to circulating levels of estrogen and progesterone 
during a woman’s reproductive years has the greatest impact on breast cancer risk.  
Proliferation rates of breast epithelial cells are high during the luteal phase of a woman’s 
menstrual cycle when the circulating levels of estrogen and progesterone are relatively 
high.  However, breast cell proliferation is relatively low after menopause when estrogen 
levels are low and progesterone is absent [87]. 
 
1.4.2.2. Age at menarche 
Early age at menarche has been established as risk factor for breast cancer.  The risk of 
breast cancer decreases by 10% -20% with each additional year delay in the onset of 
menarche.  In addition to age at onset of menarche, the time at which menstrual cycles 
become regular is also associated with risk.  It has been found that breast cancer risk is 
doubled for those women who have regular cycles within 1 year of their first menstrual 
period compared to those who only have regular cycles after five years or longer.  In 
addition, those with early age at menarche at age 12 years or younger who had 
established regular cycles within the first year of onset of their menstrual period have 
almost four times greater risk compared to those with age at menarche at age 13 years or 
later and longer duration of time with irregular cycles [87].  Reproductive processes that 
occur during the menstrual cycle reflect the underlying levels of circulating estrogen and 
progesterone.  As a consequence, a shorter cycle length indicates a longer luteal phase 
during which proliferation of breast epithelial cells and circulating estrogen and 
progesterone are at their highest levels.  Thus, due to higher rates of cell division, a 
shorter cycle length infers higher breast cancer risk [88].    
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1.4.2.3. Parity and age at first full-term pregnancy 
Parity and early age at first full-term pregnancy are two of the earliest known protective 
factors for breast cancer.  One early study found that the breast cancer risk for single and 
nulliparous married women was about 1.4 times the risk for parous married women.  On 
average, women who have experienced at least one full-term pregnancy have about 25% 
reduced risk compared to nulliparous women [89].  In addition, women who had their first 
birth at age 20 years or younger had about half the risk compared to those women whose 
first birth occurred at age 30 years or older [87].  It has been proposed that the protective 
effect of early age at first full-term pregnancy may be due to the terminal differentiation 
of mammary gland epithelium that is induced through pregnancy.  This differentiation 
reduces the likelihood of formation of precancerous lesions in the breast [90].  Increasing 
parity continues to reduce risk through the extended differentiation that is induced by 
repeated pregnancy.  Older age at first pregnancy likely infers greater risk due to an 
increased length of time when the breasts are susceptible to carcinogens attributed to the 
presence of undifferentiated cells [91].   
 
1.4.2.4. Breastfeeding 
Breastfeeding has been shown to be associated with decreased breast cancer risk.  
Substantial risk reductions have been found for parous pre-menopausal and post-
menopausal women who reported breastfeeding for longer than 15 months.  Compared to 
those who never breastfed, a 35% reduction in risk was found for pre-menopausal women 
and 30% reduction in risk was found for post-menopausal women [87].  The U.S. Cancer 
and Steroid Hormone Study which examined the association between breastfeeding and 
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breast cancer risk found that those who reported breastfeeding for at least 25 months had 
33% reduced risk compared to those who never breastfed after controlling for parity and 
age at first full-term pregnancy [89].  Breastfeeding is thought to infer its protective effect 
through causing a reduction in a woman’s cumulative number of menstrual cycles.  There 
is a significant delay in the return to experiencing regular cycles following a completed 
pregnancy [87].  The protective effect attributable to breastfeeding is likely stronger in 
younger women compared to older women [89]. 
 
 
1.4.2.5. Age at menopause 
The duration of time between onset of menstrual cycles and menopause represents a 
woman’s cumulative lifetime exposure to substantial levels of reproductive hormones.  
Thus, after menopause the circulating levels of these hormones are significantly lower.  
These reproductive processes also have an effect on the rate of breast cell proliferation 
and accumulation of damage to DNA [92].  Breast cancer incidence rates have been shown 
to plateau or increase more slowly following menopause [87].  The protective effect of 
menopause can often be seen by the slower rate of increase in incidence at around age 50 
years [89].  Late age at menopause has consistently been shown to be associated with 
increased breast cancer risk.  Those who experience early menopause have a shorter 
duration of menstrual cycles and less exposure to the hormones associated with them.  
The risk of breast cancer is about two times greater for women whose last menstrual 
period occurs at age 55 years or later compared to those who experience their last period 
at age 45 years or younger [87].  Risk has been found to increase by approximately 3% for 
each year that menopause is delayed.  Due to the protection conferred by reaching 
38 
 
menopause, pre-menopausal women are at greater risk compared to women of the same 
age who are post-menopausal [89].  
 
1.4.2.6. Oral contraceptives 
It was originally believed that use of oral contraceptives increased breast cancer risk due 
to the hormones that they contained.  It was thought that provided the body with higher 
levels of estrogen and progesterone than would have been produced during a normal 
ovulatory cycle, especially if use began at an early age.  However, a re-analysis of data 
collected from 54 different studies conducted by the Collaborative Group on Hormonal 
Factors in Breast Cancer reported that recent oral contraceptive use rather than long 
duration of use contributed more to breast cancer risk [87].  There is almost 25% increased 
risk in current users of combined oral contraceptives.  However, this risk decreases after 
cessation of use.  A significant increased risk is no longer evident 10 or more years 
following cessation.  It has also been found that use of combined oral contraceptives is 
associated more with localized tumors rather than those that have spread to other organs 
beyond the breast.  This finding suggests that the increased risk found among recent users 
may in part be attributable to increased screening practices [89].   
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1.4.2.7. Post-menopausal hormones 
Use of hormonal therapy for treatment of menopausal symptoms is often initiated at a 
time when the underlying for breast cancer is relatively high [89].  Several studies 
examining large cohorts of women who have reported prolonged use of estrogen 
replacement therapy for more than 10 year periods have found increased breast cancer 
risk.  Risk has been reported to increase by about 3% per year of use.  Combined 
hormone replacement therapies which include progestin in addition to estrogen increase 
risk substantially through enhancing the proliferative effects of estrogen.  When progestin 
is added to create a combined therapy, the increase in risk resulting from five years of use 
changes from 10% to 30% [87].  The results of the Women’s Health Initiative study 
published in 2002 shed light on the risks associated with hormone replacement therapy.  
An increased breast cancer risk was found among subjects in the combined therapy arm 
of this placebo-controlled trial.  Those in the treatment arm with combined estrogen and 
progesterone had 25% greater risk of invasive breast cancers compared to those in the 
placebo arm [93].  Similar findings were reported in the Million Women Study conducted 
in the United Kingdom [94].  These findings largely contributed to the widespread 
cessation of hormone replacement therapy and the subsequent decrease in overall breast 
cancer incidence rates [95].     
 
1.4.2.8. Diet 
There have been inconsistencies across studies regarding the effect of dietary intake on 
breast cancer risk.  The Women’s Health Initiative Dietary Modification Trial reported 
that breast cancer incidence was 9% lower in the low fat intake intervention group 
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compared to the control group.  The European Prospective Investigation into Cancer and 
Nutrition reported a weak positive association between saturated fat intake and risk.  
Despite inconsistencies across studies, there is biological plausibility to support an 
association between dietary intake and breast cancer risk.  One such hypothesis is that 
increased fat intake may increase the concentration of endogenous estrogen.  Several 
intervention studies have reported lower concentrations and bioavailability of serum sex 
hormones among those with lower fat intake.  In addition, Consumption of saturated fat 
may be associated with increased risk through having adverse effects on insulin 
resistance.  Studies have reported associations between plasma concentrations of insulin, 
C peptide, and insulin growth factor-I and breast cancer risk [96].  Inconsistencies in 
results have also been found for studies examining the association between fruit and 
vegetable intake and breast cancer risk.  There are plausible biological mechanisms to 
support this relationship.  Several fruits and vegetables contain substantial amounts of 
protective factors such as fiber, antioxidant vitamins, minerals, and other anti-
carcinogenic compounds [97].  Several large prospective studies examining this 
relationship have reported nearly null results [98].   
 
1.4.2.9. Alcohol 
Alcohol repeatedly has been shown to increase breast cancer risk.  In 2007, the 
International Agency for Research on Cancer stated there was sufficient evidence to 
conclude that alcohol causes cancer of the female breast [99].  Alcohol likely infers risk 
through its effect plasma concentrations of estrogen.  An analysis of subjects enrolled in 
the Women’s Health Study found a significant 43% increased risk for invasive breast 
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cancer among those who consumed at least 30 grams of alcohol daily compared to those 
who did not report consumption [100].  Consumption has also been shown to increase the 
risk of recurrence.  One study reported risk of recurrence as 1.3 times greater among 
those consumed three to four or more drinks per week.  In addition, this association was 
stronger among post-menopausal and overweight or obese women [101]. 
 
1.4.2.10. Obesity 
Obesity and weight gain during adult years are associated with increased risk of breast 
cancer, especially among post-menopausal women.  In 2002, the International Agency for 
Research on Cancer concluded that there was adequate evidence to support an association 
between obesity and post-menopausal breast cancer [102].  There are several biological 
mechanisms through which factors related to being overweight or obese may exert their 
effect on breast carcinogenesis.  Obese women have been found to have 35% higher 
concentrations of estrogen and 130% higher concentrations of estradiol compared to 
women classified as non-obese.  In addition, increasing levels of adiposity are also 
associated with increasing plasma concentrations of testosterone.  A strong inverse 
association is also present between obesity and sex-hormone-binding globulin (SHBG) 
levels.  Low plasma quantities of SHBG contribute to the bioavailability of androgens 
and estrogen.  Obese women also likely have concomitant hyperinsulinaemia which may 
stimulate mammary carcinogenesis through increasing levels of insulin-like growth factor 
and leptin [103].  Among post-menopausal women, the risk of breast cancer has been 
reported to be 50% higher among those who gained between 15 and 20 kilograms 
compared to women who maintained their weight [104].  High BMI is also associated with 
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a small increase in risk for larger tumors due to enhanced proliferation attributable to 
higher concentrations of circulating hormones which promote growth [105]. 
 
1.4.2.11. Family history 
About 7% of breast cancer cases are attributable to inherited genetic mutations.  Two 
such susceptibility genes that carry mutations are breast cancer susceptibility gene 
1(BRCA1) and breast cancer susceptibility gene 2 (BRCA2).  These genes are tumor 
suppressors located on the long arms of chromosomes 17 and 13.  BRCA1 and BRCA2 
proteins aid in double-strand break repair following damage to DNA.  They also function 
as transcriptional co-regulators [106].  The highest population prevalence rates of these 
genes have been found among Ashkenazi Jews.  The cumulative lifetime risk for women 
who carry mutations in either BRCA1 or BRCA2 can be as high as 80%.  On average, 
neoplasms of the breast found among carriers of these mutations are of a higher grade 
than those of non-carriers [107].  In addition, women with these familial genes likely will 
have an earlier age at onset compared to sporadic cases [108].  A carrier of a BRCA1 or 
BRCA2 mutation has almost a 3% risk of being diagnosed with breast cancer before age 
30.  This risk increases to about 50% by age 50 and increases again to between 50% and 
80% by age 70 [109].   
 
1.4.3. Rationale for analyses 
Studies of disease incidence in migrant populations residing in their host countries offer 
vital insight into factors, both environmental and genetic, that play a role in etiology.  
Migrant populations have been found to experience a change in risk for breast cancer that 
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differs from the risk of their native countries.  Thus, this change is likely due to 
environmental factors that contribute to disease [110].  Migrant studies examining breast 
cancer mortality have also suggested the importance of behavioral factors as significant 
indicators of disease outcomes [111].  
 
In the U.S. today, breast cancer incidence rates have been found to differ significantly by 
racial/ethnic groups.  When examining individual groups, the lowest overall rates are 
found among Asians.  In addition, there are substantial differences in incidence within the 
Asian group alone.   It has been reported that there is likely almost a three-fold difference 
in incidence rates of breast cancer between the populations with the highest (Japanese) 
and lowest (Laotian) rates.  Closer examination of specific Asian populations may reveal 
significant heterogeneity in lifestyles, risk factors, and health care behaviors that all 
contribute to differences in cancer outcomes [112].  When examining Asians living in the 
U.S, it has been found that these populations are heterogeneous with regard to 
immigration and acculturation.  These two factors likely play a significant role in 
explaining varying cancer outcomes [113].  Previous studies conducted in the U.S. 
examining breast cancer incidence among Asian subpopulations in the U.S. are 
summarized in Table 1-4.  We aim to update these findings and examine differences in 
stage at diagnosis and survival among Asian subpopulations in the U.S. 
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1.6. Tables and Figures 
Table 1-1: Characteristics of studies examining liver cancer incidence among Asian subpopulations in the U.S. 
Reference Source of data Asian subpopulations examined Comparison of incidence 
(Asian vs. NHW1) 
McCracken et al, 2007 [1] California Cancer Registry Chinese, Filipino, Vietnamese, 
Korean, Japanese 
Asian > NHW 
Jain, Mills, Parikh-Patel, 2005 [38] California Cancer Registry South Asians Asian > NHW 
Rosenblatt, Weiss, Schwartz, 1996 
[39]
 
SEER (Hawaii & San 
Francisco/Oakland only) 
Chinese, Japanese, Filipino Asian > NHW 
Miller et al, 2008 [4] SEER 14 South Asians, Chinese, Filipino, 
Japanese, Korean, Vietnamese, 
Laotians 
Asian > NHW 
Chang et al, 2010 [40] California Cancer Registry Chinese, Japanese, Filipino, 
Korean 
N/A 
(Asian > Hispanics) 
Chang et al, 2007 [15] Greater Bay Area Cancer Registry Chinese, Japanese, Filipino, 
Korean, Vietnamese 
Asian > NHW 
Kwong et al, 2005 [2] California Cancer Registry Chinese, Japanese, Filipino, 
Korean, Vietnamese 
N/A 
Gomez et al, 2003 [41] SEER and California Cancer 
Registry 
Korean Asian > NHW 
Le et al, 2002 [42] SEER and California Cancer 
Registry 
Vietnamese Asian > NHW 
1NHW= non-Hispanic white 
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Figure 1-1: Age-adjusted incidence rates of liver cancer in the U.S. comparing Asian/PI 
and non-Hispanic whites, 1999-2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2: Liver cancer stage at diagnosis in the U.S. by race/ethnicity 
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Table 1-2: Characteristics of studies examining stomach cancer incidence among Asian subpopulations in the U.S 
Reference Source of data Subpopulations examined Comparison of incidence 
(Asian vs. NHW1) 
McCracken et al, 2007 [1]  California Cancer Registry Chinese, Filipino, Vietnamese, 
Korean, Japanese 
Asian> NHW 
Kamineni et al, 1999 [57] SEER (Hawaii, San Francisco/Oakland, 
Washington only) 
Chinese, Japanese, Filipino Asian> NHW 
Kwong et al, 2005 [2] California Cancer Registry Chinese, Filipino, Japanese, Korean, 
Vietnamese 
N/A 
Gomez et al, 2003 [41] SEER, California Cancer Registry, 
IARC 
Korean Korean> NHW 
Miller et al, 2008 [4] SEER Chinese, Filipino, Japanese, Korean, 
Vietnamese, South Asian 
Asian> NHW 
Le et al, 2002 [42] SEER, California Cancer Registry, 
IARC 
Vietnamese Vietnamese> NHW 
Yang, Mills, Riordan, 2005 [58]  California Cancer Registry Hmong Hmong> NHW 
1NHW= non-Hispanic white 
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Figure 1-3: Age-adjusted incidence rates of stomach cancer in the U.S. comparing 
Asian/PI and non-Hispanic whites, 1999-2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-4: Stomach cancer stage at diagnosis in the U.S. by race/ethnicity 
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Table 1-3: Characteristics of studies examining cervical cancer incidence among Asian subpopulations in the U.S. 
Reference Source of data Subpopulations examined Comparison of incidence 
(Asian vs. NHW1) 
Bates et al, 2008 [77] California Cancer Registry Chinese, Japanese, Filipino, 
Korean, South Asian, Vietnamese 
Vietnamese, Korean> NHW 
McCracken et al, 2007  
[1]
 
California Cancer Registry Chinese, Filipino, Vietnamese, 
Korean, Japanese 
Asians> NHW 
Wang et al, 2010 [80]  SEER (Hawaii, LA, Seattle, San 
Francisco-Oakland, San Jose-
Monterey only) 
Chinese, Filipino, Japanese, 
Vietnamese, Korean, South Asian 
Asians> NHW 
Jain, Mills, Parikh-
Patel, 2005 [38] 
California Cancer Registry South Asian South Asians> NHW 
Gomez et al, 2003 [41] SEER and California Cancer 
Registry 
Korean Korean> NHW 
Le et al, 2002 [42] SEER and California Cancer 
Registry 
Vietnamese Vietnamese> NHW 
Miller et al, 2008 [4] SEER Chinese, Filipino, Japanese, 
Korean, Vietnamese, South Asian 
Asians> NHW 
1NHW= non-Hispanic white 
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Figure 1-5: Age-adjusted incidence rates of cervical cancer in the U.S. comparing 
Asian/PI and non-Hispanic whites, 1999-2009 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-6: Cervical cancer stage at diagnosis in the U.S. by race/ethnicity 
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Table 1-4: Characteristics of studies examining breast cancer incidence among Asian subpopulations in the U.S. 
Reference Source of data Asian subpopulations examined Comparison of incidence 
(Asian vs NHW1) 
Moran et al, 2011 [114] SEER South Asian South Asian< NHW 
Goggins & Wong, 2009 [5]  SEER South Asian South Asian< NHW 
Keegan et al, 2007 [115]  Greater Bay Area (SEER) Chinese, Japanese, Filipino, 
Korean, South Asian, Vietnamese 
N/A 
Stanford et al, 1995 [111] SEER (Hawaii, San 
Francisco/Oakland, Washington) 
Chinese, Japanese, Filipino Asian< NHW 
Deapen et al, 2002 [116] Los Angeles Cancer Surveillance 
Program 
Chinese, Japanese, Filipino, 
Korean 
Asian< NHW 
Miller et al, 2008 [4] SEER Chinese, Japanese, Filipino, 
Korean, South Asian, Vietnamese 
Asian< NHW 
McCracken et al, 2007 [1] California Cancer Registry Chinese, Filipino, Vietnamese, 
Korean, Japanese 
Asian< NHW 
Gomez et al, 2010 [112]  California Cancer Registry Chinese, Japanese, Filipino, 
Korean, South Asian, Vietnamese 
Asian< NHW 
Kwong et al, 2005 [2] California Cancer Registry Chinese, Filipino, Japanese, 
Korean, Vietnamese 
N/A 
1NHW= non-hispanic white 
 
 
 
 
Figure 1-7: Age-adjusted incidence rates of breast cancer in the U.S. comparing Asian/PI 
and non-Hispanic whites, 1999
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-8: Breast cancer stage at diagnosis in the U.S. by race/ethnicity
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2. STAGE AT DIAGNOSIS AND STAGE-SPECIFIC SURVIVAL OF 
INFECTION-ASSOCIATED (CERVICAL, LIVER, STOMACH) CANCERS 
AMONG SOUTH ASIANS AND OTHER ASIAN SUBPOPULATIONS IN THE 
UNITED STATES  
 
 
 
2.1. Abstract 
Though Asian Americans report low rates for major cancers, such as lung, colon, and 
prostate, they report high rates of cancers associated with infectious agents, including 
cancers of the cervix, liver, and stomach.  South Asians comprise a major Asian 
American subpopulation whose cancer burden has not been adequately examined and 
documented in the literature.  In order to better understand and address the outcomes 
associated with infection-associated cancers in the South Asian population in the U.S., 
we examined this group separately from the other predominant Asian subpopulations in 
the country.  Through use of data from the Surveillance, Epidemiology, and End Results 
(SEER) program, we assessed differences in stage at diagnosis and stage-specific survival 
of these cancers among South Asians and other Asian subpopulations (Chinese, Japanese, 
Filipino) compared to non-Hispanic whites in the U.S.  Logistic regression was utilized to 
examine the association between South Asian race and stage at diagnosis.  Stage-specific 
survival following cancer diagnosis was also examined among the racial groups of 
interest using proportional hazards models.  Place of birth was found to be associated 
with a decreased risk of late stage diagnosis of cervical cancer among those that were 
foreign-born compared to those that were U.S.-born (OR=0.92; 95% CI 0.84, 1.00).  
Foreign-born cases had an increased risk of late stage diagnosis of stomach cancer 
compared to those that were U.S.-born (OR=1.08; 95% CI 1.00, 1.16).  Among cervical 
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cancer cases diagnosed at late stage, Asians had a significant decreased risk (HR=0.76; 
95% CI 0.65, 0.87) of death compared to non-Hispanic whites.  Decreased risk 
(HR=0.89; 95% CI 0.84, 0.95) of death was found for foreign-born cases diagnosed at 
early stage of liver cancer compared to U.S.-born cases.  Foreign-born stomach cancer 
cases had significant decreased risk of death compared to those that were U.S.-born at 
both early (HR=0.77; 95% CI 0.71, 0.83) and late (HR=0.88; 95% CI 0.85, 0.92) stages.  
Our study findings indicated that the Asian subpopulations examined in our analyses had 
more favorable outcomes related to stage at diagnosis and stage-specific survival when 
compared to non-Hispanic whites.  However, future research should specifically examine 
these outcomes in South Asian patients in the U.S. 
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2.2. Background 
Cancer is a significant cause for public health concern among Asian Americans residing 
in the U.S.  This racial/ethnic population is the only one for which the number of deaths 
annually attributable to cancer exceeds that of heart disease. Though this group reports 
low rates for major cancers, such as lung, colon, and prostate, they report high rates of 
cancers associated with infectious agents.  These include cancers of the cervix, liver, and 
stomach [1].  Though they are the third largest Asian subpopulation in the U.S. [2], South 
Asians comprise a group whose cancer outcomes have not been well examined and 
documented in the literature [3]. 
 
A previous study which examined the burden of cervical cancer among Asian 
subpopulations using data from the California Cancer Registry revealed heterogeneity in 
incidence and mortality.  It was found that incidence rates among Asian women in the 
U.S. broadly mirrored those in their countries of origin.  However, the exception to this 
general finding was found among South Asian women.  Though relatively high cervical 
cancer incidence rates are found in India, South Asian women living in California had the 
lowest rates compared to the other subpopulations.  This difference in rates is likely 
attributable to the high level of education found among South Asians in the U.S. 
compared to other Asian subpopulations.  This study also reported more favorable 
survival among South Asians compared to non-Hispanic whites [4].  Our study aims to 
extend on these findings by also examining stage at diagnosis and place of birth as a risk 
factor associated with outcomes among South Asians and other Asian subpopulations 
through use of data from all available SEER registries in the U.S. 
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Approximately 60-80% of liver cancer cases in the Asian/Pacific Islander population are 
due to infection with hepatitis B virus (HBV).  Those that comprise this racial/ethnic 
group originate from countries where HBV infection is endemic.  In addition, most of 
these chronic infections were likely acquired before adulthood.  The significant 
racial/ethnic disparity in burden of chronic HBV infection in the U.S. is largely due to the 
fact that 67% of the Asian/Pacific Islander population is foreign-born.  Due to the high 
prevalence of chronic infection in this population, liver cancer incidence is more than 3-
fold higher among males of Asian/Pacific Islander origin compared to white males [5].  
Though the South Asian population is rapidly growing in the U.S., the liver cancer 
burden of this group has not been extensively examined.  A previous study reported a 
slight survival advantage for South Asians compared to whites [3].  We aim to build on 
these results by also examining risk of late stage diagnosis and the association of place of 
birth with stage-specific survival.  
 
Helicobacter pylori (H. pylori), a gram-negative spiral bacterium known to infect nearly 
half of the global population, is the most well-known risk factor for stomach cancer [6].  
There is widespread geographic variation in seroprevalence rates of H. pylori infection in 
Asia.  India is classified as a low-risk region for stomach cancer where the age-
standardized incidence rate is about 5.7 per 100,000 despite relatively high 
seroprevalence of infection reported at 79%.  In contrast, high-risk regions for stomach 
cancer (Japan, China, Korea) where the seroprevalence ranges from 39.3% to 59.6% 
report age-standardized incidence rates ranging from 41.4 to 69.7 per 100,000.  This 
paradox is referred to as the “Asian Enigma” and is likely attributable to host genetic 
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factors and other environmental exposures such as diet and smoking which also affect 
stomach cancer risk [7].  The presence of this phenomenon does not allow for accurate 
estimates of stomach cancer burden if various Asian subpopulations are combined to 
create one aggregate group known as Asian/Pacific Islander.  It has also been found that 
despite higher incidence of stomach cancer, Asian countries have consistently reported 
more favorable outcomes related to disease compared to Western countries.  This can be 
seen when examining 5-year survival in Japan (40-60%) compared to the U.S. and 
Europe (15-20%) [8].  This finding is consistent with a previous study which examined 
stomach cancer incidence and survival among South Asians where this group had more 
favorable survival compared to whites [3].  Our study aims to extend on these results by 
also examining risk of late stage diagnosis and the association of place of birth with 
stage-specific survival.  
 
In order to better understand and address the outcomes associated with infection-
associated cancers in the South Asian population in the U.S., this study will examine this 
group separately from the other predominant Asian subpopulations in the country.  
Through use of data from the Surveillance, Epidemiology, and End Results (SEER) 
program of the National Cancer Institute (NCI), we aim to examine differences in stage at 
diagnosis and stage-specific survival of these cancers among South Asians and other 
Asian subpopulations (Chinese, Japanese, Filipino) compared to non-Hispanic whites in 
the U.S. 
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2.3. Methods 
 
Our study population included all cases identified as South Asian, Chinese, Japanese, 
Filipino, or non-Hispanic white diagnosed with incident primary invasive cervical, liver, 
or stomach cancers between January 1, 1999 and December 31, 2009 among 17 
population-based cancer registries included in the SEER program.  South Asian race is 
defined in our study as those originating from either India or Pakistan as classified by 
SEER.  These two countries of origin have been combined to create one racial/ethnic 
category in SEER since 1988.  The following registries were included in our analyses: 
San Francisco-Oakland, Los Angeles, San Jose-Monterey, Greater California, 
Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle- Puget Sound, Utah, Atlanta, 
Greater Georgia, Rural Georgia, Kentucky, Louisiana, and New Jersey.  Patient data were 
ascertained by SEER from medical records and available information for each diagnosed 
case included demographics, tumor characteristics at diagnosis, and year of diagnosis. 
 
Patients were selected for inclusion in the cervical cancer analysis if they were assigned 
SEER tumor site codes C530-C539.  Cases diagnosed with hepatocellular carcinoma 
were selected for the liver cancer analysis using tumor site code C220.  In addition, to 
ensure that cholangiocarcinomas were excluded only cases with ICD-O-3 histology codes 
8170-8175 were selected for inclusion.  Stomach cancer cases were identified using 
tumor site codes C160-169.  Only gastric adenocarcinoma patients classified using the 
following ICD-O-3 histology codes were selected for inclusion: 8000-8001, 8010, 8020-
8021, 8050, 8140-8221, 8255-8560, and 8570-8576.  Those less than 18 years at 
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diagnosis or with unknown age at diagnosis were excluded.  Those with in situ or 
unknown stage at diagnosis were also excluded. 
 
We also examined place of birth as a variable of interest in our study.  Subjects were 
classified as either “U.S.-born” or “foreign-born” based on data extracted by SEER from 
patient medical records or death certificates.  Since one principal aim of this study was to 
make inferences regarding the effect of U.S. versus foreign birth on subsequent cancer 
outcomes, those with unknown place of birth were excluded from our analyses.  The final 
sample sizes used for analysis for each cancer were as follows: 13,982 for cervical, 
16,672 for liver, and 23,553 for stomach.  Figure 2-1 is a graphical depiction of the 
exclusions which produced the final analytic sample for each cancer.  In addition, 
demographic and tumor characteristics of the eligible Asian cases prior to these 
exclusions are shown in Appendix A.   
 
Several covariates were considered to be potential confounders in our analyses.  The 
models used in the logistic regression analysis adjusted for the effects of age at diagnosis, 
sex, year of diagnosis, and SEER registry.  Age is adjusted for as a confounder due to its 
varying distributions in the racial/ethnic subpopulations examined and due to the 
association between older age and increased risk of cancer.  Sex is considered as a 
potential confounder to take into account genetic and lifestyle differences which may 
differ by racial/ethnic group and affect the outcome of disease.  Year of diagnosis is taken 
into account since diagnosis and surveillance methods for cancer detection may have 
varied during the time period of our study.  SEER registry is adjusted for to take into 
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account the location from which the cases originated since access to care and likelihood 
of diagnosis may vary between locations.  The models used in the survival analysis also 
adjusted for the effect of grade in addition to the covariates used in the logistic regression 
analysis.  Grade is a tumor characteristic taken into account due to its effect on survival, 
since increasing grade is associated with poorer prognosis.  In addition, grade at 
diagnosis may vary due to genetic differences between the racial/ethnic subpopulations 
being compared.   
 
The primary relationship of interest in the logistic regression analysis was the association 
of South Asian race on cancer stage at diagnosis.  Subjects were categorized as having 
early or late stage disease, with the outcome of interest defined as late stage at diagnosis.  
Cervical cancer patients with AJCC stage IA-IIA at diagnosis were classified as early 
stage and those with stage greater than IIA were classified as late stage.  Liver cancer 
cases were categorized using a combination of SEER summary stage (for cases diagnosed 
1999-2003) and AJCC stage (for cases diagnosed 2004-2009).  Cases with SEER 
summary stage as ‘localized’ or ‘regional by direct extension’ were categorized as early 
stage and those with higher stages were categorized as late stage.  Cases with AJCC stage 
I-II were classified as early stage and those with stage III or greater were classified as late 
stage.  The same method combining SEER summary stage and AJCC stage was used for 
early and late stage classification of stomach cancer.     
 
Logistic regression was conducted to obtain odds ratios and their 95% confidence 
intervals to examine the association between race and late stage at diagnosis.  Age-
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adjusted associations were first obtained using models with only race and age as 
predictors.  Adjusted associations were then examined which controlled for other 
potential confounders.  We also examined the effect of place of birth by including it as a 
predictor along with race and the other covariates.  Non-Hispanic whites served as the 
referent racial group in all models.   
 
Stage-specific survival following cancer diagnosis was also examined among the 
subpopulations of interest.  Survival time was provided as a variable in the SEER 
database and was calculated by using the date of diagnosis and the earliest of the 
following: date of death, date last known to be alive, or the follow-up cutoff date of 
December 31, 2009.  In addition, vital status was provided in the data as either “alive” or 
“dead.”  The Kaplan-Meier method was utilized to test differences in overall survival 
between the racial groups being compared through use of the log-rank test.  Cox 
proportional hazards regression was utilized for multivariate adjustment to control for the 
effects of age, sex, SEER registry, stage, and grade on the observed differences in 
survival.  The proportional hazards (PH) assumption was assessed for these covariates 
prior to inclusion in the models through use of log-log plots and goodness-of-fit tests.  
Hazard ratios and 95% confidence intervals were obtained to examine the association 
between race and stage-specific survival.  Age-adjusted associations were obtained using 
models with only race and age as predictors.  Adjusted estimates were then examined 
which controlled for potential confounders.  We also examined the effect of place of birth 
by including it as a predictor along with race and the other covariates.  All analyses were 
conducted using SAS, version 9.3 (SAS Institute, Inc., Cary, NC). 
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2.4. Results 
Tables 2-1 through 2-3 show the distributions of demographic and tumor characteristics 
for each cancer examined by race.  Due to small sample sizes within the individual Asian 
subpopulations for cervical cancer, all Asians (Chinese, Japanese, Filipino, South Asians) 
were combined to create an aggregate racial/ethnic category and compared with non-
Hispanic whites for both the stage at diagnosis and stage-specific survival analyses.  As 
seen in Table 2-1, the mean age at diagnosis was slightly higher for Asian cases 
compared to non-Hispanic whites.  Table 2-2 shows the distribution of demographic and 
tumor characteristics for liver cancer.  The proportion of male and female cases was 
almost the same among Japanese while the majority of cases for the other subpopulations 
were male.  In addition, South Asians had the highest proportion of late stage cases 
compared to the other Asian subpopulations and non-Hispanic whites.  The distribution 
of these characteristics for stomach cancer is shown in Table 2-3.  South Asians had the 
youngest mean age at diagnosis and the highest proportion of late stage cases.  The 
highest proportion of cardia tumors was seen among non-Hispanic whites (35.3%), while 
non-cardia tumors accounted for more than half of the tumors found among the Asian 
subpopulations examined. 
 
Stage at diagnosis 
Cervical 
As seen in Table 2-4, it was found that Asians had a non-significant slightly increased 
risk (9%) of late stage diagnosis when compared to non-Hispanic whites in the fully 
adjusted model which controlled for the effects of age, year of diagnosis, SEER registry, 
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and place of birth.  When examining the independent effect of place of birth among all 
subjects, it was found that foreign-born cases had significantly decreased risk of late 
stage diagnosis compared to U.S. born cases. The combined effect of Asian race and 
place of birth was also examined in separate models.  However, the effect estimates 
obtained in these models were found to be close to null and non-significant. 
 
Liver 
Table 2-5 shows the results of the stage at diagnosis analysis for liver cancer.  As can be 
seen in the effect estimates, there was notable heterogeneity among the Asian 
subpopulations examined.  South Asians and Filipinos were the most similar when 
comparing their risks of late stage diagnosis to non-Hispanic whites.   Though non-
significant, there was 28% increased risk of late stage diagnosis among South Asians 
when compared to non-Hispanic whites.  The effect of place of birth was close to null 
and non-significant for this cancer site. 
 
Stomach 
Table 2-6 shows the results of the stage at diagnosis analysis for stomach cancer.  Effect 
estimates obtained for the fully adjusted model did not differ greatly among the Asian 
subpopulations.  When compared with non-Hispanic whites, the odds ratio obtained for 
South Asians was close to null.  Place of birth had a modest effect when examining all 
subjects, with foreign-born cases having an increased 8% risk of late stage diagnosis 
compared to U.S.-born cases.  However, place of birth did not have a significant effect 
when examining Asians alone.    
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Stage-specific survival 
Cervical 
Unadjusted Kaplan-Meier curves examining overall cervical cancer survival comparing 
our Asian subpopulations of interest and non-Hispanic whites are shown in Appendix B.  
The log-rank test p-value which can be used to detect significant differences in the 
survival curves is also shown.  Asians in our subpopulations of interest had more 
favorable unadjusted overall survival compared to non-Hispanic whites.  The log-rank 
test p-value of <.0001 indicated significant difference in the survival curves between the 
racial/ethnic groups being compared.  
 
Table 2-7 shows results from the cervical cancer survival analysis.  Asians had lower risk 
of death among those diagnosed at both early and late stages when compared to non-
Hispanic whites in all of the models used.  This decreased risk of death became almost 
null in the fully adjusted models which also accounted for place of birth.  When 
examining place of birth as an independent predictor, it was found that foreign-born cases 
had significant decreased risk of death compared to U.S.-born cases for both early and 
late stages.  We also examined the effect of place of birth among Asians only with U.S.-
born Asians as the referent group (results not shown).  According to these models, a 
significant decreased risk (HR=0.57; 95% CI 0.39, 0.83) was found for foreign-born 
Asians diagnosed at late stage compared to U.S.-born Asians. 
 
Liver 
Unadjusted Kaplan-Meier curves examining overall liver cancer survival comparing 
South Asians to the other Asian subpopulations and non-Hispanic whites are shown in 
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Appendix B.  South Asians had the worst overall unadjusted survival compared to the 
other Asian subpopulations.  The log-rank test p-value of <.0001 indicates significant 
difference in the survival curves between the racial/ethnic groups being compared. 
 
Table 2-8 shows the results from the liver cancer survival analysis.  There was notable 
heterogeneity in the hazard ratios obtained for those diagnosed at early stages, with the 
lowest risk of death found among Chinese and the highest risk among Filipino.  The risk 
of death obtained for South Asians compared to non-Hispanic whites was almost null for 
both early and late stages.  A significant decreased risk of death was obtained for foreign-
born cases compared to those that were U.S.-born among those diagnosed at early stages. 
 
Stomach 
Unadjusted Kaplan-Meier curves examining overall stomach cancer survival comparing 
South Asians to the other Asian subpopulations and non-Hispanic whites are shown in 
Appendix B.  South Asians had the worst overall unadjusted overall compared to the 
other Asian subpopulations.  The log-rank test p-value of <.0001 indicates significant 
difference in the survival curves between the racial/ethnic groups being compared. 
 
Table 2-9 shows the results from the stomach cancer survival analysis.  Though there 
was notable heterogeneity in the hazard ratios obtained among those with early stage 
diagnosis, they did not differ greatly among those with late stage diagnosis.  Significant 
decreased risk of death was found among foreign-born cases compared to those that were 
U.S.-born for both early and late stage cases in both models. 
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It has been previously reported that despite higher incidence of stomach cancer, Asian 
countries consistently report more favorable outcomes related to the disease compared to 
Western countries.  A potential reason for these variations in survival between regions 
likely involves inherent differences in tumor biology.  In Western countries, proximal 
(cardia) gastric tumors are more common while the majority of tumors found in Asia are 
distal (non-cardia) tumors [8].  This trend was observed among our sample of stomach 
cancer cases found in SEER since the majority of non-cardia tumors were found among 
the Asian patients.  Risk factors such as obesity and white race/ethnicity are linked with 
cardia tumors [9].  In addition, it has been reported that tumors found in the gastric cardia 
are associated with more unfavorable prognosis compared to those found at other sites in 
the stomach [10].  This likely contributes to the decreased risk of death found among the 
Asian subpopulations compared to non-Hispanic whites and those that were foreign-born 
compared to U.S.-born. 
 
We assessed differences in the outcomes of interest in our study while accounting for 
these gastric tumor subsites (cardia versus non-cardia).  When examining stage at 
diagnosis, those with cardia tumors had 8% decreased risk (OR=0.92; 95% CI 0.86, 0.99) 
of late stage diagnosis compared to those with non-cardia tumors after adjustment for 
confounders.  Among those diagnosed at early stage, cases with cardia tumors had 20% 
increased risk (HR=1.20; 95% CI 1.12, 1.29) of death compared to those with non-cardia 
tumors in the fully adjusted model.  The effect of place of birth on stage-specific survival 
was examined after restricting cases by subsite.  The results of these analyses are shown 
in Table 2-10.  As seen in the table, the effect of foreign birth did not vary greatly 
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between early and late stage cases among those with cardia tumors.  There was a greater 
protective effect of foreign birth at early stage diagnosis among those with non-cardia 
tumors. 
 
2.5. Discussion 
This study found notable heterogeneity when examining stage-specific survival of three 
common infection-associated cancers among Asian subpopulations.  Controlling for the 
effects of potential confounders such as age at diagnosis, sex, SEER registry, and grade 
did not diminish the heterogeneity of these effects.  In addition, it was also found that 
those that were foreign-born had significantly more favorable survival associated with 
these cancers compared to those that were U.S.-born.   
 
Due to limited sample sizes, all Asians were combined to create one aggregate 
racial/ethnic group in the analysis which examined differences in risk of late stage 
diagnosis of cervical cancer.  The fully adjusted model which controlled for the effects of 
confounders and place of birth produced an odds ratio which was almost null and thus 
non-significant.  However, the independent effect of place of birth was found to be 
associated with a decreased risk of late stage diagnosis among those that were foreign-
born compared to those that were U.S.-born (OR=0.92; 95% CI 0.84, 1.00).  Human 
papillomavirus (HPV) has long been identified as a necessary cause of cervical cancer.  
The natural history of cervical cancer begins by acquiring a sexually transmitted 
carcinogenic HPV infection [11].  Virtually all cases are attributable to persistent infection 
with one of almost 15 types of oncogenic HPV genotypes [12].  Several studies have found 
an association between smoking and increased risk of cervical cancer and its immediate 
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precursor, cervical intraepithelial neoplasia grade 3 (CIN3).  A study examining the role 
of smoking as a risk factor for CIN3 among HPV-positive women found that current 
smokers (OR=1.70; 95% CI 1.40, 2.10) and past smokers (OR=1.70; 95% CI 1.20, 2.40) 
were at increased risk for CIN3 or cancer compared to non-smokers.  In addition, greater 
intensity of smoking and duration strengthened the magnitude of this association.  It is 
likely that smoking exerts an effect on the interaction between HPV infection and 
biological processes in the host through a mechanism which increases the likelihood of 
pre-malignant change in the cervix.  Since carcinogenic metabolites produced through 
smoking have been detected in cervical secretions, smoking may increase the risk for 
CIN3 by promoting viral persistence or through producing genomic damage through 
genotoxins [13].  This association between smoking and increased risk for CIN3 may 
provide an explanation for the decreased risk of advanced stage diagnosis found among 
foreign-born women.  It has been reported that the prevalence of smoking among women 
in the U.S. is about 13.3-16.5%.  This is in comparison to prevalence of less than 9.8% 
among women in Asia [14].   
 
With the exception of Filipino cases, our study did not find significant odds ratio 
estimates for the risk of late stage diagnosis of liver cancer.  However, it is of clinical 
significance to note that South Asians had the highest proportion (48%) of late stage 
cases compared to the other Asian subpopulations examined.  The non-significance of the 
effect estimate produced for South Asians in our analysis was likely due to the small 
sample size of this subpopulation.  The importance of diabetes as an independent risk 
factor for liver cancer has emerged in recent studies of this disease.  A study conducted in 
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the U.S. reported that diabetes was associated with a 2-3 fold increased risk of 
hepatocellular carcinoma, regardless of the presence of other major risk factors such as 
HBV, HCV, and alcoholic liver disease [15].  This is association between diabetes and 
liver cancer is of particular importance to the South Asian population.  India reports the 
highest prevalence of diabetes compared to other countries in this region, with rates 
ranging from 18.6% in urban areas to 9.2% in rural areas [16].  A study conducted in India 
found that diabetic patients diagnosed with hepatocellular carcinoma had more advanced 
tumors of larger size and increased likelihood of intraheptic bile duct involvement [17].  
These findings highlight the need for improved monitoring among those of South Asian 
origin who are diabetic or diagnosed with other risk factors for hepatocellular carcinoma 
in order to increase the likelihood of early stage diagnosis. 
 
Our study did not find notable differences in risk of late stage diagnosis of stomach 
cancer among the Asian subpopulations compared to non-Hispanic whites.  However, 
those that were foreign-born had an increased risk of late stage diagnosis compared to 
those that were U.S.-born (OR=1.08; 95% CI 1.00, 1.16).  This increased risk is likely 
attributable to differences in dietary intake between those who are foreign born compared 
to U.S.-born.  Salt intake has been shown to be a risk factor for gastritis and amplify the 
effects of gastric carcinogens.  Mucosal damage caused by salt intake also likely 
increases the risk for persistent infection with H. pylori [18].  It has also been hypothesized 
that H. pylori infection acts synergistically with dietary factors to promote carcinogenesis 
[19]
.  H. pylori prevalence rates vary greatly between Asia and North America, ranging 
from 80% in India to 30% in the U.S. and Canada [20].  In addition, dietary salt intake is 
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considered high in the Asian subpopulations examined in our study.  Intake of spicy and 
pickled foods and dried salted meats are significant dietary behaviors which are likely 
associated with advanced stage diagnosis in India and other Asian countries [21]. 
 
Our study found that Asians had more favorable stage-specific survival for cervical 
cancer compared to non-Hispanic whites.  In addition, those that were foreign born had 
decreased risk of death compared to those that were U.S.-born.  In the adjusted model 
which controlled for age at diagnosis, SEER registry, and grade it was found that among 
those diagnosed at late stage, Asians had a significant decreased risk (HR=0.76; 95% CI 
0.65, 0.87) of death compared to non-Hispanic whites.  This risk became close to null 
(HR=0.94; 95% CI 0.81, 1.10) when place of birth was added to the model.  In addition, 
the independent effect of place of birth was statistically significant among both early 
(HR=0.76; 95% CI 0.66, 0.88) and late (HR=0.66; 95% CI 0.61, 0.72) stage cases.  
Survival outcomes associated with cervical cancer among Asian subpopulations have not 
been studied extensively in the U.S.  Our findings are consistent with a study among 
Asian subpopulations conducted in California which reported more favorable survival 
outcomes for these groups compared to non-Hispanic whites.  This study also concluded 
that differences in histology did not affect the risk estimates obtained [4].  Another study 
examining survival differences for cervical cancer in Asian subpopulations reported more 
favorable unadjusted cause-specific 5-year survival for Chinese (79.4%) and Filipino 
(81.4%) cases compared to non-Hispanic whites (77.8%) [22].  The decreased risk of 
death found among Asian cases may be due to differences in other risk factors associated 
with cervical cancer outcomes, such as smoking and oral contraceptive use.  It has been 
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hypothesized that oral contraceptives may affect the likelihood of clearance or 
persistence of HPV infection.  It may also affect the regression or progression of pre-
neoplastic and neoplastic lesions [23].  The use of oral contraceptive varies greatly among 
women in the U.S. compared to those in the Asian countries examined in our study.  A 
study examining hormonal contraceptive use among women tested for the presence of 
oncogenic HPV at clinical centers in the U.S. found that about 58% of women ever 
reported use of oral contraceptives [24].  In comparison, a study examining oral 
contraceptive use and HPV reported that 1.1% of Indian women and 3.2% of Chinese 
women reported ever using oral contraceptives among women tested for infection [25].  
Thus, this variation in oral contraceptive use and differences in prevalence of smoking as 
discussed previously may contribute to favorable cervical cancer survival outcomes 
found among Asian women.   
 
The stage-specific survival analysis for liver cancer did not produce significant effect 
estimates for South Asians in our study.  However, significantly decreased risk of death 
was found for Chinese cases at both early and late stage.  In addition, decreased risk 
(HR=0.89; 95% CI 0.84, 0.95) of death was also found for foreign-born cases diagnosed 
at early stage compared to U.S-born cases.  Our findings are generally consistent with 
several previous studies conducted in the U.S. which have reported more favorable 
survival among the Asian/Pacific Islander racial/ethnic category compared to non-
Hispanic whites [3, 26].  Another recent study reported that among cases diagnosed 
between 1992 and 2004, Asians/Pacific Islanders consistently had higher one-year 
survival compared to whites [27].  These differences in survival outcomes may be 
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associated with the underlying etiology of hepatocellular carcinoma in the U.S. compared 
to that of the Asian countries examined in our study.  A study which reported population 
attributable fractions (PAF) characterizing the impact of co-morbid conditions on risk of 
hepatocellular carcinoma in the U.S. reported varying PAF’s between whites and Asians 
for the well-known risk factors.  Among whites, the greatest PAF (38.9%) was found for 
diabetes and/or obesity, while among Asians the highest PAF (43.9%) was associated 
with HCV infection and alcohol use [28].  Thus, more favorable outcomes may be 
associated with risk factors found among Asian liver cancer patients compared to those 
found among non-Hispanic whites.         
 
Due to limited sample sizes, our study did not find significant effect estimates for South 
Asians in the stage-specific survival analysis for stomach cancer.  However, significant 
decreased risk of death was found for Chinese patients at both early and late stages.  In 
addition, foreign-born cases had significant decreased risk of death compared to those 
that were U.S.-born at both early (HR=0.77; 95% CI 0.71, 0.83) and late (HR=0.88; 95% 
CI 0.85, 0.92) stages.  Further analysis of gastric cancer subsite revealed that cardia 
tumors were associated with increased risk of death compared to non-cardia tumors.  In 
our sample, cardia tumors were diagnosed in 35.3% of the non-Hispanic white subjects 
while the proportions of these tumors ranged from 10.5% to 21.6% in the Asian 
subpopulations.  As mentioned previously, since tumors located in the cardia are 
associated with poorer prognosis compared to those in non-cardia regions, the greater 
distribution of the former among non-Hispanic whites may explain the decreased risk of 
death found among the Asian subpopulations.  It has been previously proposed that 
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countries reporting higher incidence rates of stomach cancer also have more favorable 
survival compared to countries with lower incidence rates.  This finding is also attributed 
to the differences in survival associated with tumor subsite since gastric cardia tumors are 
associated with decreased 5-year survival and higher risk of operative mortality.  In 
addition, host-related factors play a role in survival differences since it has been reported 
that stomach cancers diagnosed among those of Asian origin have better prognosis when 
compared with non-Asians [10]. 
  
A strength of this study is that it is one of the few studies focusing specifically on South 
Asians and their outcomes for these infection-associated cancers in the U.S.  Most studies 
to date focusing on these cancers have focused on incidence and mortality rates among 
Asian subpopulations or the Asian/Pacific Islander racial/ethnic group as a whole.  
Though the estimates were non-significant, heterogeneity of odds ratios among the Asian 
subpopulations was observed when examining risk of late stage liver cancer.  Notable 
heterogeneity in hazard ratios was also observed among those diagnosed at early stages 
of both liver and stomach cancers.  Thus, our results highlight the need for individual 
examination of these subpopulations when examining outcomes associated with these 
infection-associated cancers.  
 
To our knowledge, this is one of the few studies to also examine place of birth as an 
independent risk factor for outcomes associated with these infection-associated cancers 
among Asians using SEER in the U.S.  Significant effect estimates were obtained for this 
covariate in the majority of the Cox regression models examining stage-specific survival.  
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Thus, it is a significant indicator of outcomes associated with infection-associated 
cancers.  Our findings are indicative of certain dietary and other environmental exposures 
which are associated with more favorable outcomes among patients that are foreign-born 
compared to those that are U.S.-born.      
 
One limitation of our study is the lack of data regarding the etiology and risk factors 
related to the infection-associated cancers examined.  There are likely significant 
differences in prevalence of risk factors such as HPV infection, tobacco and alcohol use, 
viral hepatitis infection, and H. pylori infection among the Asian subpopulations and non-
Hispanic whites.  These factors likely play a role in the differing outcomes observed in 
our analyses.  Another limitation is the exclusion of cases with unknown place of birth 
data since the effect of this covariate was of significant interest in our study.  However, 
inclusion of cases with known place of birth did not significantly affect the effect 
estimates obtained in our analyses.  Misclassification of our main exposure of interest, 
race/ethnicity, was also possible.  However, a recent study examining the accuracy this 
variable among the Asian subpopulations used in our study in a SEER registry in 
California reported that this misclassification is not a significant issue [29].  Our study also 
had small sample sizes for the South Asian cases in particular for all of the cancers 
examined.  This is due to limited SEER coverage of the Asian population.  A recent study 
reported that SEER only covers 53% of the Asian population in the U.S [30].  However, 
SEER is currently the only population-based source of data for examining cancer burden 
in the U.S.  
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Conclusion 
Our study findings indicate that certain Asian subpopulations examined in our analyses 
had more favorable outcomes related to stage at diagnosis and stage-specific survival 
when compared to non-Hispanic whites.  However, future research should specifically 
examine these outcomes in South Asian patients in the U.S.  Due to limited sample size, 
the effect estimates for this significant Asian subpopulation in the U.S. obtained in our 
analyses did not achieve statistical significance.  However, South Asians had the highest 
proportion of late stage liver cancer cases in our study.  Recent studies have suggested 
that this group may have certain risk factors, such as high diabetes prevalence, associated 
with negative outcomes related to liver cancer.  This needs to be examined further in 
order to tailor cancer prevention programs to this specific subpopulation.  In addition, 
SEER coverage of the Asian population in the U.S. must be more sufficient to achieve 
accurate estimates of the cancer burden among this major racial/ethnic group. 
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2.7. Tables and Figures 
Figure 2-1: Exclusions used to create final analytic samples for analysis 
Cervical cancer 
           29, 682 cases available for analysis 
 
            Primary tumors only (n=1625) 
 
28, 057 cases 
 
            Age, <18 years or unknown (n=25) 
                                                              
   28, 032 cases 
 
            Stage, in situ or unknown (n=2068) 
     
                                                            25, 964 cases 
       
            Place of birth, unknown (n=11982) 
    
    13, 982 cases used for analysis 
 
 
 
Liver cancer 
             32, 593 cases available for analysis 
 
            Primary tumors only (n=3767) 
 
28, 826 cases 
 
            Age, <18 years or unknown (n=84) 
                                                              
    28, 742 cases 
 
            Stage, in situ or unknown (n=5989) 
     
                                                            22, 753 cases 
       
            Place of birth, unknown (n=6081) 
    
    16, 672 cases used for analysis 
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Figure 2-1 (continued) 
Stomach cancer 
       45, 981 cases available for analysis 
 
            Primary tumors only (n=8021) 
 
37, 960 cases 
 
            Age, <18 years or unknown (n=10) 
                                                              
  37, 950 cases 
 
            Stage, in situ or unknown (n=5345) 
     
                                                            32, 605 cases 
       
            Place of birth, unknown (n=9052) 
    
    23, 553 cases used for analysis 
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Table 2-1: Demographic and tumor characteristics among 13, 982 cases diagnosed with primary 
cervical cancer by race, 1999-2009 
Characteristic Asian (n=950) Non-Hispanic 
White 
(n=13, 032) 
*P-value 
Age at diagnosis 
(years) 
   
Mean ± SD 
Year of diagnosis 
54 ± 15 51 ± 15  
1999-2001 234 (24.6) 3578 (27.5) 0.204 
2002-2004 282 (29.7) 3833 (29.4)  
2005-2007 262 (27.6) 3500 (26.9)  
2008-2009 172 (18.1) 2121 (16.3)  
SEER registry    
San Francisco-Oakland 112 (11.8) 391 (3.0) <.0001 
Los Angeles 309 (32.5) 3057 (23.5)  
San Jose-Monterey 46 (4.8) 320 (2.5)  
Greater California 10 (1.1) 960 (7.4)  
Connecticut 9 (1.0) 670 (5.1)  
Detroit 5 (0.5) 384 (3.0)  
Hawaii 146 (15.4) 83 (0.6)  
Iowa 7 (0.7) 395 (3.0)  
New Mexico 0 (0.0) 226 (1.7)  
Seattle-Puget Sound 53 (5.6) 580 (4.5)  
Utah 1 (0.1) 190 (1.5)  
Atlanta 16 (1.7) 337 (2.6)  
Greater Georgia 189 (19.9) 3128 (24.0)  
Rural Georgia 0 (0.0) 23 (0.2)  
Kentucky 1 (0.1) 524 (4.0)  
Louisiana 1 (0.1) 424 (3.3)  
New Jersey 45 (4.7) 1340 (10.3)  
Stage at diagnosis    
Early 461 (48.5) 6291 (48.3) 0.880 
Late 489 (51.5) 6741 (51.7)  
Grade    
I 82 (8.6) 1050 (8.1)    0.600 
II 268 (28.2) 3844 (29.5)  
III 302 (31.8) 4213 (32.3)  
IV 24 (2.5) 397 (3.1)  
Unknown 274 (28.8) 3528 (27.1)  
Place of birth    
U.S-born 151 (15.9) 8852 (67.9)    <.0001 
Foreign-born 799 (84.1) 4180 (32.1)  
* P-values based on the χ2 test 
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Table 2-2: Demographic and tumor characteristics among 16, 672 cases diagnosed with primary hepatocellular carcinoma by race, 1999-2009 
Characteristic South Asian 
(n=73) 
Chinese (n=1130) Japanese (n=464) Filipino (n=729) Non-Hispanic 
White (n=14,276) 
*P-value 
Age at diagnosis, y 
Mean ± SD 
Sex 
Male 
Female 
Year of diagnosis 
 
62 ± 11  
 
56 (76.7) 
17 (23.3) 
 
 
63 ± 13 
 
857 (75.8) 
273 (24.2) 
 
68 ± 11 
 
241 (51.9) 
223 (48.1) 
 
63 ± 13 
 
558 (76.5) 
171 (23.5) 
 
63 ± 12 
 
11024 (77.2) 
3252 (22.8) 
 
 
 
<.0001 
1999-2001 12 (16.4) 251 (22.2) 105 (22.6) 161 (22.1) 2763 (19.4) <.0001 
2002-2004 20 (27.4) 334 (29.6) 152 (32.8) 195 (26.8) 3749 (26.3)  
2005-2007 20 (27.4) 330 (29.2) 123 (26.5) 245 (33.6) 4504 (31.6)  
2008-2009 21 (28.8) 215 (19.0) 84 (18.1) 128 (17.6) 3260 (22.8)  
SEER registry       
San Francisco-
Oakland 
3 (4.1) 343 (30.4) 28 (6.0) 133 (18.2) 578 (4.1) <.0001 
Los Angeles 3 (4.1) 355 (31.4) 80 (17.2) 174 (23.9) 2101 (14.7)  
San Jose-Monterey 2 (2.7) 79 (7.0) 14 (3.0) 40 (5.5) 339 (2.4)  
Greater California 0 (0.0) 5 (0.4) 0 (0.0) 0 (0.0) 809 (5.7)  
Connecticut 4 (5.5) 11 (1.0) 4 (0.9) 5 (0.7) 805 (5.6)  
Detroit 10 (13.7) 14 (1.2) 4 (0.9) 8 (1.1) 790 (5.5)  
Hawaii 0 (0.0) 70 (6.2) 210 (45.3) 113 (15.5) 122 (0.9)  
Iowa 0 (0.0) 4 (0.4) 1 (0.2) 1 (0.1) 537 (3.8)  
New Mexico 1 (1.4) 1 (0.1) 1 (0.2) 1 (0.1) 453 (3.2)  
Seattle-Puget Sound 7 (9.6) 71 (6.3) 30 (6.5) 34 (4.7) 1000 (7.0)  
Utah 1 (1.4) 2 (0.2) 4 (0.9) 1 (0.1) 245 (1.7)  
Atlanta 6 (8.2) 7 (0.6) 1 (0.2) 0 (0.0) 288 (2.0)  
Greater Georgia 2 (2.7) 120 (10.6) 83 (17.9) 189 (25.9) 3481 (24.4)  
Rural Georgia 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25 (0.2)  
Kentucky 0 (0.0) 3 (0.3) 0 (0.0) 0 (0.0) 591 (4.1)  
Louisiana 1 (1.4) 4 (0.4) 1 (0.2) 3 (0.4) 716 (5.0)  
New Jersey 33 (45.2) 41 (3.6) 3 (0.7) 27 (3.7) 1396 (9.8)  
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Table 2-2 (continued) 
       
Stage at diagnosis 
Early 
Late 
 
38 (52.0) 
35 (48.0) 
 
745 (65.9) 
385 (34.1) 
 
312 (67.2) 
152 (32.8) 
 
419 (57.5) 
310 (42.5) 
 
8574 (60.1) 
5702 (39.9) 
 
<.0001 
Grade       
I 8 (11.0) 135 (12.0) 67 (14.4) 88 (12.1) 1904 (13.3) 0.037 
II 14 (19.2) 200 (17.7) 79 (17.0) 133 (18.2) 2256 (15.8)  
III 8 (11.0) 112 (9.9) 49 (10.6) 96 (13.2) 1294 (9.1)  
IV 1 (1.4) 9 (0.8) 5 (1.1) 7 (1.0) 155 (1.1)  
Unknown 42 (57.5) 674 (59.7) 264 (56.9) 405 (55.6) 8667 (60.7)  
 
Place of birth 
      
U.S-born 
Foreign-born 
3 (4.1) 
70 (95.9) 
68 (6.0) 
1062 (94.0) 
248 (53.5) 
216 (46.5) 
77 (10.6) 
652 (89.4) 
11574 (81.1) 
2702 (18.9) 
<.0001 
* P-values based on the χ2 test 
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Table 2-3: Demographic and tumor characteristics among 23, 553 cases diagnosed with primary gastric adenocarcinoma by race, 1999-2009 
Characteristic South Asian 
(n=97) 
Chinese (n=883) Japanese 
(n=1055) 
Filipino (n=496) Non-Hispanic 
White (n=21, 
022) 
*P-value 
Age at diagnosis, y 
Mean ± SD 
Sex 
Male 
Female 
Year of diagnosis 
 
62 ± 15 
 
63 (65.0) 
34 (35.0) 
 
68 ± 15 
 
513 (58.1) 
370 (41.9) 
 
73 ± 12 
 
581 (55.1) 
474 (44.9) 
 
68 ± 14 
 
258 (52.0) 
238 (48.0) 
 
67 ± 14 
 
13631 (64.8) 
7391 (35.2) 
 
 
 
<.0001 
1999-2001 14 (14.4) 230 (26.1) 358 (33.9) 113 (22.8) 5543 (26.4) <.0001 
2002-2004 37 (38.1) 252 (28.5) 313 (29.7) 159 (32.1) 6348 (30.2)  
2005-2007 25 (25.8) 224 (25.4) 258 (24.5) 133 (26.8) 5672 (27.0)  
2008-2009 21 (21.7) 177 (20.1) 126 (11.9) 91 (18.4) 3459 (16.5)  
Stage at diagnosis       
Early 
Late 
28 (28.9) 
69 (71.1) 
318 (36.0) 
565 (64.0) 
393 (37.2) 
662 (62.8) 
157 (31.7) 
339 (68.3) 
6662 (31.7) 
14360 (68.3) 
0.0003 
SEER registry       
San Francisco-
Oakland 
8 (8.3) 223 (25.3) 48 (4.6) 64 (12.9) 684 (3.3) <.0001 
Los Angeles 1 (1.0) 287 (32.5) 219 (20.8) 99 (20.0) 3103 (14.8)  
San Jose-Monterey 2 (2.1) 57 (6.5) 27 (2.6) 25 (5.0) 400 (1.9)  
Greater California 1 (1.0) 4 (0.5) 3 (0.3) 1 (0.2) 1043 (5.0)  
Connecticut 1 (1.0) 9 (1.0) 4 (0.4) 4 (0.8) 1786 (8.5)  
Detroit 15 (15.5) 6 (0.7) 2 (0.2) 5 (1.0) 1356 (6.5)  
Hawaii 2 (2.1) 69 (7.8) 565 (53.6) 114 (23.0) 153 (0.7)  
Iowa 1 (1.0) 1 (0.1) 1 (0.1) 0 (0.0) 1028 (4.9)  
New Mexico 0 (0.0) 1 (0.1) 1 (0.1) 0 (0.0) 575 (2.7)  
Seattle-Puget Sound 8 (8.3) 51 (5.8) 52 (4.9) 29 (5.9) 1290 (6.1)  
Utah 0 (0.0) 0 (0.0) 6 (0.6) 1 (0.2) 457 (2.2)  
Atlanta 8 (8.3) 15 (1.7) 4 (0.4) 0 (0.0) 418 (2.0)  
Greater Georgia 2 (2.1) 94 (10.7) 110 (10.4) 126 (25.4) 3724 (17.7)  
Rural Georgia 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 38 (0.2)  
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Table 2-3 (continued) 
 
      
Kentucky 0 (0.0) 1 (0.1) 4 (0.4) 0 (0.0) 937 (4.5)  
Louisiana 1 (1.0) 7 (0.8) 1 (0.1) 3 (0.6) 860 (4.1)  
New Jersey 47 (48.5) 58 (6.6) 8 (0.8) 25 (5.0) 3170 (15.1)  
Grade       
I 3 (3.1) 25 (2.8) 44 (4.2) 10 (2.0) 677 (3.2) <.0001 
II 28 (28.9) 156 (17.7) 235 (22.3) 94 (19.0) 4533 (21.6)  
III 55 (56.7) 577 (65.4) 665 (63.0) 323 (65.1) 12124 (57.7)  
IV 1 (1.0) 23 (2.6) 16 (1.5) 6 (1.2) 455 (2.2)  
Unknown 10 (10.3) 102 (11.6) 95 (9.0) 63 (12.7) 3233 (15.4)  
Tumor subsite 
Cardia 
Non-cardia 
Overlapping/NOS 
Place of birth 
 
21 (21.6) 
50 (51.5) 
26 (26.8) 
 
93 (10.5) 
587 (66.5) 
203 (23.0) 
 
138 (13.1) 
663 (62.8) 
254 (24.1) 
 
79 (15.9) 
285 (57.5) 
132 (26.6) 
 
7421 (35.3) 
8649 (41.1) 
4952 (23.6) 
 
<.0001 
U.S-born 
Foreign-born 
4 (4.1) 
93 (95.9) 
61 (6.9) 
822 (93.1) 
722 (68.4) 
333 (31.6) 
63 (12.7) 
433 (87.3) 
15319 (72.9) 
5703 (27.1) 
<.0001 
* P-values based on the χ2 test 
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Table 2-4: Risk of late stage cervical cancer diagnosis by race, 1999-2009 (n=13, 982) 
 
Race 
 
 
Age-adjusted model (Race, age, and  
place of birth only) 
OR (95% CI) 
 
 
*Fully adjusted model 
OR (95% CI) 
White 
Asian 
1.00 (Referent) 
1.02 (0.89, 1.18) 
1.00 (Referent) 
1.09 (0.94, 1.26) 
Place of birth (all subjects) 
U.S.-born 
Foreign-born                              
Place of birth (Asians only)  
U.S.-born 
Foreign-born 
 
1.00 (Referent) 
                   0.79 (0.73, 0.85) 
 
1.00 (Referent) 
1.11 (0.76, 1.62) 
 
 1.00 (Referent) 
        0.92 (0.84, 1.00) 
 
1.00 (Referent) 
1.02 (0.66, 1.59) 
*Adjusted for age at diagnosis, year of diagnosis, SEER registry, and place of birth 
 
 
 
 
Table 2-5: Risk of late stage liver cancer diagnosis by race, 1999-2009 (n=16, 672) 
 
Race 
 
Age-adjusted model (Race age, and  
place of birth only) 
OR (95% CI) 
 
 
*Fully adjusted model 
OR (95% CI) 
White 1.00 (Referent) 1.00 (Referent) 
South Asian 1.45 (0.91, 2.30) 1.28 (0.80, 2.05) 
Chinese 0.79 (0.69, 0.91) 0.88 (0.75, 1.02) 
Japanese 0.74 (0.61, 0.90) 0.91 (0.73, 1.14) 
Filipino 1.14 (0.97, 1.34) 1.25 (1.05, 1.48) 
Place of birth (all subjects)   
U.S.-born 
Foreign-born 
Place of birth (Asians only) 
U.S.-born 
Foreign-born 
1.00 (Referent) 
0.95 (0.88, 1.03) 
 
1.00 (Referent) 
1.01 (0.78, 1.31) 
1.00 (Referent) 
1.02 (0.94, 1.11) 
 
1.00 (Referent) 
1.03 (0.77, 1.38) 
*Adjusted for age at diagnosis, sex, year of diagnosis, SEER registry, and place of birth 
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Table 2-6: Risk of late stage stomach cancer diagnosis by race, 1999-2009 (n=23, 553) 
 
Race 
 
Age-adjusted model (Race, age, and  
place of birth only) 
OR (95% CI) 
 
 
*Fully adjusted model 
OR (95% CI) 
White 1.00 (Referent) 1.00 (Referent) 
South Asian 0.97 (0.62, 1.52) 0.96 (0.61, 1.52) 
Chinese 0.81 (0.70, 0.94) 0.81 (0.69, 0.95) 
Japanese 0.91 (0.80, 1.03) 0.84 (0.71, 0.99) 
Filipino 1.00 (0.82, 1.22) 0.98 (0.80, 1.20) 
Place of birth (all subjects) 
U.S.-born 
Foreign-born 
Place of birth (Asians only) 
U.S.-born 
Foreign-born 
 
      1.00 (Referent) 
1.05 (0.98, 1.12) 
 
1.00 (Referent) 
0.93 (0.74, 1.16) 
 
1.00 (Referent) 
1.08 (1.00, 1.16) 
 
1.00 (Referent) 
0.95 (0.73, 1.24) 
*Adjusted for age at diagnosis, sex, year of diagnosis, SEER registry, and place of birth 
 
 
Table 2-7: Cervical cancer stage-specific survival by race, 1999-2009 (n=13, 982) 
Race 
Race 
 
Age-adjusted model (Race and age only) 
HR (95% CI) 
 
*Fully adjusted model 
HR (95% CI) 
Early stage (IA-IIA)   
White 1.00 (Referent) 1.00 (Referent) 
Asian 0.57 (0.44, 0.72) 0.82 (0.63, 1.06) 
Late stage (>IIA)   
White 1.00 (Referent) 1.00 (Referent) 
Asian 0.63 (0.55, 0.72) 0.76 (0.65, 0.87) 
 
Race 
 
Age-adjusted model (Race, place of birth,  
and age only) 
HR (95% CI) 
 
**Fully adjusted model 
HR (95% CI) 
Early stage (IA-IIA)   
White 1.00 (Referent) 1.00 (Referent) 
Asian 0.80 (0.62, 1.02) 0.94 (0.72, 1.23) 
Place of birth   
U.S. born 1.00 (Referent) 1.00 (Referent) 
Foreign 0.51 (0.45, 0.58) 0.76 (0.66, 0.88) 
Late stage (>IIA)   
White 1.00 (Referent) 1.00 (Referent) 
Asian 
Place of birth 
0.88 (0.77, 1.01) 0.94 (0.81, 1.10) 
U.S. born 1.00 (Referent) 1.00 (Referent) 
Foreign born 0.55 (0.51, 0.59) 0.66 (0.61, 0.72) 
*Adjusted for age at diagnosis, SEER registry, and grade 
**Adjusted for age at diagnosis, SEER registry, grade, and place of birth 
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Table 2-8: Liver cancer stage-specific survival by race, 1999-2009 (n=16, 672) 
Race 
Race 
 
Age-adjusted model (Race, age, and 
place of birth only) 
HR (95% CI) 
 
*Fully adjusted model 
HR (95% CI) 
Early stage (I/II)   
White 1.00 (Referent) 1.00 (Referent) 
South Asian 
Chinese 
             1.28 (0.88, 1.87) 
             0.64 (0.57, 0.71) 
1.03 (0.70, 1.50) 
0.69 (0.62, 0.78) 
Japanese   0.77 (0.67, 0.88) 0.84 (0.72, 0.98) 
Filipino   1.02 (0.90, 1.15) 1.13 (0.99, 1.29) 
Place of birth   
U.S.-born 
Foreign-born 
1.00 (Referent) 
0.80 (0.75, 0.85) 
1.00 (Referent) 
0.89 (0.84, 0.95) 
Late stage (III/IV)   
White 1.00 (Referent) 1.00 (Referent) 
South Asian 
Chinese 
1.09 (0.75, 1.58) 
0.77 (0.68, 0.87) 
1.06 (0.73, 1.54) 
0.79 (0.70, 0.90) 
Japanese 0.90 (0.76, 1.07) 0.89 (0.73, 1.08) 
Filipino 0.87 (0.76, 1.00) 0.90 (0.78, 1.03) 
Place of birth   
U.S.- born 
Foreign-born 
1.00 (Referent) 
                      0.97 (0.91, 1.04) 
1.00 (Referent) 
  1.03 (0.96, 1.11) 
*Adjusted for age at diagnosis, sex, SEER registry, grade, and place of birth 
 
 
Table 2-9: Stomach cancer stage-specific survival by race, 1999-2009 (n=23, 553) 
Race 
Race 
 
Age-adjusted model (Race, age, and 
place of birth only) 
HR (95% CI) 
 
*Fully adjusted model 
HR (95% CI) 
Early stage (I/II)   
White 1.00 (Referent) 1.00 (Referent) 
South Asian 
Chinese 
            1.65 (0.99, 2.75) 
            0.59 (0.49, 0.71) 
1.39 (0.83, 2.32) 
0.65 (0.53, 0.79) 
Japanese 0.66 (0.58, 0.76) 0.87 (0.73, 1.04) 
Filipino 0.94 (0.76, 1.16) 1.02 (0.82, 1.28) 
Place of birth   
U.S. born 1.00 (Referent) 1.00 (Referent) 
Foreign 0.64 (0.60, 0.69) 0.77 (0.71, 0.83) 
Late stage (III/IV)   
White 1.00 (Referent) 1.00 (Referent) 
South Asian 
Chinese 
0.87 (0.67, 1.13) 
0.77 (0.70, 0.85) 
0.87 (0.67, 1.12) 
0.80 (0.72, 0.89) 
Japanese 0.75 (0.69, 0.82) 0.77 (0.69, 0.85) 
Filipino 0.91 (0.81, 1.03) 0.91 (0.80, 1.03) 
Place of birth   
U.S. born 1.00 (Referent) 1.00 (Referent) 
Foreign born 0.83 (0.80, 0.87) 0.88 (0.85, 0.92) 
*Adjusted for age at diagnosis, sex, SEER registry, grade, and place of birth 
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Table 2-10: Effect of place of birth on stomach cancer stage-specific survival by subsite 
  *HR (95% CI) 
Cardia   
Early stage U.S.-born 
Foreign born 
1.00 (Referent) 
0.87 (0.74, 1.03) 
 
Late stage 
 
 
U.S.-born 
Foreign born 
 
1.00 (Referent) 
0.89 (0.81, 0.98) 
 
Non-cardia 
  
Early stage U.S.-born 
Foreign born 
1.00 (Referent) 
0.76 (0.68, 0.84) 
 
Late stage 
 
U.S.-born 
Foreign born 
 
1.00 (Referent) 
0.89 (0.83, 0.95) 
*Adjusted for age at diagnosis, sex, SEER registry, and grade 
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3. BREAST CANCER STAGE AT DIAGNOSIS AND STAGE-SPECIFIC 
SURVIVAL AMONG SOUTH ASIANS AND OTHER ASIAN 
SUBPOPULATIONS IN THE UNITED STATES 
 
 
 
3.1 Abstract 
Asian subpopulations living in the United States are heterogeneous with regard to time 
since immigration and acculturation.  Both of these factors likely play a significant role in 
explaining varying breast cancer outcomes among these groups.  Despite being the third 
largest Asian subpopulation in the U.S., South Asians comprise a group whose cancer 
outcomes have not been well examined and documented in the literature.  We utilized 
data from the Surveillance, Epidemiology, and End Results (SEER) program to examine 
differences in breast cancer stage at diagnosis and stage-specific survival among South 
Asian women and other Asian (Chinese, Japanese, Filipino) women compared to non-
Hispanic white women in the U.S.  Logistic regression was utilized to examine the 
association between South Asian race and breast cancer stage at diagnosis.  Stage-
specific survival following breast cancer diagnosis was also examined among the racial 
groups of interest using proportional hazards models.  Among the Asian subpopulations, 
the highest risk for late stage diagnosis of breast cancer when compared to non-Hispanic 
whites was found among South Asians.  Though non-significant, the adjusted model 
which also accounted for place of birth found 3% (OR=0.97; 95% CI 0.81, 1.16) reduced 
risk for late stage diagnosis for this group compared to non-Hispanic whites.  South 
Asian women had the most favorable stage-specific survival for both early and late stage 
diagnosis among the other Asian subpopulations when compared to non-Hispanic whites.  
The adjusted model which also accounted for place of birth showed that among those 
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diagnosed with early-stage disease, South Asians had 39% significant reduced risk (95% 
CI 0.44, 0.84) of death when compared to non-Hispanic whites.  Among those diagnosed 
with late-stage disease, this group had 20% reduced risk (95% CI 0.59, 1.09) of death 
when compared to non-Hispanic whites.  Our findings revealed that South Asians were 
more likely to present with advanced stage at diagnosis compared to the other Asian 
subpopulations we examined.  This may be attributable to genetic differences which are 
associated with the more aggressive features common for tumors diagnosed among South 
Asian women.  There are also likely differences in health-seeking behaviors which exist 
among these groups.  Our findings highlight a true need for more individualized 
prevention methods for South Asians in the U.S. in order to improve outcomes associated 
with breast cancer.     
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3.2. Background 
Breast cancer is the most common cancer and the second leading cause of death 
attributable to cancer among women in the United States [1].  There are currently 
approximately three million women in the U.S. who have been diagnosed with invasive 
breast cancer [2].  Breast cancer incidence varies across countries due to factors such as 
racial/ethnic differences in genetics, reproductive behaviors, and lifestyle exposures such 
as diet which differ across countries [3].   
 
When examining Asians living in the U.S., it has been found that these populations are 
heterogeneous with regard to time since immigration and acculturation.  Both of these 
factors likely play a significant role in explaining varying breast cancer outcomes among 
these groups [4].  Several previous studies have shown differences in breast cancer 
incidence rates among Asian subpopulations in the U.S [5-13].  However, few have 
examined differences in outcomes such as stage at diagnosis and stage-specific survival.  
It has been reported that when assessed collectively, Asian/Pacific Islander women do not 
differ greatly from non-Hispanic whites when examining stage at diagnosis and overall 
survival.  However, variations in these outcomes may be observed when examining the 
individual groups that comprise this aggregate population [14]. 
 
Despite being the third largest Asian subpopulation in the U.S. [15], South Asians 
comprise a group whose cancer outcomes have not been well examined and documented 
in the literature [6].  Studies examining breast cancer outcomes, such as stage at diagnosis 
and stage-specific survival, among South Asians residing in the U.S. are limited.  A study 
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published in 2003 examining breast cancers diagnosed among Asian subpopulations in 
the U.S. between 1992 and 1998 reported that South Asians were at increased risk of late 
stage diagnosis but had more favorable survival compared to non-Hispanic whites [14].  
We aim to extend on these findings by also examining the association of place of birth 
with these outcomes.  It has been previously reported that though South Asians are 
generally of higher socioeconomic status compared to other Asian subpopulations, 
adherence to breast cancer screening guidelines is relatively low.  This is especially true 
among recent immigrants to the U.S.  The majority of studies reporting on the breast 
cancer burden in this predominant Asian subpopulation have been conducted overseas.  
Thus, the findings of these studies cannot be generalized to South Asians living in the 
U.S since factors such as diet and reproductive behaviors, which are known to be 
associated with breast cancer outcomes, likely vary between countries [5].    
 
In order to better understand and address the breast cancer burden on the South Asian 
population in the U.S., this study will examine this racial/ethnic group separately from 
the other predominant Asian subpopulations in the country.  Through use of data from the 
Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer 
Institute (NCI), we aim to examine differences in breast cancer stage at diagnosis and 
stage-specific survival among South Asian women and other Asian (Chinese, Japanese, 
Filipino) women compared to non-Hispanic white women in the U.S. 
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3.3. Methods 
Our study population included all women identified as South Asian, Chinese, Japanese, 
Filipino, or non-Hispanic white diagnosed with incident primary invasive breast cancer 
between January 1, 1999 and December 31, 2009 among 17 population-based cancer 
registries included in the SEER program.  South Asian is defined in our study as those 
originating from either India or Pakistan as classified by SEER.  Since 1988, these two 
countries of origin have been combined to create one racial/ethnic category in SEER.  
The following registries were included in our analyses: San Francisco-Oakland, Los 
Angeles, San Jose-Monterey, Greater California, Connecticut, Detroit, Hawaii, Iowa, 
New Mexico, Seattle- Puget Sound, Utah, Atlanta, Greater Georgia, Rural Georgia, 
Kentucky, Louisiana, and New Jersey.  Patient data were ascertained by SEER from 
medical records and available information for each diagnosed case included 
demographics, tumor characteristics at diagnosis, and year of diagnosis. 
 
A total of 616,156 female breast cancer cases belonging to our subpopulations of interest 
were available for analysis.  We first excluded women whose primary diagnosis was not 
breast cancer (n=190,132).  Those less than 18 years at diagnosis or with unknown age at 
diagnosis were also excluded (n=29).  In addition, those with in situ or unknown stage at 
diagnosis were also excluded (n=24,674).  We examined place of birth as a variable of 
interest in our study.  Subjects were classified as either “U.S.-born” or “foreign-born” 
based on data extracted by SEER from patient medical records or death certificates.  
Since one principal aim of this study was to make inferences regarding the effect of U.S. 
versus foreign birth on subsequent breast cancer outcomes, those with unknown place of 
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birth were excluded from our analyses (n=217,775).  Demographic and tumor 
characteristics of the eligible Asian cases prior to these exclusions are shown in 
Appendix C.  A total of 183,546 women met these inclusion criteria and were included 
in our analytic sample.   
 
Several covariates were considered to be potential confounders in our analyses.  The 
models used in the logistic regression analysis adjusted for the effects of age at diagnosis, 
year of diagnosis, and SEER registry.  Age is adjusted for as a confounder due to its 
varying distributions in the racial/ethnic subgroups examined and due to the association 
between older age and increased risk of cancer.  Year of diagnosis is taken into account 
since diagnosis and surveillance methods for cancer detection may have varied during the 
time period of our study.  SEER registry is adjusted for to take into account the location 
from which the cases originated since access to care and likelihood of diagnosis may vary 
between locations.  The models used in the survival analysis also adjusted for the effects 
of grade, ER status, and PR status in addition to the covariates used in the logistic 
regression analysis.  These tumor characteristics are taken into account due to their effect 
on survival.  In addition, these characteristics may vary due to genetic differences 
between the racial/ethnic subgroups being compared.   
 
The primary association of interest in the logistic regression analysis was the effect of 
South Asian race on breast cancer stage at diagnosis.  Subjects were categorized as 
having early (I or II) or late (III or IV) stage disease using AJCC staging, with the 
outcome of interest defined as late stage at diagnosis.  Logistic regression was conducted 
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to obtain odds ratios and 95% confidence intervals to examine the association between 
race and late stage at diagnosis while controlling for potential confounding by age at 
diagnosis, year of diagnosis, and SEER registry.  Age-adjusted associations were first 
obtained using models with only race and age as predictors.  Adjusted associations were 
then examined which controlled for potential confounders.  We also examined the effect 
of place of birth by including it as a predictor along with race and the other covariates.  
Non-Hispanic whites served as the referent racial group in all models.   
 
We also examined potential interactions between race and place of birth.  All Asians 
were combined to create one category and compared to the reference group of non-
Hispanic whites in a crude model which included Asian race, place of birth, and the 
interaction of these covariates.  An aggregate categorical indicator for Asian race was 
used due to the small sample sizes found when examining the individual subpopulations 
separately.  Place of birth was categorized as U.S or foreign-born with the U.S.-born 
cases serving as the reference group.   
 
Stage-specific survival following breast cancer diagnosis was also examined among the 
racial groups of interest.  Survival time was provided as a variable in the SEER database 
and was calculated by using the date of diagnosis and the earliest of the following: date of 
death, date last known to be alive, or the follow-up cutoff date of December 31, 2009.  In 
addition, vital status was provided in the data as either “alive” or “dead.”  The Kaplan-
Meier method was utilized to detect significant differences in overall survival between 
the racial groups being compared through use of the log-rank test.  Cox proportional 
106 
 
hazards regression was utilized for multivariate adjustment to assess the effects of age, 
SEER registry, stage, grade, estrogen receptor (ER) status, and progesterone receptor 
(PR) status on the observed racial differences in survival.  The proportional hazards (PH) 
assumption was assessed for these covariates prior to inclusion in the models through use 
of log-log plots and assessment of time-varying covariates.  Violation of the PH 
assumption was observed for stage and age, resulting in stratification by stage and 
inclusion of a time-varying covariate for age.  In addition, non-parallelism in the 
graphical test of the PH assumption for ER status, PR status, and grade resulted in 
exclusion of cases in the unknown categories of these variables.  Hazard ratios and 95% 
confidence intervals were obtained to examine the association between race and stage-
specific survival.  Age-adjusted associations were obtained using models with only race 
and age as predictors.  Adjusted estimates were then examined which controlled for 
potential confounders.  We also examined the effect of place of birth by including it as a 
predictor along with race and the other covariates.  All analyses were conducted using 
SAS, version 9.3 (SAS Institute, Inc., Cary, NC).   
 
3.4. Results 
The distribution of demographic and tumor characteristics of interest by race is shown in 
Table 3-1.  South Asian women had the highest proportion of diagnosed cases in the 
youngest age category (18-39 years, 15%) among the racial groups, while Japanese 
women had the highest proportion in the oldest age category (≥70 years, 36.7%).  The 
majority of South Asian cases were reported from New Jersey while the other Asian 
groups were reported mostly from registries in California and Hawaii.  Non-Hispanic 
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white cases were also mostly obtained from reporting sites in California.  The highest 
proportions of stage III and IV cancers among the racial groups were found in South 
Asians while the lowest proportions were in Japanese women.  This pattern was also 
found among tumors diagnosed at grades III and IV.  South Asians also had the highest 
proportions among the racial groups of tumors diagnosed as ER and PR negative.  
Foreign-born cases were highest among Filipino women, while the lowest proportion was 
found among Japanese women. 
 
Table 3-2 shows the results obtained from the age-adjusted and fully adjusted logistic 
regression models examining the association between race and late stage at diagnosis.  
When examining the age-adjusted model with race and age as the only predictors, South 
Asians had significantly increased risk (24%) of late stage diagnosis compared to non-
Hispanic whites.  In comparison, the other Asian groups had significantly decreased risk 
according to this model.  The elevated risk among South Asians became non-significant 
and reduced to 7% increased risk after adjusting for age at diagnosis, year at diagnosis, 
and SEER registry.  The decreased risk observed among the other Asian groups remained 
significant in this adjusted model, with the exception of Filipino cases.        
 
Place of birth was also included as a covariate to examine its potential to confound the 
association between race and late stage at diagnosis.  Though it did not achieve statistical 
significance, the age-adjusted model with race, age, and place of birth as predictors 
showed that South Asians had increased risk (18%) of late stage diagnosis compared to 
non-Hispanic whites.  The odds ratio estimate obtained for the fully adjusted model 
showed that the risk was no longer elevated (OR=0.97; 95% CI 0.81, 1.16) after 
108 
 
controlling for the effects of confounders.  When examining the independent effect of 
place birth after adjusting for the other covariates, it was observed that U.S.-born cases 
had significantly lower risk of late stage at diagnosis compared to those that were 
foreign-born in all of the models used.   
 
We also assessed the interaction between race and place of birth.  The crude model found 
a significant effect for the interaction term (OR=1.26; 95% CI 1.12, 1.42), suggesting that 
the association between Asian race and late stage at diagnosis may vary by place of birth.  
This significant effect estimate for the interaction between race and place of birth 
indicates that there is an increased risk of late stage diagnosis among Asians who are 
foreign-born. However, this interaction term was no longer significant when included in 
the fully adjusted model (OR=0.98; 95% CI 0.86, 1.12).  In addition, interaction between 
individual Asian races and place of birth was also examined.  However, these interaction 
effects were found to be non-significant.  
 
Figure 3-1 shows the proportion of late stage diagnosis by place of birth among the 
Asian groups examined.  The proportion of late stage cases is higher among the foreign-
born across the racial groups, with the exception of Japanese cases where the proportion 
is greater among the U.S.-born cases.  South Asian cases had the greatest proportion of 
late stage diagnoses for both U.S. and foreign-born cases, while the lowest was seen 
among Japanese cases.  The greatest difference in proportion of late stage cases according 
to place of birth was also seen among the South Asians, although this difference was not 
statistically significant. 
 
109 
 
Figure 3-2 show unadjusted Kaplan-Meier curves examining overall survival comparing 
South Asians to the other Asian groups of interest in our study and non-Hispanic whites.  
The log-rank test p-value which can be used to detect significant differences in the 
survival curves is also shown.  As can be seen in the figure, South Asians had worse 
unadjusted overall survival compared to the other Asian groups.  However, they had 
more favorable unadjusted overall survival when compared to non-Hispanic whites.  The 
log-rank test p-value of <.0001 indicates significant difference in the survival curves 
between the racial/ethnic groups being compared.  Figure 3-3 shows the unadjusted 
curves of the Asian subpopulations only.  The log-rank test p-value of 0.001 shows that 
significant differences in the survival curves remain after exclusion of non-Hispanic 
whites.  
 
Figures 3-4 through 3-6 display the distributions of ER status, PR status, and tumor 
grade among the Asian groups examined.  All of these tumor characteristics play a major 
role in determining outcomes associated with breast cancer.  More favorable outcomes 
are often found when tumors are diagnosed as positive for hormone receptors, such as ER 
and PR.  South Asians had the lowest proportions of both ER and PR positive tumors 
when compared to the other Asian groups.  This group also had the highest proportion of 
tumors diagnosed at grades III and IV. 
 
The results of the Cox regression analysis examining the association between race and 
stage-specific survival are shown in Table 3-3.  Stage-specific survival was examined by 
conducting the analyses separately among those diagnosed with early (I or II) and late (III 
or IV) stage breast cancer.  When examining the age-adjusted model with only race and 
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age as predictors, it was found that among those diagnosed with early stage disease, 
South Asians had significantly decreased risk (HR=0.61; 95% CI 0.44, 0.84) of death 
compared to non-Hispanic whites.  The other Asian groups also had significantly 
decreased risk of death in this model.  This decreased risk of death among South Asians 
remained significant (HR=0.53; 95% CI 0.38, 0.73) and the protective effect of race was 
not as strong after adjusting for the potentially confounding effects of age at diagnosis, 
SEER registry, grade, ER status, and PR status.  The lowest risk of death was found 
among South Asians when compared to non-Hispanic whites.  The adjusted model also 
produced significant hazard ratios for the other Asian groups as well.  South Asians also 
had the lowest risk of death when examining those diagnosed with late stage disease.  
According to the adjusted model, South Asians had 30% reduced risk (HR=0.70, 95% CI 
0.51, 0.94) of death compared to non-Hispanic whites among those diagnosed with late 
stage disease. 
 
Place of birth was also included as a covariate to examine its effect on the association 
between race and stage-specific survival.  When examining the age-adjusted model with 
race, age, and place of birth as predictors, it was found that among those diagnosed with 
early stage disease, South Asians still had reduced risk (HR=0.79; 95% CI 0.57, 1.09) of 
death compared to non-Hispanic whites.  The other Asian groups had significantly 
decreased risk of death in this model. The decreased risk of death among South Asians 
became statistically significant (HR=0.61; 95% CI 0.44, 0.84) in the fully adjusted 
model.  This model also found the lowest risk of death among South Asians when 
compared to non-Hispanic whites.  Though non-significant (HR=0.80; 95% CI 0.59, 
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1.09), South Asians were again found to have the lowest risk of death when examining 
those diagnosed with late stage disease in the fully adjusted model. 
 
Potential interaction effects between race and place of birth associated with stage-specific 
survival were also examined in the same method used previously for the logistic 
regression analysis.  The crude model which included the main effects of Asian race and 
place of birth in addition to their interaction found a significant effect (HR=1.57; 95% CI 
1.40, 1.76) for the interaction term.  This significant effect estimate for the interaction 
between Asian race and place of birth indicates that there is an increased risk of death 
among Asians who are foreign-born.  This interaction remained significant in the fully 
adjusted models among those diagnosed at early (HR=1.29; 95% CI 1.10, 1.50) and late 
(HR=1.32; 95% CI 1.05, 1.67) stages.  In addition, interactions between individual Asian 
races and place of birth were also examined and found to be highly non-significant.   
 
3.5. Discussion 
 
This study found notable heterogeneity of risk when examining late stage breast cancer 
diagnosis among South Asians and other Asian subpopulations when compared to non-
Hispanic whites.  South Asians had the highest risk of late stage diagnosis and most 
favorable stage-specific survival among the Asian groups when compared to non-
Hispanic whites.  Controlling for the effects of age at diagnosis, year of diagnosis, and 
SEER registry did not diminish the heterogeneity of these effects.  Heterogeneity of 
effect estimates was also found among the Asian groups when examining stage-specific 
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breast cancer survival by race, further highlighting the need for individual assessment of 
breast cancer burden in this aggregate population. 
 
Among the Asian subpopulations, the highest risk for late stage diagnosis of breast cancer 
when compared to non-Hispanic whites was found among South Asians.  Though non-
significant, the adjusted model which also accounted for place of birth found 3% 
(OR=0.97; 95% CI 0.81, 1.16) reduced risk for late stage diagnosis for this group 
compared to non-Hispanic whites.  However, much lower risk was found among the 
other Asian groups examined.  This increased risk for late stage diagnosis found among 
South Asians compared to non-Hispanic whites was also observed in an earlier study 
examining the association between race/ethnicity and breast cancer outcomes [14].  
Diagnosis of breast cancer at an advanced stage of disease greatly increases risk of 
mortality and thus reduces survival time.  Risk factors for advanced stage diagnosis 
include low socioeconomic status, belonging to a racial/ethnic minority group, and 
foreign birth.  Studies among immigrant women in the U.S. have found that they are at 
increased risk for unfavorable breast cancer outcomes due to limited English language 
proficiency, insufficient health insurance, and experience barriers to access such as social 
exclusion.  As a result, they are less likely to have sufficient knowledge regarding cancer 
prevention and thus less likely to receive adequate screening prior to diagnosis of disease 
[16]
.  However when examining South Asians, it has been found that this minority 
population is in fact comprised of the highest educated, highest paid, and best insured 
immigrants in the U.S.  Despite seemingly high socioeconomic status, this group has 
reported insufficient adherence to breast cancer prevention recommendations, such as 
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regular screenings.  This is especially true among recent immigrants to the U.S [5].  The 
lack of proper prevention methods likely contributes greatly to the advanced stage 
presentation of breast cancer found among South Asian women.      
 
Our study further demonstrated that South Asian women were more likely to be 
diagnosed with tumors different from other Asian subpopulations and non-Hispanic 
whites with regard to clinical and pathological presentation.  This group had the greatest 
proportion of cases (15%) in the youngest age category of 18-39 years.  In addition to 
having the greatest proportion of cases presenting at stages III and IV (23.4%), these 
women also had the greatest proportion of tumors at grades III and IV (50.6%).  They 
also presented with the greatest proportion of ER and PR- negative tumors.  This is 
consistent with the findings of Moran et al which also reported that South Asian women 
were diagnosed with tumors of greater stage, larger size, and higher grade when 
compared to non-Hispanic whites [5].  A recent review of breast cancer burden among 
South Asian women found that ER and PR status are reported as positive in only about 
20-45% of Indian patients.  In addition, the proportion of ER-positive tumors was lower 
overall among these women compared to those of western countries.  Negative hormone 
receptor status tumors are known to be more aggressive and their growth largely can not 
be controlled with traditional chemotherapy treatment [17]. These pathological 
characteristics of advanced stage, grade, and negative hormone receptor status, are all 
indicative of more aggressive and fast-growing breast tumors and likely play a key role in 
the greater risk of advanced stage diagnosis found among South Asians compared to 
other Asian subpopulations.    
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Our findings also showed that when examining the independent effect of place of birth on 
late stage at diagnosis, the risk was lower among cases that were U.S.-born compared to 
those that were foreign-born.  In the adjusted model that also accounted for age at 
diagnosis, year of diagnosis, and SEER registry, it was observed that U.S.-born cases had 
13% reduced risk (95% CI 0.84, 0.90) of late stage diagnosis compared to those that were 
foreign-born.  This increased risk found among foreign-born women is likely attributable 
to several factors, such as length of residency in the U.S, English language proficiency, 
and cultural beliefs towards screening and other preventive practices.  A review of breast 
cancer screening practices among Asian women in the U.S. found that adequate screening 
according to established guidelines was not conducted in this group.  This lack of 
preventive care undoubtedly leads to increased risk of late stage diagnosis.  It has widely 
been reported that the Asian population in the U.S. is primarily composed of immigrants, 
with the majority of them reporting foreign-birth [18].  Thus, they likely have differing 
cultural beliefs regarding health that will at times negatively impact cancer outcomes.  
These beliefs may include self-sufficiency and greater emphasis on familial obligations 
rather than individual health.  These behaviors likely contribute to decreased contact with 
primary care and lack of preventive care, such as regular screenings [4].  It has been found 
that immigrant South Asian women in particular mistakenly view breast cancer as a 
disease common only to women from westernized societies and do not believe that they 
are susceptible to the disease [19].  Thus, interventions which target these racial 
subpopulations is of great public health importance in order to promote breast cancer 
awareness and to increase uptake of preventive practices such as regular screenings and 
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self- examinations which will likely lead to reduced advanced stage diagnosis and poor 
disease outcomes. 
 
Figure 3-7 is a graphical depiction of all of these factors which likely contribute to the 
association between race/ethnicity and late stage at diagnosis.  
 
Our findings showed that South Asian women had the most favorable stage-specific 
survival for both early and late stage diagnosis among the other Asian subpopulations 
when compared to the referent group of non-Hispanic whites.  The adjusted model which 
also accounted for place of birth showed that among those diagnosed with early-stage 
disease, South Asians had 39% significant reduced risk (95% CI 0.44, 0.84) of death 
when compared to non-Hispanic whites.  Among those diagnosed with late-stage disease, 
this group had 20% reduced risk (95% CI 0.59, 1.09) of death when compared to non-
Hispanic whites.  This finding is consistent with an earlier study which also found a 
decreased risk (HR=0.80; 95% CI 0.60, 1.50) of death among South Asians compared to 
non-Hispanic whites [14].   
 
It has been well established that risk factors such as late child bearing age, low parity, 
consumption of high-fat, high-caloric foods, obesity, and physical inactivity are all 
associated with decreased survival from breast cancer.  These reproductive and lifestyle 
behaviors are also associated with westernized culture [20].  This finding is consistent with 
our results which showed that Asian women in our subpopulations of interest had better 
survival compared to non-Hispanic white women in the U.S.  The majority of South 
Asians in the U.S. today are recent immigrants.  Only approximately 9% of Asian Indians 
and 6% of Pakistanis older than 18 years were born in the U.S. according to the 2000 
116 
 
U.S. census.  Most adults that comprise this Asian subpopulation immigrated to the U.S. 
after 1985.  As a result of their recent immigration, the extent of acculturation present in 
this group is relatively low compared to other immigrant groups in the U.S [6].  Our 
results showed that this group had the best stage-specific survival among the Asian 
subpopulations examined.  The recency of immigration to the U.S. for the majority of this 
group is likely an explanation for this finding. 
 
Place of birth may be used as a measure of acculturation.  Breast cancer cases that are 
U.S.-born are thus more likely to demonstrate lifestyle behaviors native to the U.S., such 
as a diet high in fat intake.  Those that were U.S.-born had an increased risk of death 
compared to those that were foreign born in all of the models used in our analyses.  This 
finding is consistent with previous studies which have reported an association between 
westernized lifestyles and poor breast cancer survival.  The decreased risk of death 
observed among the foreign-born in our study is likely attributable to differences in 
lifestyle among those that are Asian immigrants who have not yet fully acculturated to 
the lifestyle behaviors of those native to the U.S [21].  Foreign-born Asian women in 
particular have been found to consume less dietary fat, report older age at menarche, have 
children at younger ages, and also breastfeed at greater rates compared to U.S.-born 
descendants of immigrant women [4].  All of these factors likely contribute to more 
favorable breast cancer outcomes among these immigrant women compared to non-
Hispanic white women in the U.S.   
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Figure 3-8 is a graphical depiction of all of these factors which likely contribute to the 
association between race/ethnicity and overall survival following breast cancer diagnosis.  
 
Both the late stage at diagnosis and stage-specific survival analyses produced adjusted 
effect estimates that were closer to the null than the crude estimates for all of the Asian 
subpopulations examined.  This shift may be attributable to variations in the distribution 
of age at diagnosis in these groups.  Differences in age likely played a role in the 
heterogeneity of effect estimates found across the groups examined in our study.  As seen 
in Table 3-1, the proportions of cases in each age category notably varied among the 
Asian subpopulations.  This trend may be a reflection of varying genetic differences in 
etiology and subsequent aggressiveness in tumor progression in these populations. 
 
A strength of this study is that it is one of the few studies focusing on breast cancer 
outcomes among South Asians in the U.S.  To date, most studies focusing on this major 
Asian subpopulation have been conducted abroad in countries such as the U.K.  
Numerous studies conducted in the South Asian region have reported findings indicating 
risk factors for more aggressive disease and subsequent advanced stage at diagnosis in 
this population, such as higher tumor grade and greater proportions of tumors which are 
hormone-receptor negative [5].  Thus, it is becoming increasingly important to examine 
these outcomes in South Asians residing in the U.S. in order to better understand the 
burden of disease and to create effective interventions which target this major population 
of immigrants.    
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The findings of our analyses also highlight the need to examine breast cancer burden in 
this group independently of other the other Asian subpopulations, especially when 
focusing on stage at diagnosis.  Though non-significant, this specific subpopulation had 
the highest risk for late stage diagnosis compared to the other Asian groups examined and 
provides further support for the notion that Asians and Pacific Islanders can not be 
aggregated into a collective racial/ethnic category in epidemiological studies.  The 
decreased risk of late stage diagnosis found among the other Asian subpopulations 
examined in our study was not apparent for the South Asians cases.  Our findings are 
indicative of certain health-seeking behaviors present among the South Asian community 
in particular residing in the U.S. which need to be addressed independently of other Asian 
subpopulations.       
 
To our knowledge, this study is one of the few to take place of birth into account when 
examining breast cancer outcomes among Asian subpopulations in the U.S.  Stanford et 
al [8] examined differences in breast cancer incidence among Asian immigrants to the 
U.S. and their descendants, while Pineda et al [21] previously examined survival among 
Chinese, Japanese, and Filipino immigrants compared to U.S.-born Asians and 
Caucasians.  Neither of these studies took South Asians into account in their analyses.  
As mentioned previously, place of birth is a significant indicator of breast cancer 
outcomes when examining Asians living in the U.S., as it has been found that this racial 
group is heterogeneous with regard to immigration and acculturation. 
 
A limitation of our study is the exclusion of cases with unknown place of birth data.  The 
proportion of cases with unknown place of birth ranged from 28% among Filipino to 55% 
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among non-Hispanic whites.  It was found that the proportion of late stage diagnosis was 
slightly higher among those with known (58.4%) place of birth compared to those with 
unknown (41.6%).  The degree of completeness regarding this data is a reflection of the 
methods used by medical staff when ascertaining personal information from patients.  In 
a study examining completeness of birthplace data in the Greater Bay Area Cancer 
Registry in California, Gomez et al reported that Asians with unknown place of birth data 
were more likely to be U.S.-born compared to those with recorded place of birth.  Thus, 
the degree of completeness of this data may be differential according to place of birth if 
hospital staff choose to selectively inquire about this information if a patient is assumed 
to be foreign-born.  Any possible bias introduced by incompleteness of place of birth data 
can only be addressed through improving data ascertainment methods at the local hospital 
level [22]. 
Another limitation of this study is the possible misclassification of our main exposure of 
interest, which is race/ethnicity.  A recent study [23] examining the accuracy of the 
race/ethnicity variable in a SEER registry in California used predictive value positive 
(PV+) and sensitivity to quantify the misclassification of this variable.  Among the Asian 
subpopulations of interest in our study, it was reported that PV+ ranged from 80%-92% 
and sensitivity ranged from 77%-80%.  Thus, there is potential underestimation of 
subpopulation size in our analyses.  Another limitation may be the classification of 
subjects as “foreign-born” if not born within the U.S.  Since place of birth is not reported 
for every subject, it is not feasible to include specific countries of origin when examining 
this exposure due to small sample sizes for the Asian subpopulations.  Despite these 
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limitations, SEER is currently the most comprehensive source of data regarding cancer 
burden among the general population currently available in the U.S.  
 
Conclusion 
Through individual examination of the major Asian subpopulations that comprise the 
aggregate Asian/Pacific Islander racial/ethnic category in the U.S., our findings revealed 
notable heterogeneity in risk of late stage breast cancer at diagnosis and stage-specific 
survival.  Breast cancer is one of the few cancers that responds effectively to treatment 
when diagnosed at an early stage.  Thus, it is becoming increasingly important to create 
targeted interventions for groups that may be at higher risk for poor outcomes.  It is vital 
to understand which populations are more likely to present with advanced stages of breast 
cancer in order to ensure that these groups are utilizing proper prevention and 
management practices.  Our findings revealed that South Asians were more likely to 
present with advanced stage at diagnosis compared to the other Asian subpopulations we 
examined.  This may be attributable to genetic differences which are associated with the 
more aggressive features common for tumors diagnosed among South Asian women.  
There are also likely differences in health-seeking behaviors which exist among these 
groups.  It has been previously reported that only 5% of Asian Indian women complete 
breast self-examinations on a monthly basis, whereas 23% of Chinese and 51% of 
Filipino women engage in this preventive behavior [6].  Thus, there is a true need for more 
individualized prevention for this major immigrant population in the U.S. in order to 
improve outcomes associated with breast cancer.     
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3.7. Tables and Figures 
Table 3-1: Demographic and tumor characteristics among 183,546 women diagnosed with invasive breast cancer by race, 1999-2009 
Characteristic South Asian 
(n=698) 
Chinese (n=3631) Japanese (n=3172) Filipino (n=5792) Non-Hispanic White 
(n=170,253) 
Age at diagnosis, y      
18-39 105 (15.0) 322 (8.9) 149 (4.7) 387 (6.7) 9233 (5.4) 
40-49 188 (26.9) 1052 (29.0) 510 (16.1) 1346 (23.2) 29213 (17.2) 
50-59 207 (29.7) 1008 (27.8) 685 (21.6) 1795 (31.0) 39674 (23.3) 
60-69 130 (18.6) 602 (16.6) 664 (20.9) 1332 (23.0) 36966 (21.7) 
≥70 68 (9.7) 647 (17.8) 1164 (36.7) 932 (16.1) 55167 (32.4) 
Year of diagnosis      
1999-2001 137 (19.6) 862 (23.7) 951 (30.0) 1345 (23.2) 47591 (28.0) 
2002-2004 176 (25.2) 1046 (28.8) 984 (31.0) 1613 (27.9) 50130 (29.4) 
2005-2007 209 (29.9) 1042 (28.7) 787 (24.8) 1746 (30.2) 44711 (26.3) 
SEER Registry      
San Francisco-Oakland 30 (4.3) 943 (26.0) 166 (5.2) 850 (14.7) 7584 (4.5) 
Los Angeles 27 (3.9) 1237 (34.1) 766 (24.2) 1910 (33.0) 28479 (16.7) 
San Jose-Monterey 30 (4.3) 255 (7.0) 100 (3.2) 242 (4.2) 3835 (2.3) 
Greater California 37 (5.3) 398 (11.0) 327 (10.3) 1478 (25.5) 40638 (23.9) 
Connecticut 61 (8.7) 40 (1.1) 9 (0.3) 31 (0.5) 13502 (7.9) 
Detroit 23 (3.3) 13 (0.4) 8 (0.3) 13 (0.2) 4999 (2.9) 
Hawaii 3 (0.4) 347 (9.6) 1616 (51.0) 669 (11.6) 1691 (1.0) 
New Mexico 3 (0.4) 1 (0.03) 3 (0.1) 3 (0.1) 2992 (1.8) 
Seattle-Puget Sound 48 (6.9) 132 (3.6) 125 (3.9) 232 (4.0) 10196 (6.0) 
Utah 5 (0.7) 7 (0.2) 10 (0.3) 3 (0.1) 3060 (1.8) 
Atlanta 86 (12.3) 40 (1.1) 6 (0.2) 9 (0.2) 5880 (3.5) 
Greater Georgia 40 (5.7) 8 (0.2) 7 (0.2) 15 (0.3) 12794 (7.5) 
Rural Georgia 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 311 (0.2) 
Kentucky 4 (0.6) 2 (0.1) 3 (0.1) 4 (0.1) 5748 (3.4) 
Louisiana 8 (1.2) 4 (0.1) 0 (0.0) 10 (0.2) 5152 (3.0) 
 
124 
 
Table 3-1 (continued) 
 
     
New Jersey 292 (41.8) 198 (5.5) 26 (0.8) 319 (5.5) 18365 (10.8) 
Stage at diagnosis      
I 262 (37.5) 1716 (47.3) 1745 (55.0) 2435 (42.0) 74616 (43.8) 
II 273 (39.1) 1417 (39.0) 1105 (34.8) 2379 (41.1) 63530 (37.3) 
III 110 (15.8) 370 (10.2) 209 (6.6) 673 (11.6) 19612 (11.5) 
IV 53 (7.6) 128 (3.5) 113 (3.6) 305 (5.3) 12495 (7.3) 
Grade      
I 72 (10.3) 601 (16.6) 790 (24.9) 796 (13.7) 31483 (18.5) 
II 222 (31.8) 1421 (39.1) 1377 (43.4) 2277 (39.3) 64271 (37.8) 
III 338 (48.4) 1273 (35.1) 833 (26.3) 2216 (38.3) 57063 (33.5) 
IV 15 (2.2) 77 (2.1) 38 (1.2) 105 (1.8) 2676 (1.6) 
Unknown 51 (7.3) 259 (7.1) 134 (4.2) 398 (6.9) 14760 (8.7) 
ER Status      
Positive/borderline 464 (66.5) 2565 (70.6) 2445 (77.1) 4076 (70.4) 119453 (70.2) 
Negative 171 (24.5) 705 (19.4) 506 (16.0) 1199 (20.7) 32697 (19.2) 
Unknown 63 (9.0) 361 (9.9) 221 (7.0) 517 (8.9) 18103 (10.6) 
PR Status      
Positive/borderline 398 (57.0) 2169 (59.7) 2113 (66.6) 3320 (57.3) 98925 (58.1) 
Negative 233 (33.4) 1049 (28.9) 769 (24.2) 1769 (30.5) 50024 (29.4) 
Unknown 67 (9.6) 413 (11.4) 290 (9.1) 703 (12.1) 21304 (12.5) 
Place of birth      
Foreign-born 611 (87.5) 3051 (84.0) 959 (30.2) 5328 (92.0) 28041 (16.5) 
U.S.-born 87 (12.5) 580 (16.0) 2213 (69.8) 464 (8.0) 142212 (83.5) 
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Table 3-2: Risk of late stage breast cancer diagnosis by race, 1999-2009 (n=183,546) 
 
Race 
 
Age-adjusted model (Race and age only) 
OR (95% CI) 
 
 
*Fully adjusted model 
OR (95% CI) 
 
 
  
White 1.00 (Referent) 1.00 (Referent) 
South Asian 1.24 (1.04, 1.48) 1.07 (0.89, 1.28) 
Chinese 0.66 (0.60, 0.73) 0.76 (0.69, 0.83) 
Japanese 0.49 (0.44, 0.55) 0.63 (0.55, 0.71) 
Filipino 0.86 (0.80, 0.92) 0.98 (0.92, 1.06) 
 
Race 
 
Age-adjusted model (Race, age, and  
place of birth only) 
OR (95% CI) 
 
**Fully adjusted model 
OR (95% CI) 
 
  
White 1.00 (Referent) 1.00 (Referent) 
South Asian 1.18 (0.99, 1.41) 0.97 (0.81, 1.16) 
Chinese 0.63 (0.57, 0.70) 0.70 (0.63, 0.77) 
Japanese 0.48 (0.43, 0.54) 0.61 (0.54, 0.69) 
Filipino 0.82 (0.76, 0.88) 0.89 (0.83, 0.96) 
Place of birth 
Foreign 
U.S.-born 
 
1.00 (Referent) 
             0.93 (0.90, 0.96) 
 
1.00 (Referent) 
0.87 (0.84, 0.90) 
OR indicates odds ratio; 95% CI, confidence interval 
*Adjusted for age at diagnosis, year of diagnosis, SEER registry 
**Adjusted for age at diagnosis, year of diagnosis, SEER registry, and place of birth 
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Figure 3-1: Proportion of late stage breast cancer diagnosis by place of birth 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Compared with South Asians, proportions significantly different as tested by Chi-square  
             p-value < 0.05 
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Figure 3-2: Unadjusted Kaplan-Meier curves of overall breast cancer survival comparing South 
Asians to other Asian subpopulations and non-Hispanic whites 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3: Unadjusted Kaplan-Meier curves of overall breast cancer survival comparing South 
Asians to other Asian subpopulations  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log rank p-value: 0.001 
Log-rank p-value:  <.0001 
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Figure 3-4: Distribution of ER status among Asian subpopulations, 1999-2009 
 
     Compared with South Asians, proportions significantly different as tested by Chi-square  
      p-value < 0.05  
 
 
 
 
Figure 3-5: Distribution of PR status among Asian subpopulations, 1999-2009 
 
      Compared with South Asians, proportions significantly different as tested by Chi-square  
      p-value < 0.05  
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Figure 3-6: Distribution of breast tumor grade at diagnosis among Asian subpopulations, 1999-
2009 
 
     Compared with South Asians, proportions significantly different as tested by Chi-square  
      p-value < 0.05  
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Table 3-3: Breast cancer stage-specific survival by race, 1999-2009 (n=150,241) 
Race 
Race 
 
Age-adjusted model (Race and age only) 
HR (95% CI) 
 
*Adjusted model 
HR (95% CI) 
Early stage (I/II)   
White 1.00 (Referent) 1.00 (Referent) 
South Asian 
Chinese 
0.61 (0.44, 0.84) 
0.47 (0.41, 0.53) 
0.53 (0.38, 0.73) 
0.70 (0.61, 0.79) 
Japanese 0.46 (0.41, 0.51) 0.74 (0.65, 0.84) 
Filipino 0.57 (0.52, 0.63) 0.81 (0.73, 0.90) 
Late stage (III/IV)   
White 1.00 (Referent) 1.00 (Referent) 
South Asian 
Chinese 
0.86 (0.63, 1.16) 
0.56 (0.47, 0.68) 
0.70 (0.51, 0.94) 
0.72 (0.60, 0.87) 
Japanese 0.68 (0.56, 0.83) 0.79 (0.64, 0.98) 
Filipino 0.69 (0.61, 0.78) 0.87 (0.77, 0.99) 
 
Race 
 
Age-adjusted model (Race, age and  
place of birth only) 
HR (95% CI) 
 
**Adjusted model 
HR (95% CI) 
Early stage (I/II)   
White 1.00 (Referent) 1.00 (Referent) 
South Asian 
Chinese 
0.79 (0.57, 1.09) 
0.58 (0.51, 0.66) 
0.61 (0.44, 0.84) 
0.78 (0.68, 0.89) 
Japanese 0.47 (0.42, 0.52) 0.76 (0.67, 0.86) 
Filipino 0.74 (0.67, 0.82) 0.93 (0.83, 1.03) 
Place of birth   
Foreign 1.00 (Referent) 1.00 (Referent) 
U.S. born 1.42 (1.37, 1.48) 1.20 (1.15, 1.25) 
Late stage (III/IV)   
White 1.00 (Referent) 1.00 (Referent) 
South Asian 
Chinese 
1.14 (0.84, 1.54) 
0.72 (0.60, 0.88) 
0.80 (0.59, 1.09) 
0.81 (0.66, 0.98) 
Japanese 0.71 (0.58, 0.86) 0.81 (0.65, 1.01) 
Filipino 0.92 (0.81, 1.04) 0.99 (0.87, 1.13) 
Place of birth   
Foreign 1.00 (Referent) 1.00 (Referent) 
U.S. born 1.47 (1.40, 1.55) 1.20 (1.13, 1.27) 
HR indicates hazard ratio; 95% CI, confidence interval 
*Adjusted for age at diagnosis, SEER registry, grade, ER status, PR status 
**Adjusted for age at diagnosis, SEER registry, grade, ER status, PR status, and place of birth 
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Figure 3-7: Association between race/ethnicity and advanced stage at breast cancer diagnosis 
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Figure 3-8: Association between race/ethnicity and survival after breast cancer diagnosis  
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4. PRIMARY CARE AND BREAST CANCER OUTCOMES AMONG ASIAN 
SUBPOPULATIONS ENROLLED IN MEDICARE 
 
 
 
4.1. Abstract 
Regular visits with primary care physicians (PCP) significantly impact breast cancer 
prognosis through increasing the likelihood of early detection.  Few studies have utilized 
population-based data to quantify the association between health care service use and 
breast cancer outcomes among Asian Americans.  We aimed to examine this association 
among Asians compared to non-Hispanic whites through use of the linked SEER-
Medicare database.  Racial/ethnic differences in the association between primary care 
utilization and stage at breast cancer diagnosis was examined using logistic regression.  
Stage-specific survival following breast cancer diagnosis was examined using Cox 
regression.  Significant associations were found between PCP visits and use of 
mammography among both Asians and non-Hispanic whites.  Asians in the highest 
quartile of total PCP visits had 57% (OR=0.43; 95% CI 0.27, 0.70) decreased risk of late 
stage diagnosis compared to those in the lowest quartile.  Foreign-born status was 
significantly protective among Asians diagnosed at late stages, with these cases having 
62% (HR=0.38; 95% CI 0.21, 0.70) decreased risk of death compared to those that were 
U.S.-born.  This study provided notable findings regarding health-related behaviors and 
existing health conditions among older Asian American women which impact breast 
cancer outcomes.  Public health programs which promote regular visits to PCPs must be 
promoted in this population. 
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4.2. Background 
Breast cancer remains a disease of significant public health concern in the U.S. today.  In 
2014, it is estimated that approximately 232,670 women will be newly diagnosed with 
the disease and about 40,000 deaths will occur as a result of breast cancer.  Since primary 
prevention of breast cancer is not a viable option, early detection remains the focus of 
public health efforts to combat the disease.  Prognosis is significantly improved when the 
disease is detected in its early stages compared to diagnosis at more advanced stages [1].   
 
Physicians involved in primary care can have a significant impact on early detection of 
breast cancer [2].  They are often the most direct source of information regarding the 
benefits of cancer prevention methods [3].  It has consistently been reported that a 
recommendation from a primary care physician (PCP) is strongly associated with 
receiving mammography screening [4].  In addition, they may also influence breast cancer 
survival through decreasing diagnostic delays following screenings [5].  Older women in 
particular have been found to have less knowledge compared to younger women 
regarding factors related to breast cancer prognosis and treatment and require this 
information to be provided by their PCPs [6].     
 
Racial/ethnic disparities in receipt of medical services such as screening, diagnosis, and 
treatment associated with health conditions including cancer have been found to exist in 
the U.S.  As a result, unfavorable disease outcomes are often found among minority 
populations.  Asian/Pacific Islander women in the U.S. report the lowest early detection 
rates for breast cancer among all other racial/ethnic groups [7].  Despite strong evidence 
for the association between screening and breast cancer survival and strong 
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recommendations for mammograms to be conducted regularly, immigrant women are 
less likely to report having a mammogram in the past two years.  Barriers to receipt of 
mammograms among these groups include lack of primary care and health insurance [8].  
A study examining the relationship between Asian Americans and their PCPs reported an 
association between physician recommendations and cancer screenings in this group.  It 
was also found that among Chinese Americans, the only significant predictor for 
receiving a mammography was recommendation from a physician [3].  Thus, physician-
patient interactions are an integral part of early detection strategy for the Asian American 
population.         
 
Despite being the fastest- growing minority group in the U.S. today, Asian Americans are 
a population for which data regarding cancer control and prevention are limited, 
particularly for immigrants.  The majority of studies focusing on cancer prevention 
strategies in this group have focused on differences in health behaviors and attitudes 
regarding breast cancer.  Few studies have utilized population-based data to quantify the 
association between health care service use and breast cancer outcomes.  Thus, we aim to 
examine this association among Asians compared to non-Hispanic whites through use of 
the linked SEER-Medicare database which allows for examination of health care 
utilization through use of claims data.   Roetzheim et al [2] examined this association 
using cases of all racial/ethnic categories diagnosed between 1994 and 2005.  We aim to 
extend these results to Asian subpopulations in the U.S. by only including this group in 
addition to non-Hispanic whites.  In addition, since Asians in the U.S. are primarily 
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foreign-born, we will also examine the association between place of birth with the 
outcomes. 
 
4.3. Methods 
The SEER-Medicare database links two large population-based datasets that contain 
detailed information regarding Medicare beneficiaries diagnosed with cancer.  This 
combined database contains tumor characteristics and demographic information obtained 
from SEER, in addition to Medicare billing claims for covered health care services 
received during the time of Medicare eligibility until death.  The linkage is updated 
biennially and about 93% of subjects in the SEER registries aged 65 and over are 
successfully matched to their Medicare claims. 
 
The SEER-Medicare linked database was used to examine the use of primary care and its 
association with stage at diagnosis and stage-specific survival among female Medicare 
beneficiaries diagnosed with primary, invasive breast cancer between January 1, 1999 
and December 31, 2009.  The analysis was limited to those having at least two years of 
Medicare claims prior to cancer diagnosis.  Thus, only subjects aged 67 years or older 
identified as South Asian, Chinese, Japanese, Filipino, or non-Hispanic white were 
eligible for inclusion.  These specific countries of origin were chosen for analysis since 
they are currently the largest Asian subpopulations in the U.S.  Those identified in SEER 
as originating from these countries were classified as Asian in our analyses.  Patient data 
were ascertained by SEER from medical records and available information for each 
diagnosed case included demographics, tumor characteristics at diagnosis, and year of 
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diagnosis.  Claims data from Medicare were used to calculate total number of PCP visits, 
use of mammography, and the Charlson comorbidity index. 
 
A total of 332,839 women diagnosed with breast cancer during our study period were 
available for inclusion in our study sample.  Those enrolled in a Medicare health 
maintenance organization (HMO) during the year of breast cancer diagnosis or the year 
prior to diagnosis were excluded from the sample since claims for such cases were not 
available (n=60,543).  In addition, those without continuous part A and part B Medicare 
coverage during the year of diagnosis and the year prior to diagnosis were also excluded 
since these cases also would not have claims available for analysis (n=131,287).  We also 
excluded cases whose primary cancer diagnosis was not breast cancer (n=4692).  Women 
eligible for Medicare coverage due to end-stage renal disease were excluded due to 
potential confounding by unknown factors associated with this diagnosis (n=262).  These 
exclusions resulted in a sample size of 136,055.  Due to the large size of the non-Hispanic 
white sample, we utilized simple random sampling to select 10% of this racial/ethnic 
group for analysis.  This resulted in the sample size being reduced to 16,650 cases.  We 
also excluded cases less than 67 years (n=1505) and those with in situ or unknown stage 
at diagnosis (n=3331).  Demographic and tumor characteristics of the eligible Asian cases 
prior to these exclusions are shown in Appendix D.  A total of 11,814 women were in the 
final analytic sample.  
 
Our primary exposure of interest was PCP visits prior to breast cancer diagnosis.  We 
utilized Medicare carrier claims (National Claims History, NCH) to identify primary care 
utilization using the following CPT codes representing routine office visits: 99201-99205 
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and 99211-99215.  We assessed physician claims during the 24 months prior to breast 
cancer diagnosis.  The Charlson comorbidity index [9] was determined for all cases 
through use of a macro provided by the NCI utilizing inpatient, outpatient, and physician 
claims.  We assessed claims for comorbidities included in the index for conditions 
diagnosed up to 23 months prior to cancer diagnosis.  We also examined place of birth as 
a variable of interest in our study.  Subjects were classified as either “U.S.-born” or 
“foreign-born” based on data extracted by SEER from patient medical records or death 
certificates. 
 
Several covariates were considered to be potential confounders in our multivariable 
analyses.  The models used in the logistic regression analysis adjusted for the effects of 
age at diagnosis, year of diagnosis, SEER registry, census tract median income (quartiles 
based on entire sample), comorbidity index, and receipt of mammography within 2 years 
prior to diagnosis.  Age is adjusted for as a confounder due to its varying distributions in 
the racial/ethnic groups examined and due to the association between older age and 
increased risk of cancer.  Year of diagnosis is taken into account since diagnosis and 
surveillance methods for cancer detection may have varied during the time period of our 
study.  SEER registry is adjusted for to take into account the location from which the 
cases originated, since access to care and likelihood of diagnosis may vary between 
locations.  Census tract median income is adjusted for to take into account varying 
socioeconomic characteristics of the regions included in our study.  Comorbidities are 
taken into account since they may be associated with both race/ethnicity and breast 
cancer outcomes.  Use of mammography is adjusted for due to its effect on stage at 
diagnosis.  The models used in the survival analysis also adjusted for the effects of grade, 
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ER status, and PR status in addition to the covariates used in the logistic regression 
analysis.  These tumor characteristics are taken into account due to their effect on 
survival.  In addition, these characteristics may vary due to genetic differences between 
the racial/ethnic groups being compared.   
   
Racial/ethnic differences in the association between primary care utilization and stage at 
breast cancer diagnosis were examined using logistic regression.  Due to small sample 
sizes within the individual Asian subpopulations, these cases were combined to create an 
aggregate Asian racial/ethnic category.  Subjects were categorized as having early (I or 
II) or late (III or IV) stage disease using AJCC staging, with the outcome of interest 
defined as late stage at diagnosis.  The exposure of interest, total number of PCP visits, 
was categorized into quartiles.  Logistic regression was conducted to obtain odds ratios 
and 95% confidence intervals to examine racial/ethnic differences in the association 
between primary care utilization and late stage at diagnosis while controlling for potential 
confounding by age at diagnosis, year of diagnosis, SEER registry, census tract median 
income, comorbidity index, and use of mammography.  Age-adjusted associations were 
first obtained using models with only PCP visits and age as predictors.  Fully adjusted 
associations were then examined which controlled for potential confounders.  We also 
examined the effect of place of birth by including it as a predictor along with PCP visits 
and the other covariates. 
 
Stage-specific survival following breast cancer diagnosis was also examined among the 
racial groups of interest.  Survival time was provided as a variable in SEER and was 
calculated by using the date of diagnosis and the earliest of the following: date of death, 
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date last known to be alive, or the follow-up cutoff date of December 31, 2009.  In 
addition, vital status was provided in the data as either “alive” or “dead.”  Cox 
proportional hazards regression was utilized for multivariable adjustment to assess the 
effects of age, SEER registry, census tract median income, comorbidity index, use of 
mammography, stage, grade, estrogen receptor (ER) status, and progesterone receptor 
(PR) status on the observed racial differences in survival.  The proportional hazards (PH) 
assumption was assessed for these covariates prior to inclusion in the models through use 
of log-log plots and goodness-of-fit tests.  Hazard ratios and 95% confidence intervals 
were obtained to examine the association between PCP visits and stage-specific survival.  
Age-adjusted associations were obtained using models with only PCP visits and age as 
predictors.  Adjusted estimates were then examined which controlled for potential 
confounders.  We also examined the effect of place of birth by including it as a predictor 
along with PCP visits and the other covariates.  All analyses were conducted using SAS, 
version 9.3 (SAS Institute, Inc., Cary, NC).   
 
4.4. Results 
Table 4-1 shows the distributions of demographic and tumor characteristics for the 
analytic sample.  The Asian cases had a greater proportion of younger women compared 
to non-Hispanic whites, with 50.3% of subjects diagnosed between the ages of 67 and 75 
years.  Asians also had more cases in the highest quartile of census tract median income 
(33%).  A slightly higher proportion of Asian cases had a comorbidity score of 1 or 
greater.  Some select characteristics are examined by Asian subpopulation in Table 4-2.  
South Asians had a much greater proportion of cases (63.2%) diagnosed between the ages 
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of 67 and 75 years compared to the other groups.  This group also had the lowest 
proportion of cases (7.9%) in the lowest quartile of census tract median income and the 
lowest proportion (13.2%) in the highest quartile of percent with less than high school 
education.  The lowest proportion of cases (63.2%) receiving a mammogram was also 
found among South Asians.     
 
We assessed the statistical significance of associations between place of birth and other 
covariates which are likely to have effects on our outcomes of interest.  Table 4-3 shows 
analysis of the association between place of birth and mammography use among our 
study subjects.  As can be seen in the table, significant associations were detected 
between place of birth and use of mammography among the two racial/ethnic groups 
examined.  The proportion of cases receiving mammography was lower among the 
foreign born cases in both populations.  We also used an age-adjusted logistic regression 
model to examine whether the odds of having had a mammography differed between 
whites and Asians.  The odds ratio obtained for this association was non-significant 
(OR=0.95; 95% CI 0.86, 1.04). 
 
The results of the association between place of birth and comorbidity score are shown in 
Table 4-4.  Higher proportions of cases with scores of 1 or greater were found among the 
foreign-born when examining both Asians only and whites only.  Table 4-5 shows 
analysis of the association between place of birth and PCP visits.  A significant 
association was not found for these two covariates among the Asian cases.  We also 
examined the association between PCP visits and use of mammography as shown in 
Table 4-6.  The majority of cases who did not receive mammograms were in the lowest 
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quartile of total PCP visits among both Asians and whites.  Similarly, the highest 
proportion of cases receiving mammography was in the highest quartiles of PCP visits. 
 
Table 4-7 shows the results from the multiple logistic regression analysis examining the 
risk of late stage breast cancer diagnosis associated with total number of PCP visits 
among Asians and non-Hispanic whites.  A significant decreased risk of late stage 
diagnosis was found among Asians with 20 or more visits compared to those with 0-6 
visits.  A significant decrease in the risk of late stage diagnosis with increasing number of 
visits was also found among non-Hispanic whites.  In addition, there was a significant 
39% increased risk found among foreign-born non-Hispanic whites. 
 
Table 4-8 shows the results of the stage-specific survival analysis.  A significant 
decreased risk of death was found among Asians diagnosed at early stages with 7-12 
visits in the fully adjusted model.  In addition to significant decreased risk with 
increasing visits among Whites diagnosed at early stages, a protective association was 
also found among the foreign-born cases in this group.  Foreign-born status was found to 
be significantly protective among Asians diagnosed at late stages, with these cases having 
62% decreased risk of death compared to those that were U.S.-born.  Significantly 
protective associations were again found for White cases diagnosed at late stages. 
 
4.5. Discussion 
This study found significant effects of place of birth when examining the association 
between health-related behaviors, such as PCP visits and use of screening 
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mammography, and breast cancer outcomes.  Utilization of primary care services was 
found to be associated with decreased risk of late stage diagnosis as well as decreased 
risk of death among Asians and non-Hispanic whites examined in our analyses.   
 
Due to limited sample sizes in the Asian cases, our subpopulations of interest were 
combined to create one aggregate racial/ethnic group in our analyses.  However, a 
detailed examination of these individual subpopulations revealed notable demographic 
differences that likely play a role in breast cancer outcomes among these groups.  Asians 
as a whole were found to be diagnosed at younger ages compared to non-Hispanic 
whites.  A closer assessment of the individual subpopulations revealed that South Asians 
had the highest proportion of cases between the ages of 67 and 75 years.  This is 
consistent with previous findings reporting younger cases in this group compared to non-
Hispanic whites [10].  In addition, our findings are consistent with previous studies which 
have found this particular Asian subpopulation to be of high socioeconomic status.  The 
majority of South Asian cases in our analyses resided in areas of higher median income 
and educational attainment compared to the other Asian groups.  Though South Asians in 
the U.S. are generally of higher socioeconomic status compared to other minority 
populations, they have consistently been found to under-utilize screening services, such 
as mammography [11].  This was confirmed by our results which showed that this group 
had the lowest proportion of cases (63.2%) receiving mammography.  Though breast 
cancer incidence has previously been examined among South Asians reported in SEER 
registries, our study is the first to our knowledge examining these characteristics in 
Medicare beneficiaries belonging to this group.      
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Place of birth is a covariate which has not been examined extensively in studies of cancer 
among Asians in the U.S.  We examined the association between place of birth and 
several covariates in our study which likely have effects on our outcomes of interest.  
Significant associations were found between place of birth and use of mammography.  In 
particular, the proportion of cases who received mammography was lower among the 
foreign born compared to U.S.-born cases in both populations. It has previously been 
found that the Asian population in the U.S. is primarily composed of immigrants, with 
the majority of them reporting foreign birth [12].  Thus, they are more likely to have 
cultural beliefs regarding health that may potentially have an adverse impact on outcomes 
related to cancer.  These beliefs, such as self-sufficiency and greater emphasis on familial 
obligations rather than individual health, likely contribute to the lack of preventive care 
sought by this minority group [13].  Significant associations were also found between 
place of birth and comorbidity scores.  Higher proportions of cases with scores of 1 or 
greater were found among the foreign-born when examining both Asians only and whites 
only.  Diabetes is one comorbid condition that is highly prevalent among Asian groups.  
Asian Americans are at greater risk for diabetes compared to non-Hispanic whites.  
Japanese Americans in particular have been found to be twice as likely to develop 
diabetes compared to non-Hispanic whites [14].  A study conducted among Indian 
immigrants in Georgia reported that the overall prevalence of diabetes among Indians 
was 18.3%, a rate which was higher compared to Whites, Blacks, and Hispanics [15].  The 
association between place of birth and PCP visits was not statistically significant. 
However, the highest proportion of foreign-born Asian cases was found to be in the 
lowest quartile of total PCP visits.  A previous study examining the breast cancer 
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experience of Asian American women found that they are not actively engaged in matters 
related to their own health.  This is especially common among recent immigrants who are 
less acculturated to western culture.  In addition, these women have been reported to 
depend on both westernized as well as alternative remedies for ailments [7].  Most 
importantly, significant associations were detected between PCP visits and use of 
mammography among both Asians and non-Hispanic whites.  Previous studies have 
reported that physicians serve as significant liaisons regarding public health issues among 
Asian Americans.  They are the most essential source of knowledge regarding cancer risk 
and serve as primary resources for providing screening information and recommendations 
[3]
.  A study examining preventive health services delivery to South Asians in the U.S. 
found that the likelihood of being current with preventive health care services was greater 
when one had a regular source of healthcare [16].  Thus, this association is of public health 
importance when creating interventions targeted towards improving breast cancer 
outcomes in these groups.   
 
Our findings provided further evidence for favorable breast cancer outcomes associated 
with regular PCP visits.  Primary care visits were associated with decreased risk of late 
stage diagnosis of breast cancer among both Asians and non-Hispanic whites.  Asians in 
the highest quartile of total PCP visits had 57% (OR=0.43; 95% CI 0.27, 0.70) decreased 
risk of late stage diagnosis compared to those in the lowest quartile.  This significant 
association remained after controlling for potential confounders.  Both foreign-born 
Asians and non-Hispanic whites were found to have increased risk for late stage at 
diagnosis.  Regular visits with a PCP likely affect breast cancer stage at diagnosis by 
increasing the likelihood of earlier diagnosis following onset of symptoms or by reducing 
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diagnostic delays following abnormal mammogram results.  In addition, regular visits 
may be associated with overall healthier lifestyles that are related to progression of 
disease [2].     
 
Increasing visits was associated with decreased risk of death in our survival analysis.  
Due to limited sample sizes, the majority of effect estimates did not reach statistical 
significance for the Asian cases.  Foreign-born status was significantly protective among 
Asians diagnosed at late stages, with these cases having 62% (HR=0.38; 95% CI 0.21, 
0.70) decreased risk of death compared to those that were U.S.-born.  Place of birth may 
be used as a measure of acculturation to support this finding.  Breast cancer cases that are 
U.S.-born likely have an increased risk of death because they practice Westernized 
lifestyles, such as diets high in fat intake, that are known to increase breast cancer risk.  It 
has been well established that risk factors associated with Westernized culture such as 
obesity, physical inactivity, diets high in fat, late child bearing age, and low parity, are 
associated with decreased survival following breast cancer diagnosis [17].      
 
Comorbidities associated with breast cancer are a factor which has not been examined 
extensively among Asian immigrants in the U.S.  When examining the individual Asian 
subpopulations used in our analyses, South Asians and Filipinos had nearly half of all 
cases with comorbidity scores of 1 or greater.  It has previously been suggested that 
racial/ethnic differences in the presence of comorbidities may also lead to disparities in 
the use of screening methods, such as mammography [18].  This is likely due to competing 
demand that those with chronic conditions must face when determining allotment of time, 
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resources, and attention.  This competing risk will undoubtedly take away from the 
delivery of preventive health services [19].  The relatively high prevalence of 
comorbidities among Asian subpopulations must be taken into consideration when 
examining breast cancer outcomes among these cases. 
 
When considering the Asian SEER cases aged 67 years and older and belonging to our 
subpopulations of interest diagnosed during our study period, we found that the 
percentage of these cases also found in SEER-Medicare ranged from 50-75%.  The 
percentage of cases in SEER also found in SEER-Medicare was as follows: 70.3% of 
Chinese cases, 74.9% of Japanese cases, 49.8% of Filipino cases, and 75.2% of South 
Asian cases.  Inclusion in the SEER-Medicare database is likely dependent on factors 
such as recency of immigration to the U.S. and socioeconomic status. 
 
To our knowledge, this is the first study to examine Asian subpopulations using the 
linked SEER-Medicare database.  In addition, previous studies examining breast cancer 
outcomes in the Asian population in the U.S. have not taken comorbidities into account.  
We were also able to provide further support for the significant effect of place of birth on 
cancer outcomes.  Studies examining the effect of primary care utilization in this group 
are also limited.  Our findings revealed strong associations between PCP visits and stage 
at diagnosis and stage-specific survival.  This is an association that needs to be studied 
further among the individual subpopulations that comprise the Asian immigrant 
population in the U.S. 
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A few limitations regarding the use of claims data must be taken into account when 
interpreting the findings of our study.  Our analysis utilized data from Medicare, a federal 
fee-for-service insurance provider.  Thus, since all of the subjects included in our 
analyses were insured under this program, our findings may not apply to those not 
covered by Medicare.  It is also important to note that in order to receive Medicare 
coverage among those over 65 years of age, it is required that one must have been 
employed in the U.S. for a minimum of 10 years.  Thus, those not covered by Medicare 
are likely recent immigrants and may have differing socioeconomic status compared to 
those covered by Medicare.  In addition, the analysis is subject to limitations associated 
with claims data, such as incomplete data and coding errors.  We also did not have 
information on the specific reason for a patient’s PCP visit.  The data provided by SEER-
Medicare did not allow for examination of individual Asian subpopulations since our 
cases were limited to Medicare beneficiaries living in areas covered by SEER registries. 
 
 
Conclusion 
Our study provided notable findings regarding health-related behaviors and existing 
health conditions among older Asian American women which impact breast cancer 
outcomes.  Though statistical significance was not achievable for the individual 
subpopulations in our multivariable analyses, notable differences were found when 
comparing Asian Americans as an aggregate to non-Hispanic whites.  The proportion of 
cases receiving mammography was lower among the foreign born compared to U.S.-born 
cases.  Significant associations were also detected between PCP visits and use of 
mammography.  Thus, programs which promote regular visits to PCPs must be promoted 
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in this population.  The SEER-Medicare population in general is unique since these 
subjects have medical insurance and have equal access to healthcare.  However, 
utilization of these services differ by race/ethnicity since variations in the breast cancer 
outcomes examined were observed.  Reasons for these differences in outcomes in this 
population need to be examined further in future studies. Future public health 
interventions which target these Asian immigrants also need to account for factors such 
as place of birth and recency of immigration in order to meet the needs of this rapidly 
growing minority population in the U.S.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
149 
 
4.6. List of References 
 
 
 
1. Caplan, L., Delay in breast cancer: implications for stage at diagnosis and 
survival. Front Public Health, 2014. 2: p. 87. 
 
2. Roetzheim, R.G., et al., Influence of primary care on breast cancer outcomes 
among Medicare beneficiaries. Ann Fam Med, 2012. 10(5): p. 401-11. 
 
3. Kwon, H.T., et al., Primary care physicians' cancer screening recommendation 
practices and perceptions of cancer risk of Asian Americans. Asian Pac J Cancer 
Prev, 2013. 14(3): p. 1999-2004. 
 
4. Van Harrison, R., et al., Characteristics of primary care physicians and their 
practices associated with mammography rates for older women. Cancer, 2003. 
98(9): p. 1811-21. 
 
5. Fisher, K.J., et al., The effects of primary care on breast cancer mortality and 
incidence among Medicare beneficiaries. Cancer, 2013. 119(16): p. 2964-72. 
 
6. Maly, R.C., B. Leake, and R.A. Silliman, Breast cancer treatment in older 
women: impact of the patient-physician interaction. J Am Geriatr Soc, 2004. 
52(7): p. 1138-45. 
 
7. Tam Ashing, K., et al., Understanding the breast cancer experience of Asian 
American women. Psycho-Oncology, 2003. 12(1): p. 38-58. 
 
8. Ryu, S.Y., C.M. Crespi, and A.E. Maxwell, What Factors Explain Disparities in 
Mammography Rates Among Asian-American Immigrant Women? A Population-
Based Study in California. Women's Health Issues, 2013. 23(6): p. e403-e410. 
 
9. Charlson, M.E., et al., A new method of classifying prognostic comorbidity in 
longitudinal studies: development and validation. J Chronic Dis, 1987. 40(5): p. 
373-83. 
 
10. Moran, M.S., et al., Breast cancers in U.S. residing Indian-Pakistani versus non-
Hispanic White women: comparative analysis of clinical-pathologic features, 
treatment, and survival. Breast Cancer Res Treat, 2011. 128(2): p. 543-51. 
 
11. Goggins, W. and G. Wong, Cancer among Asian Indians/Pakistanis living in the 
United States: low incidence and generally above average survival. Cancer 
Causes & Control, 2009. 20(5): p. 635-643. 
 
150 
 
12. Wu, T.Y., B.J. Guthrie, and J.M. Bancroft, An integrative review on breast cancer 
screening practice and correlates among Chinese, Korean, Filipino, and Asian 
Indian American women. Health Care Women Int, 2005. 26(3): p. 225-46. 
 
13. Gomez, S.L., et al., Disparities in Breast Cancer Survival Among Asian Women 
by Ethnicity and Immigrant Status: A Population-Based Study. American Journal 
of Public Health, 2010. 100(5): p. 861-869. 
 
14. McNeely, M.J. and E.J. Boyko, Type 2 diabetes prevalence in Asian Americans: 
results of a national health survey. Diabetes Care, 2004. 27(1): p. 66-9. 
 
15. Shibusawa, T. and A. Mui, Health Status and Health Services Utilization Among 
Older Asian Indian Immigrants. Journal of Immigrant and Minority Health, 2010. 
12(4): p. 527-533. 
 
16. Bharmal, N. and S. Chaudhry, Preventive Health Services Delivery to South 
Asians in the United States. Journal of Immigrant and Minority Health, 2012. 
14(5): p. 797-802. 
 
17. Jemal, A., et al., Global patterns of cancer incidence and mortality rates and 
trends. Cancer Epidemiol Biomarkers Prev, 2010. 19(8): p. 1893-907. 
 
18. Curtis, E., et al., Racial and ethnic differences in breast cancer survival: how 
much is explained by screening, tumor severity, biology, treatment, comorbidities, 
and demographics? Cancer, 2008. 112(1): p. 171-80. 
 
19. Yasmeen, S., et al., Comorbidities and mammography use interact to explain 
racial/ethnic disparities in breast cancer stage at diagnosis. Cancer, 2011. 
117(14): p. 3252-3261 
 
 
 
 
 
 
 
 
 
151 
 
4.7. Tables and Figures 
Table 4-1: Demographic and tumor characteristics among 11, 814 female Medicare beneficiaries 
diagnosed with invasive breast cancer in SEER-Medicare 
Characteristic Asian 
(n=2325) 
Non-hispanic white 
(n=9489) 
*P-value 
Age at diagnosis, y 
67-70 
71-75 
76-80 
81-85 
86+ 
 
416 (17.9) 
753 (32.4) 
590 (25.4) 
372 (16.0) 
194 (8.3) 
 
1565 (16.5) 
2415 (25.5) 
2422 (25.5) 
1804 (19.0) 
1283 (13.5) 
 
<.0001 
 
Year of diagnosis 
1999-2001 
2002-2004 
2005-2007 
2008-2009 
 
 
514 (22.1) 
633 (27.2) 
720 (31.0) 
458 (19.7) 
 
 
2437 (25.7) 
2759 (29.1) 
2536 (26.7) 
1757 (18.5) 
 
 
<.0001 
 
Income (of census 
tract) 
Quartile 1 
Quartile 2 
Quartile 3 
Quartile 4 
Unknown 
 
 
 
420 (18.1) 
500 (21.5) 
628 (27.0) 
766 (33.0) 
11 (0.5) 
 
 
 
2534 (26.7) 
2454 (25.9) 
2325 (24.5) 
2116 (22.3) 
60 (0.6) 
 
 
 
<.0001 
 
Education (% <HS 
in census tract) 
Quartile 1 
Quartile 2 
Quartile 3 
Quartile 4 
Unknown 
 
 
 
613 (26.4) 
538 (23.1) 
555 (23.9) 
608 (26.2) 
11 (0.5) 
 
 
 
2743 (28.9) 
2341 (24.7) 
2101 (22.1) 
2244 (23.7) 
60 (0.6) 
 
 
 
0.007 
 
Total primary care 
visits, n 
0-6 
7-12 
12-20 
20+ 
 
 
 
637 (27.4) 
563 (24.2) 
577 (24.8) 
548 (23.6) 
 
 
 
2660 (28.0) 
2383 (25.1) 
2206 (23.3) 
2240 (23.6) 
 
 
 
0.419 
 
Comorbidity score 
0 
1 
2+ 
 
 
1457 (62.7) 
578 (24.9) 
290 (12.5) 
 
 
6112 (64.4) 
2087 (22.0) 
1290 (13.6) 
 
 
0.009 
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Table 4-1 (continued) 
 
Mammography 
No 
Yes 
 
Place of birth 
U.S.-born 
Foreign-born 
Unknown 
 
Stage at diagnosis 
Early 
Late 
 
Grade at diagnosis 
I 
II 
III 
IV 
Unknown 
 
ER Status 
Positive/borderline 
Negative 
Unknown 
 
PR Status 
Positive/borderline 
Negative 
Unknown 
 
 
 
710 (30.5) 
1615 (69.5) 
 
 
627 (27.0) 
918 (39.5) 
780 (33.6) 
 
 
2082 (89.6) 
243 (10.5) 
 
 
508 (21.9) 
1022 (44.0) 
506 (21.8) 
26 (1.1) 
263 (11.3) 
 
 
1679 (72.2) 
302 (13.0) 
344 (14.8) 
 
 
1415 (60.9) 
557 (24.0) 
353 (15.2) 
 
 
2921 (30.8) 
6568 (69.2) 
 
 
4408 (46.5) 
479 (5.1) 
4602 (48.5) 
 
 
8351 (88.0) 
1138 (12.0) 
 
 
2213 (23.3) 
3836 (40.4) 
2218 (23.4) 
80 (0.8) 
1142 (12.0) 
 
 
6886 (72.6) 
1203 (12.7) 
1400 (14.8) 
 
 
5763 (60.7) 
2281 (24.0) 
1445 (15.2) 
 
 
0.818 
 
 
 
<.0001 
 
 
 
 
0.038 
 
 
 
0.018 
 
 
 
 
 
 
0.916 
 
 
 
 
0.994 
*P-values based on the χ2 test 
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Table 4-2: Demographic and tumor characteristics among 2, 325 Asian female Medicare 
beneficiaries diagnosed with invasive breast cancer in SEER-Medicare  
Characteristic South Asian 
(n=76) 
Chinese 
(n=584) 
Japanese 
(n=1040) 
Filipino 
(n=625) 
*P-value 
Age at diagnosis, y 
67-70 
71-75 
76-80 
81-85 
86+ 
 
16 (21.1) 
32 (42.1) 
13 (17.1) 
9 (11.8) 
6 (7.9) 
 
97 (16.6) 
161 (27.6) 
150 (25.7) 
107 (18.3) 
69 (11.8) 
 
172 (16.5) 
331 (31.8) 
281 (27.0) 
171 (16.4) 
85 (8.2) 
 
131 (21.0) 
229 (36.6) 
146 (23.4) 
85 (13.6) 
34 (5.4) 
 
<.0001 
 
Income (of census 
tract) 
Quartile 1 
Quartile 2 
Quartile 3 
Quartile 4 
Unknown 
 
 
 
6 (7.9) 
11 (14.5) 
22 (29.0) 
37 (48.7) 
0 (0.0) 
 
 
 
123 (21.1) 
105 (18.0) 
137 (23.5) 
213 (36.5) 
6 (1.0) 
 
 
 
173 (16.6) 
238 (22.9) 
287 (27.6) 
341 (32.8) 
1 (0.1) 
 
 
 
118 (18.9) 
146 (23.4) 
182 (29.1) 
175 (28.0) 
4 (0.6) 
 
 
 
<.0001 
 
Education (% <HS in 
census tract) 
Quartile 1 
Quartile 2 
Quartile 3 
Quartile 4 
Unknown 
 
 
 
28 (36.8) 
19 (25.0) 
19 (25.0) 
10 (13.2) 
0 (0.0) 
 
 
 
183 (31.3) 
115 (19.7) 
114 (19.5) 
166 (28.4) 
6 (1.0) 
 
 
 
299 (28.8) 
270 (26.0) 
258 (24.8) 
212 (20.4) 
1 (0.1) 
 
 
 
103 (16.5) 
134 (21.4) 
164 (26.2) 
220 (35.2) 
4 (0.6) 
 
 
 
<.0001 
 
Total primary care 
visits, n 
0-6 
7-12 
12-20 
20+ 
 
 
 
19 (25.0) 
24 (31.6) 
17 (22.4) 
16 (21.1) 
 
 
 
155 (26.5) 
114 (19.5) 
139 (23.8) 
176 (30.1) 
 
 
 
259 (24.9) 
278 (26.7) 
276 (26.5) 
227 (21.8) 
 
 
 
204 (32.6) 
147 (23.5) 
145 (23.2) 
129 (20.6) 
 
 
 
<.0001 
 
Comorbidity score 
0 
1 
2+ 
 
 
42 (55.3) 
24 (31.6) 
10 (13.2) 
 
 
357 (61.1) 
143 (24.5) 
84 (14.4) 
 
 
720 (69.2) 
240 (23.1) 
80 (7.7) 
 
 
338 (54.1) 
171 (27.4) 
116 (18.6) 
 
 
<.0001 
 
Mammography 
No 
Yes 
 
 
28 (36.8) 
48 (63.2) 
 
 
197 (33.7) 
387 (66.3) 
 
 
267 (25.7) 
773 (74.3) 
 
 
218 (34.9) 
407 (65.1) 
 
 
<.0001 
*P-values based on the χ2 test 
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Table 4-3: Association between place of birth and use of mammography 
 Use of mammography   
All (Whites & Asians) No Yes *P-value 
U.S.-born 1723 (34.2) 3312 (65.8) <.0001 
Foreign born 502 (35.9) 895 (64.1)  
Unknown 1406 (26.1) 3976 (73.9)  
    
Asians only    
U.S.-born 168 (26.8) 459 (73.2) 0.0018 
Foreign born 318 (34.6) 600 (65.4)  
Unknown 224 (28.7) 556 (71.3)  
    
Whites only    
U.S.-born 1555 (35.3) 2853 (64.7) <.0001 
Foreign born 184 (38.4) 295 (61.6)  
Unknown 1182 (25.7) 3420 (74.3)  
*P-values based on chi-square test of independence 
 
 
Table 4-4: Association between place of birth and comorbidity score 
 Comorbidity score    
All (Whites & Asians) 0 1 2+ *P-value 
U.S.-born 3102 (61.6) 1175 (23.3) 758 (15.1) <.0001 
Foreign born 829 (59.3) 348 (24.9) 220 (15.8)  
Unknown 3638 (67.6) 1142 (21.2) 602 (11.2)  
     
Asians only     
U.S.-born 406 (64.8) 156 (24.9) 65 (10.4) 0.088 
Foreign born 552 (60.1) 231 (25.2) 135 (14.7)  
Unknown 499 (64.0) 191 (25.0) 90 (11.5)  
     
Whites only     
U.S.-born 2696 (61.2) 1019 (23.1) 693 (15.7) <.0001 
Foreign born 277 (57.8) 117 (24.4) 85 (17.8)  
Unknown 3139 (68.2) 951 (20.7) 512 (11.1)  
*P-values based on chi-square test of independence 
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Table 4-5: Association between place of birth and PCP visits 
 Physician visits     
All (Whites & 
Asians) 
0-6 7-12 13-20 20+ *P-value 
U.S.-born 1456 (28.9) 1226 (24.4) 1144 (22.7) 1209 (24.0) <.0001 
Foreign born 411 (29.4) 305 (21.8) 313 (22.4) 368 (26.3)  
Unknown 1430 (26.6) 1415 (26.3) 1326 (24.6) 1211 (22.5)  
      
Asians only      
U.S.-born 150 (23.9) 163 (26.0) 162 (25.8) 152 (24.2) 0.152 
Foreign born 273 (29.7) 213 (23.2) 209 (22.8) 223 (24.3)  
Unknown 214 (27.4) 187 (24.0) 206 (26.4) 173 (22.2)  
      
Whites only      
U.S.-born 1306 (29.6) 1063 (24.1) 982 (22.3) 1057 (24.0) <.0001 
Foreign born 138 (28.8) 92 (19.2) 104 (21.7) 145 (30.3)  
Unknown 1216 (26.4) 1228 (26.7) 1120 (24.3) 1038 (22.6)  
*P-values based on chi-square test of independence 
 
 
 
Table 4-6: Association between PCP visits and use of mammography 
 Physician visits     
All (Whites & 
Asians) 
0-6 7-12 13-20 20+ *P-value 
No 
Yes 
1650 (45.4) 
1647 (20.1) 
803 (22.1) 
2143 (26.2) 
620 (17.1) 
2163 (26.4) 
558 (15.4) 
2230 (27.3) 
<.0001 
 
      
Asians only      
No 
Yes 
331 (46.6) 
306 (19.0) 
138 (19.4) 
425 (26.3) 
130 (18.3) 
447 (27.7) 
111 (15.6) 
437 (27.1) 
<.0001 
 
      
Whites only      
No 
Yes 
1319 (45.2) 
1341 (20.4) 
665 (22.8) 
1718 (26.2) 
490 (16.8) 
1716 (26.1) 
447 (15.3) 
1793 (27.3) 
<.0001 
*P-values based on chi-square test of independence 
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Table 4-7: Risk of late stage breast cancer diagnosis by race/ethnicity among Asian 
subpopulations enrolled in Medicare, 1999-2009 (n=11, 814) 
Total number of visits Age-adjusted model (visits and age 
only) 
OR (95% CI) 
*Fully adjusted model 
OR (95% CI) 
Asian 
0-6 
7-12 
13-20 
20+ 
 
1.00 (Referent) 
0.54 (0.38, 0.78) 
0.64 (0.45, 0.91) 
0.41 (0.27, 0.60) 
 
1.00 (Referent) 
0.67 (0.44, 1.00) 
0.81 (0.54, 1.22) 
0.43 (0.27, 0.70)  
Place of birth 
U.S.-born 
Foreign-born 
Unknown 
 
White 
0-6 
7-12 
13-20 
20+ 
 
 
 
 
 
 
1.00 (Referent) 
0.55 (0.46, 0.64) 
0.51 (0.43, 0.60) 
0.44 (0.37, 0.53) 
 
1.00 (Referent) 
1.19 (0.79, 1.79) 
0.74 (0.48, 1.12) 
 
 
1.00 (Referent) 
0.66 (0.55, 0.78) 
0.65 (0.53, 0.78) 
0.54 (0.44, 0.66) 
Place of birth 
U.S.-born 
Foreign-born 
Unknown 
  
1.00 (Referent) 
1.39 (1.07, 1.80) 
0.51 (0.44, 0.59) 
*Adjusted for age at diagnosis, year of diagnosis, SEER registry, census tract median income, 
comorbidity score, mammography, place of birth 
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Table 4-8: Stage-specific breast cancer survival by race/ethnicity among Asian subpopulations 
enrolled in Medicare, 1999-2009 (n=11, 371) 
Total number of visits Age-adjusted model (visits 
and age only) 
HR (95% CI) 
*Fully adjusted model 
HR (95% CI) 
Early stage (I/II) 
Asian 
0-6 
7-12 
13-20 
20+ 
Place of birth 
U.S.-born 
Foreign-born 
Unknown 
 
 
1.00 (Referent) 
0.72 (0.54, 0.97) 
0.73 (0.54, 0.97) 
1.13 (0.87, 1.48) 
 
 
 
 
1.00 (Referent) 
0.66 (0.49, 0.90) 
0.76 (0.56, 1.04) 
1.00 (0.74, 1.35) 
 
1.00 (Referent) 
0.80 (0.61, 1.05) 
0.35 (0.25, 0.49) 
White 
0-6 
7-12 
13-20 
20+ 
Place of birth 
U.S.-born 
Foreign-born 
Unknown 
 
1.00 (Referent) 
0.80 (0.72, 0.90) 
0.87 (0.78, 0.97) 
1.15 (1.04, 1.29) 
 
 
 
1.00 (Referent) 
0.78 (0.69, 0.87) 
0.75 (0.67, 0.85) 
0.90 (0.80, 1.01) 
 
1.00 (Referent) 
0.76 (0.64, 0.91) 
0.24 (0.21, 0.26) 
Late stage (III/IV) 
Asian 
0-6 
7-12 
13-20 
20+ 
Place of birth 
U.S.-born 
Foreign-born 
Unknown 
 
 
1.00 (Referent) 
1.14 (0.63, 2.04) 
0.82 (0.47, 1.45) 
1.57 (0.89, 2.76) 
 
 
 
 
1.00 (Referent) 
0.96 (0.49, 1.90) 
0.73 (0.39, 1.37) 
1.20 (0.59, 2.45) 
 
1.00 (Referent) 
0.38 (0.21, 0.70) 
0.25 (0.12, 0.53) 
White 
0-6 
7-12 
13-20 
20+ 
Place of birth 
U.S.-born 
Foreign-born 
Unknown 
 
1.00 (Referent) 
0.76 (0.62, 0.94) 
0.71 (0.57, 0.88) 
0.78 (0.63, 0.98) 
 
 
 
1.00 (Referent) 
0.78 (0.63, 0.97) 
0.75 (0.59, 0.95) 
0.73 (0.57, 0.94) 
 
1.00 (Referent) 
0.62 (0.46, 0.84) 
0.32 (0.25, 0.39) 
*Adjusted for age at diagnosis, SEER registry, census tract median income, comorbidity score, 
mammography, grade at diagnosis, ER status, PR status, place of birth 
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5. CONCLUSIONS AND RECOMMENDATIONS 
 
There is currently a significant lack of epidemiological studies examining the cancer 
burden of the South Asian population in the United States today, despite the recent rapid 
growth of this immigrant group.  As this predominant Asian subpopulation in the U.S. 
continues to increase, it is essential that we understand the cancer burden impacting this 
group in order to tailor prevention efforts to address the needs of this expanding 
population.  Existing literature has included this group in an aggregate racial/ethnic 
category known as Asian/Pacific Islander (PI).  The racial/ethnic category often referred 
to as Asian/PI is in fact comprised of several heterogeneous populations with very 
different cultural and lifestyle characteristics which lead to differences in cancer 
outcomes.  The use of such combined categorizations of race obscures significant 
differences in cancer occurrence patterns among specific subpopulations, such as those of 
South Asian origin.   
 
In this study we utilized data from the National Cancer Institute’s SEER program and the 
linked SEER-Medicare database to examine differences in cancer outcomes, specifically 
stage at diagnosis and stage-specific survival, among South Asians and the three other 
predominant Asian subpopulations in the U.S. compared to non-Hispanic whites.  Three 
infection-associated cancers which are common among those of Asian origin were 
examined in addition to breast cancer.  While these outcomes have been studied among 
these groups in California, limited studies have utilized nationwide data when examining 
outcomes in these groups.  In addition, this study greatly contributes to the existing 
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literature by also examining the independent effect of place of birth when examining 
these cancer outcomes. 
 
In our study of infection-associated cancers, it was found that South Asians had the 
highest proportion (48%) of late stage liver cancer cases compared to the other Asian 
subpopulations examined.  The non-significance of the advanced stage at diagnosis odds 
ratio obtained for South Asians in this analysis was likely due to the small sample size of 
this group.  However, this finding of increased late stage diagnosis is of clinical 
significance in this Asian subpopulation due to the recent emergence of diabetes as an 
independent risk factor for liver cancer.  India reports the highest prevalence of diabetes 
compared to other countries in the neighboring region, with rates ranging from 18.6% in 
urban areas to 9.2% in rural areas [1].  In addition, a study conducted in India reported that 
diabetic patients with liver cancer had more advanced tumors of larger size and increased 
likelihood of intraheptic bile duct involvement [2].  These findings highlight the need for 
improved monitoring among those of South Asian origin who are diabetic or diagnosed 
with other risk factors associated with liver cancer in order to increase the likelihood of 
early stage diagnosis. 
 
When examining breast cancer outcomes among the Asian subpopulations, the highest 
risk for late stage diagnosis when compared to non-Hispanic whites was found among 
South Asians. Though non-significant, the adjusted model which also accounted for place 
of birth found 3% (OR=0.97; 95% CI 0.81, 1.16) reduced risk for late stage diagnosis for 
this group compared to non-Hispanic whites.  However, much lower risk was found 
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among the other Asian groups examined.  Diagnosis of breast cancer at an advanced 
stage of disease greatly increases the risk of death.  Studies among immigrant women in 
the U.S. have found that they are at increased risk for unfavorable breast cancer outcomes 
due to limited English language proficiency, insufficient health insurance, and barriers to 
access such as social exclusion.  As a result, they are less likely to have sufficient 
knowledge regarding cancer prevention and consequently less likely to receive adequate 
screening prior to diagnosis of cancer [3].  However, South Asians have in fact been 
categorized as the highest educated, highest paid, and best insured immigrants in the U.S.  
Despite seemingly high socioeconomic status, South Asian origin is reportedly associated 
with insufficient adherence to breast cancer prevention recommendations, such as regular 
screenings.  This is especially true among recent immigrants to the U.S [4].  The lack of 
proper prevention methods likely contributes greatly to the advanced stage presentation 
of breast cancer found among South Asian women.      
 
Our findings further revealed that South Asians had the most favorable stage-specific 
survival for both early and late stage diagnosis among the other Asian subpopulations 
when compared to non-Hispanic whites.  The adjusted model which also controlled for 
place of birth showed that among those diagnosed with early-stage disease, South Asians 
had 39% significant reduced risk (95% CI 0.44, 0.84) of death when compared to non-
Hispanic whites.  Among those diagnosed with late-stage disease, this group had 20% 
reduced risk (95% CI 0.59, 1.09) of death when compared to non-Hispanic whites.  The 
recency of immigration to the U.S. for the majority of those that comprise this group is 
likely an explanation for this finding.  The majority of South Asians in the U.S. today are 
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recent immigrants.  Only approximately 9% of Asian Indians and 6% of Pakistanis older 
than 18 years were born in the U.S. according to the 2000 U.S. census.  Most adults that 
comprise this Asian subpopulation immigrated to the U.S. after 1985.  As a result of their 
recent immigration, the extent of acculturation present in this group is relatively low 
compared to other immigrant groups in the U.S [5].  Acculturation plays an important role 
since reproductive and lifestyle characteristics known to decrease breast cancer survival, 
such as late child-bearing age, obesity, and physical inactivity, are associated with 
westernized culture. 
 
Through individual examination of the major Asian subpopulations that comprise the 
aggregate Asian/PI racial/ethnic category in the U.S., our findings revealed heterogeneity 
in risk of late stage at diagnosis and stage-specific survival of three common infection-
associated cancers and breast cancers.  Our findings revealed that South Asians were 
more likely to present with advanced stage at diagnosis for these cancers compared to the 
other Asian subpopulations we examined.  Thus, there is a true need for more 
individualized prevention for this major immigrant population in the U.S. in order to 
improve outcomes associated with cancer.  In addition, our results provided further 
evidence for the inappropriate use of an aggregate racial/ethnic category when examining 
these subpopulations since true differences in outcomes exist.     
 
Due to small sample sizes, we were not able to examine the Asian subpopulations 
individually in our analyses utilizing the SEER-Medicare database.  However, our 
findings revealed significant effects of place of birth when examining the association 
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between factors such as use of screening mammography and comorbidities and breast 
cancer outcomes.  Significant associations were found between place of birth and use of 
mammography.  In particular, the proportion of cases receiving mammography was lower 
among the foreign born compared to U.S.-born cases in both Asians and non-Hispanic 
whites.  Our results also revealed significant associations between place of birth and 
comorbidity scores.  Higher proportions of cases with scores of 1 or greater were found 
among the foreign-born when examining both Asians only and whites only.    In addition, 
our findings provided further evidence for favorable breast cancer outcomes associated 
with regular primary care physician visits.  Primary care visits were associated with 
decreased risk of late stage diagnosis of breast cancer among both Asians and non-
Hispanic whites.  Asians in the highest quartile of total physician visits had 57% 
(OR=0.43; 95% CI 0.27, 0.70) decreased risk of late stage diagnosis compared to those in 
the lowest quartile. 
 
Our analysis of Asian subpopulations using SEER-Medicare provided important findings 
regarding health-related behaviors and existing health conditions among older Asian 
American women which impact breast cancer outcomes.  To our knowledge, this is the 
first study to examine Asian subpopulations using the linked SEER-Medicare database.  
The majority of studies focusing on cancer prevention strategies in this group have 
focused on differences in health behaviors and attitudes regarding breast cancer.  Few 
studies have utilized population-based data to quantify the association between health 
care services used and breast cancer outcomes among Asian American immigrants.     
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Recommendations 
Cancer registries are the most comprehensive data sources available for assessment of 
cancer incidence and outcomes.  Thus, it is imperative that these data are up-to-date and 
as complete as possible.  One variable that must be improved with regard to completeness 
is place of birth.  This variable was missing for approximately 30% of the Asian 
subpopulations examined and almost 50% of the non-Hispanic white population.  
Previous research has provided evidence to support a strong association between 
environmental exposures and subsequent cancer outcomes.  Complete data regarding 
place of birth may have resulted in stronger, more statistically significant associations 
between this variable and stage at diagnosis or stage-specific survival.  Cancer registries 
should improve their ascertainment of this important variable when collecting 
demographic data from patients. 
 
SEER is currently the most complete source for cancer data on Asian subpopulations in 
the U.S.  However, it does not have reporting registries in areas known to have high 
concentrations of Asian residents.  Coverage is not available in areas such as New York, 
Pennsylvania, and Texas.  This is likely an explanation for the relatively low coverage of 
Asian immigrants reported by SEER [6].  Registries located in areas known to have high 
concentrations of Asian immigrants must be included in SEER to allow for adequate 
assessment of the cancer burden in these predominant Asian immigrant groups in the 
U.S. 
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In summary, our findings provide evidence for the need to examine Asian subpopulations 
as individual groups rather than using the aggregate racial/ethnic category known as 
Asian/PI.  True heterogeneity in cancer outcomes exists within these separate groups and 
requires targeted interventions for specific subpopulations.  We have also shed light on 
the need for individualized interventions for South Asians, particularly for early breast 
cancer detection.  This group has been found to have true histologic differences in their 
tumors that increase the risk for poor breast cancer prognosis.  Despite being a highly 
educated Asian subpopulation, this group does not seek adequate cancer prevention 
services, such as breast cancer screening.  It is our hope that our findings guide future 
interventional studies aimed at the South Asian population in the U.S.   
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APPENDIX A. Demographic and tumor characteristics of eligible Asian cases with 
infection-associated cancers prior to sample exclusions 
 
 
 
Demographic and tumor characteristics among 1,525 Asian cases diagnosed with primary 
cervical cancer prior to study sample exclusions 
Characteristic N (%) 
Age at diagnosis (years) 
Mean ± SD 
 
54 ± 28 
Year of diagnosis 
1999-2001 
2002-2004 
2005-2007 
2008-2009 
 
346 (22.7) 
431 (28.3) 
431 (28.3) 
317 (20.8) 
SEER registry 
San Francisco-Oakland 
Los Angeles 
San Jose-Monterey 
Greater California 
Connecticut 
Detroit 
Hawaii 
Iowa 
New Mexico 
Seattle-Puget Sound 
Utah 
Atlanta 
Greater Georgia 
Rural Georgia 
Kentucky 
Louisiana 
New Jersey 
 
224 (14.7) 
418 (27.4) 
85 (5.6) 
13 (0.9) 
11 (0.7) 
12 (0.8) 
232 (15.2) 
9 (0.6) 
3 (0.2) 
75 (4.9) 
5 (0.3) 
30 (2.0) 
298 (19.5) 
0 (0.0) 
1 (0.1) 
5 (0.3) 
104 (6.8) 
Stage at diagnosis 
In situ 
Early 
Late 
Unknown 
 
0 (0.0) 
782 (51.3) 
654 (42.9) 
89 (5.8) 
Grade 
I 
II 
III 
IV 
Unknown 
 
145 (9.6) 
415 (27.2) 
447 (29.3) 
41 (2.7) 
477 (31.3) 
Place of birth 
U.S.-born 
Foreign-born 
Unknown 
 
171 (11.2) 
896 (58.8) 
458 (30.0) 
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Demographic and tumor characteristics among 4,051 Asian cases diagnosed with primary 
hepatocellular carcinoma prior to study sample exclusions 
Characteristic South Asian 
(n=130) 
Chinese 
(n=1989) 
Japanese 
(n=793) 
Filipino 
(n=1139) 
Age at diagnosis (years) 
Mean ± SD 
 
61 ± 12 
 
65 ± 13 
 
70 ± 11 
 
64 ± 13 
Sex     
Male 103 (79.2) 1459 (73.4) 384 (48.4) 861 (75.6) 
Female 27 (20.8) 530 (26.7) 409 (51.6) 278 (24.4) 
Year of diagnosis 
1999-2001 
2002-2004 
2005-2007 
2008-2009 
 
18 (13.9) 
35 (26.9) 
31 (23.9) 
46 (35.4) 
 
433 (21.8) 
552 (27.8) 
600 (30.2) 
404 (20.3) 
 
160 (20.2) 
243 (30.6) 
220 (27.7) 
170 (21.4) 
 
232 (20.4) 
293 (25.7) 
382 (33.5) 
232 (20.4) 
SEER registry 
San Francisco-Oakland 
Los Angeles 
San Jose-Monterey 
Greater California 
Connecticut 
Detroit 
Hawaii 
Iowa 
New Mexico 
Seattle-Puget Sound 
Utah 
Atlanta 
Greater Georgia 
Rural Georgia 
Kentucky 
Louisiana 
New Jersey 
 
9 (6.9) 
7 (5.4) 
3 (2.3) 
2 (1.5) 
5 (3.9) 
15 (11.5) 
0 (0.0) 
0 (0.0) 
2 (1.5) 
9 (6.9) 
2 (1.5) 
8 (6.2) 
12 (9.2) 
0 (0.0) 
1 (0.8) 
2 (1.5) 
53 (40.8) 
 
698 (35.1) 
570 (28.7) 
151 (7.6) 
6 (0.3) 
17 (0.9) 
21 (1.1) 
94 (4.7) 
4 (0.2) 
4 (0.2) 
95 (4.8) 
2 (0.1) 
14 (0.7) 
228 (11.5) 
0 (0.0) 
4 (0.2) 
5 (0.3) 
76 (3.8) 
 
65 (8.2) 
135 (17.0) 
36 (4.5) 
1 (0.1) 
5 (0.6) 
7 (0.9) 
310 (39.1) 
1 (0.1) 
3 (0.4) 
52 (6.6) 
8 (1.0) 
2 (0.3) 
158 (19.9) 
0 (0.0) 
1 (0.1) 
1 (0.1) 
8 (1.0) 
 
220 (19.3) 
283 (24.9) 
71 (6.2) 
1 (0.1) 
7 (0.6) 
9 (0.8) 
150 (13.2) 
1 (0.1) 
1 (0.1) 
55 (4.8) 
1 (0.1) 
0 (0.0) 
282 (24.8) 
0 (0.0) 
0 (0.0) 
5 (0.4) 
53 (4.7) 
Stage at diagnosis 
In situ 
Early 
Late 
Unknown 
 
0 (0.0) 
59 (45.4) 
56 (43.1) 
15 (11.5) 
 
 
0 (0.0) 
1064 (53.5) 
560 (28.2) 
365 (18.4) 
 
0 (0.0) 
448 (56.5) 
212 (26.7) 
133 (16.8) 
 
0 (0.0) 
559 (49.1) 
386 (33.9) 
194 (17.0) 
Grade 
I 
II 
III 
IV 
Unknown 
 
12 (9.2) 
22 (16.9) 
14 (10.8) 
2 (1.5) 
80 (61.5) 
 
220 (11.1) 
292 (14.7) 
175 (8.8) 
12 (0.6) 
1290 (64.9) 
 
115 (14.5) 
127 (16.0) 
70 (8.8) 
6 (0.8) 
475 (59.9) 
 
148 (13.0) 
188 (16.5) 
130 (11.4) 
12 (1.1) 
661 (58.0) 
Place of birth 
U.S.-born 
Foreign-born 
Unknown 
 
4 (3.1) 
80 (61.5) 
46 (35.4) 
 
98 (4.9) 
1398 (70.3) 
493 (24.8) 
 
339 (42.8) 
304 (38.3) 
150 (18.9) 
 
97 (8.5) 
852 (74.8) 
190 (16.7) 
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Demographic and tumor characteristics among 4,635 Asian cases diagnosed with primary gastric 
adenocarcinoma prior to study sample exclusions 
Characteristic South Asian 
(n=176) 
Chinese 
(n=1750) 
Japanese 
(n=1874) 
Filipino 
(n=835) 
Age at diagnosis (years) 
Mean ± SD 
 
62 ± 16 
 
70 ± 15 
 
75 ± 11 
 
69 ± 14  
Sex     
Male 114 (64.8) 1001 (57.2) 1051 (56.1) 447 (53.5) 
Female 62 (35.2) 749 (42.8) 823 (43.9) 388 (46.5) 
Year of diagnosis 
1999-2001 
2002-2004 
2005-2007 
2008-2009 
 
27 (15.3) 
54 (30.7) 
54 (30.7) 
41 (23.3) 
 
442 (25.3) 
475 (27.1) 
485 (27.7) 
348 (19.9) 
 
562 (30.0) 
518 (27.6) 
479 (25.6) 
315 (16.8) 
 
184 (22.0) 
236 (28.3) 
247 (29.6) 
168 (20.1) 
SEER registry 
San Francisco-Oakland 
Los Angeles 
San Jose-Monterey 
Greater California 
Connecticut 
Detroit 
Hawaii 
Iowa 
New Mexico 
Seattle-Puget Sound 
Utah 
Atlanta 
Greater Georgia 
Rural Georgia 
Kentucky 
Louisiana 
New Jersey 
 
14 (8.0) 
5 (2.8) 
7 (4.0) 
4 (2.3) 
2 (1.1) 
24 (13.6) 
2 (1.1) 
2 (1.1) 
1 (0.6) 
8 (4.6) 
2 (1.1) 
15 (8.5) 
9 (5.1) 
0 (0.0) 
3 (1.7) 
1 (0.6) 
77 (43.8) 
 
553 (31.6) 
536 (30.6) 
146 (8.3) 
6 (0.3) 
14 (0.8) 
13 (0.7) 
97 (5.5) 
3 (0.2) 
2 (0.1) 
64 (3.7) 
2 (0.1) 
28 (1.6) 
163 (9.3) 
0 (0.0) 
4 (0.2) 
9 (0.5) 
110 (6.3) 
 
123 (6.6) 
403 (21.5) 
80 (4.3) 
7 (0.4) 
7 (0.4) 
5 (0.3) 
888 (47.4) 
4 (0.2) 
2 (0.1) 
85 (4.5) 
9 (0.5) 
9 (0.5) 
232 (12.4) 
0 (0.0) 
5 (0.3) 
2 (0.1) 
13 (0.7) 
 
132 (15.8) 
165 (19.8) 
50 (6.0) 
1 (0.1) 
6 (0.7) 
10 (1.2) 
163 (19.5) 
0 (0.0) 
0 (0.0) 
41 (4.9) 
1 (0.1) 
0 (0.0) 
220 (26.4) 
0 (0.0) 
0 (0.0) 
3 (0.4) 
43 (5.2) 
Stage at diagnosis 
In situ 
Early 
Late 
Unknown 
 
0 (0.0) 
45 (25.6) 
106 (60.2) 
25 (14.2) 
 
0 (0.0) 
574 (32.8) 
929 (53.1) 
247 (14.1) 
 
0 (0.0) 
687 (36.7) 
972 (51.9) 
215 (11.5) 
 
0 (0.0) 
257 (30.8) 
477 (57.1) 
101 (12.1) 
Grade 
I 
II 
III 
IV 
Unknown 
 
8 (4.6) 
40 (22.7) 
101 (57.4) 
1 (0.6) 
26 (14.8) 
 
45 (2.6) 
354 (20.2) 
1071 (61.2) 
35 (2.0) 
245 (14.0) 
 
78 (4.2) 
436 (23.3) 
1114 (59.5) 
28 (1.5) 
218 (11.6) 
 
19 (2.3) 
169 (20.2) 
509 (61.0) 
10 (1.2) 
128 (15.3) 
Place of birth 
U.S.-born 
Foreign-born 
Unknown 
 
8 (4.6) 
113 (64.2) 
55 (31.3) 
 
86 (4.9) 
1087 (62.1) 
577 (33.0) 
 
1053 (56.2) 
450 (24.0) 
371 (19.8) 
 
85 (10.2) 
572 (68.5) 
178 (21.3) 
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APPENDIX B. Unadjusted Kaplan-Meier curves of overall survival among cases 
diagnosed with infection-associated cancers 
 
 
 
Unadjusted Kaplan-Meier curves of overall cervical cancer survival comparing Asians to non-
Hispanic whites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unadjusted Kaplan-Meier curves of overall cervical cancer survival comparing South Asians to 
other Asian subgroups and non-Hispanic whites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log-rank p-value: <.0001 
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Unadjusted Kaplan-Meier curves of overall liver cancer survival comparing South Asians to other 
Asian subgroups and non-Hispanic whites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unadjusted Kaplan-Meier curves of overall stomach cancer survival comparing South Asians to 
other Asian subgroups and non-Hispanic whites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log rank p-value: <.0001 
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APPENDIX C. Demographic and tumor characteristics of eligible Asian cases with 
breast cancer prior to sample exclusions 
 
 
 
Demographic and tumor characteristics among 31,572 Asian women diagnosed with primary 
breast cancer prior to study sample exclusions 
Characteristic South Asian  
(n=2054) 
Chinese  
(n=9186) 
Japanese  
(n=8076) 
Filipino  
(n=12256) 
Age at diagnosis, y     
Mean ± SD 
Year of diagnosis 
54 ± 12 57 ± 14 63 ± 17 57 ± 12 
1999-2001 381 (18.6) 1978 (21.5) 2161 (26.8) 2514 (20.5) 
2002-2004 502 (24.4) 2397 (26.1) 2255 (27.9) 3200 (26.1) 
2005-2007 622 (30.2) 2662 (29.0) 2089 (25.9) 3724 (30.4) 
2008-2009 549 (26.7) 2149 (23.4) 1571 (19.5) 2818 (23.0) 
SEER Registry     
San Francisco-Oakland 130 (6.3) 2926 (31.9) 558 (6.9) 2022 (16.5) 
Los Angeles 69 (3.4) 2281 (24.8) 1511 (18.7) 3270 (26.7) 
San Jose-Monterey 120 (5.8) 810 (8.8) 400 (5.0) 642 (5.2) 
Greater California 84 (4.1) 21 (0.2) 21 (0.3) 36 (0.3) 
Connecticut 138 (6.7) 80 (0.9) 23 (0.3) 63 (0.5) 
Detroit 149 (7.3) 82 (0.9) 31 (0.4) 69 (0.6) 
Hawaii 5 (0.2) 799 (8.7) 3916 (48.5) 1517 (12.4) 
Iowa 9 (0.4) 19 (0.2) 6 (0.1) 11 (0.1) 
New Mexico 15 (0.7) 6 (0.1) 13 (0.2) 11 (0.1) 
Seattle-Puget Sound 115 (5.6) 358 (3.9) 389 (4.8) 551 (4.5) 
Utah 13 (0.6) 21 (0.2) 60 (0.7) 11 (0.1) 
Atlanta 171 (8.3) 98 (1.1) 21 (0.3) 16 (0.1) 
Greater Georgia 149 (7.3) 1065 (11.6) 994 (12.3) 3146 (25.7) 
Rural Georgia 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 
Kentucky 19 (0.9) 8 (0.1) 16 (0.2) 14 (0.1) 
Louisiana 31 (1.5) 24 (0.3) 13 (0.2) 17 (0.1) 
New Jersey 836 (40.7) 588 (6.4) 104 (1.3) 860 (7.0) 
Stage at diagnosis     
In situ 
I 
416 (20.3) 
616 (30.0) 
2319 (25.2) 
3217 (35.0) 
1998 (24.7) 
3360 (41.6) 
2843 (23.2) 
3951 (32.2) 
II 626 (30.5) 2453 (26.7) 1930 (23.9) 3602 (29.4) 
III 213 (10.4) 570 (6.2) 367 (4.5) 986 (8.0) 
IV 
Unknown 
78 (3.8) 
105 (5.1) 
220 (2.4) 
407 (4.4) 
183 (2.3) 
238 (2.9) 
446 (3.6) 
428 (3.5) 
Grade     
I 252 (12.3) 1437 (15.6) 1906 (23.6) 1651 (13.5) 
II 668 (32.5) 3520 (38.3) 3273 (40.5) 4685 (38.2) 
III 800 (39.0) 2751 (30.0) 1956 (24.2) 4023 (32.8) 
IV 48 (2.3) 466 (5.1) 277 (3.4) 613 (5.0) 
Unknown 286 (13.9) 1012 (11.0) 664 (8.2) 1284 (10.5) 
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ER Status 
Positive/borderline 1232 (60.0) 5734 (62.4) 5421 (67.1) 7743 (63.2) 
Negative 414 (20.2) 1468 (16.0) 1041 (12.9) 2135 (17.4) 
Unknown 408 (19.9) 1984 (21.6) 1614 (20.0) 2378 (19.4) 
PR Status     
Positive/borderline 1059 (51.6) 4884 (53.2) 4619 (57.2) 6337 (51.7) 
Negative 564 (27.5) 2172 (23.6) 1679 (20.8) 3190 (26.0) 
Unknown 431 (21.0) 2130 (23.2) 1778 (22.0) 2729 (22.3) 
Place of birth     
U.S.-born 117 (5.7) 932 (10.2) 3639 (45.1) 711 (5.8) 
Foreign-born 892 (43.4) 4629 (50.4) 1519 (18.8) 7993 (65.2) 
Unknown 1045 (50.9) 3625 (39.5) 2918 (36.1) 3552 (29.0) 
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APPENDIX D. Demographic and tumor characteristics of eligible Asian Medicare 
beneficiaries with breast cancer prior to sample exclusions 
 
 
 
Demographic and tumor characteristics among 13,293 Asian female Medicare beneficiaries 
diagnosed with invasive breast cancer in SEER-Medicare prior to study sample exclusions 
Characteristic N (%) 
Age at diagnosis, y 
Mean ± SD 
 
68 ± 10 
Year of diagnosis 
1999-2001 
2002-2004 
2005-2007 
2008-2009 
 
3715 (28.0) 
3753 (28.2) 
3522 (26.5) 
2303 (17.3) 
Income (of census 
tract) 
Quartile 1 
Quartile 2 
Quartile 3 
Quartile 4 
Unknown 
 
 
2230 (16.8) 
2680 (20.2) 
3928 (30.0) 
4408 (33.2) 
47 (0.4) 
Education (% <HS 
in census tract) 
Quartile 1 
Quartile 2 
Quartile 3 
Quartile 4 
Unknown 
 
 
2895 (21.8) 
3334 (25.1) 
3473 (26.1) 
3544 (26.7) 
47 (0.4) 
Place of birth 
U.S.-born 
Foreign-born 
Unknown 
Stage at diagnosis 
In situ 
Early 
Late 
Unknown 
Grade at diagnosis 
I 
II 
III 
IV 
Unknown 
ER Status 
Positive/borderline 
Negative 
Unknown 
 
 
 
2850 (21.4) 
5893 (44.3) 
4550 (34.2) 
 
2850 (21.4) 
8638 (65.0) 
1233 (9.3) 
572 (4.3) 
 
2531 (19.0) 
5317 (40.0) 
3472 (26.1) 
520 (3.9) 
1453 (10.9) 
 
8366 (62.9) 
1897 (14.3) 
3030 (22.8) 
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PR Status 
Positive/borderline 
Negative 
Unknown 
6859 (51.6) 
3108 (23.4) 
3326 (25.0) 
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